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Abstract 
Due to their interesting biological properties and complex molecular architectures, the 
rubromycin family of natural products, have attracted the attention of a number research 
groups over the last sixty years.  Despite this significant interest, there is still a 
requirement for a short, robust, and modular synthetic route towards these intriguing 
secondary metabolites.  This thesis presents an investigation into the application and 
development of Bray’s recent [4+2] cycloaddition methodology, towards achieving this 
goal (Scheme I). 
 
Scheme I. Retrosynthetic analysis of the rubromycin scaffold 
The initial introductory chapter outlines the structural relationships and biological 
properties of the rubromycins, in addition to providing details of the current 
understanding of their biochemical synthesis.  This is followed by a comprehensive 
review of the five synthetic strategies used to construct the challenging [5,6]-bis-
benzannulated spiroketal rubromycin core outlined in turn.  In the third and final 
introductory chapter, the application and relative merits of these strategies towards the 
synthesis of fully elaborated rubromycin scaffolds is discussed. 
 
The results of this investigation towards a flexible and modular synthesis of 
γ-rubromycin are then presented and discussed in chapter four.  The three main topics 
covered are; exploration of synthetic routes towards the napthazarin (II), exploration 
of synthetic routes towards the ortho-quinone methide (III), and utility of the ortho-
quinone methide in ‘inverse’ electron-demand [4+2] cycloaddition reactions.  The 
experimental details of this investigation and selected 1H and 13C are also reported in 
chapters 5 and 6 respectively.  
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Chapter 1: 
Introduction 
 
“Few scientists acquainted with the chemistry of biological systems at the molecular 
level can avoid being inspired.” 
 
 
Donald James Cram (1919 –2001) 
American Chemist & Nobel Laureate 
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1.1 Introduction to the Rubromycins 
 
Fig. 1. γ-Rubromycin 
Since the initial isolation and discovery of “rubromycin” (2) from Streptomyces collinus 
in 1953 by Brockmann and Renneberg,1 the rubromycin family initially proved to be of 
interest to the scientific community due to their intriguing biological properties. However 
their complex hexacyclic [5,6]-bis-benzannulated spiroketal core, connecting the 
napthazarin and isocoumarin moieties (Fig. 1), that are difficult to access via chemical 
synthesis has attracted the attention of several natural products research groups.  
 
Scheme 1. Structural relationship between α-,β- and γ-rubromycin 
Brockmann and Renneberg subsequently found that treatment of “rubromycin” (2) with 
pyridine at reflux afforded “collinomycin” (3), which they had also isolated previously 
from Streptomyces collinus.2  Conversely treatment of “rubromycin” (2) with dilute 
hydrochloric acid afforded a novel red pigment (1) (Scheme 1).  Due to the evident 
structural relationship of these three molecules they were subsequently renamed α (3), β 
(2) and γ-rubromycin (1) in accordance with their respective Rf values.3 
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Fig. 2. Rubromycin structures 
Since these early works a number of other “rubromycin” type natural products have been 
isolated.  These include 3’-hydroxy-β-rubromycin (4) and δ-rubromycin (5) 
(from Streptomyces)4; pupuromycin (6) (from Actinoplanes ianthinogenes)5,6; 
griseorhodin A (7), C (8) and G (9) (from Streptomyces californicus and griseus)7,8,9 and 
heliquinomycin (10) (from Streptomyces sp. MJ 929-SF2).10 
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1.2  Biological and Pharmological Activity of the Rubromycins 
Since their initial isolation, the rubromycins have been known to be potent antimicrobial 
agents capable of inhibiting the growth of various bacteria and fungi at micro to 
nanomolar concentrations.11  The biological properties of rubromycins and their 
analogues were further examined in 2000 by Hayashi and co-workers. Interestingly their 
results showed micromolar levels of inhibition of human immunodeficiency virus type 1 
reverse transcriptase (HIV-1 RT) and telomerase (Table 1) both high profile 
pharmaceutical targets, sparking a renewal of interest.12   
 
Compound 
IC50 (µM) of TS-Aa concentration of IC50 (µM) 
of HIV-1 
RT 0.2 µM 2.0 µM 
α-Rubromycin (3) >200 >200 >200 
β-Rubromycin (2) 3.06 ± 0.85 8.64 ± 2.3 33.3 ± 2.4 
γ-Rubromycin (1) 2.64 ± 0.09 17.8 ± 2.0 19.9 ± 1.6 
Purpomycin (6) 3.19 ± 0.45 15.9 ± 2.1 22.9 ± 0.45 
Griseorhodin A (7) 12.2 ± 3.1 41.6 ± 9.8 10.5 ± 1.2 
Griseorhodin C (8) 5.87 ± 0.44 2.58 ± 1.7 11.4 ± 1.8 
Table 1. Comparison of the biological activity of the rubromycins 
From the results of Hayashi’s study it appears that the benzannulated spiroketal moiety of 
the rubromycins is the essential pharmacophore for both telomerase and HIV1-RT 
activity as α-rubromycin (3), an open-chain member of the rubromycin family exhibits 
dramatically reduced levels of inhibition (IC50 >200 µM) (Fig. 3).13   
 
 
Fig. 3. Pharmaceutical importance of the 5,6-spiroketal 
                                                 
a Telomerase Substrate Primer. 
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1.3 Pharmaceutical Importance of HIV1-RT 
  
Fig. 4. Computer generated image of HIV-1 RT (blue/pink) DNA (green/orange) complex 14 
HIV1-RT is a retroviral enzyme that facilitates transcription of retroviral RNA into 
retroviral DNA inside a host cell.  This is the reverse process of regular cellular 
transcription processes and is central to the infectious nature of retroviruses, several of 
which cause disease in human hosts, such as acquired immune deficiency 
syndrome (AIDS) and human T-cell lymphotrophic virus 1 (HTLV-1), which can 
subsequently lead to leukaemia.  
Currently, non-nucleoside based small molecule type reverse transcriptase inhibitors 
(NNRTIs) are believed to bind to a hydrophobic pocket of the enzyme near the 
polymerase active site (see Fig. 4, polymerase active site occupied by DNA).15  It appears 
that this allosterically distorts the enzyme sufficiently that polymerase cannot occur 
despite binding of both the required nucleic acid and reverse transcription (RT) substrates.  
This mechanism of inhibition is however still somewhat unclear and therefore greater 
understanding of the RT mechanism of action is currently required for more targeted drug 
discovery processes.16,17 
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1.4 Pharmaceutical Importance of Telomerase  
 
Fig. 5. Surface representation of TERT with modelled RNA (green) and DNA (purple).17 
 
Telomerase is a unique ribonucleoprotein complex,18 comprised of two major 
components, a catalytic subunit (TERT, Telomerase Reverse Transcriptase) and an 
integral RNA component (TER, Telomerase RNA) that require stable association to form 
the functional holoenzyme (Fig. 5).  It is this complex that is responsible for maintaining 
length and integrity of linear chromosome termini known as telomeres [Greek; telos (end) 
meros (part)] during cellular replication processes.19,20,21,22  It is believed that as telomeres 
are shortened due to replication processes such as mitosis, cells age and can therefore 
only replicate a finite number of times until reaching critical length (Hayflick limit),23 at 
which point cell-replication cannot continue.   
It is therefore essential that telomere length is maintained.  Telomerase is over-expressed 
in most tumour cells from virtually all types of cancer (80-90%).  As telomerase is 
essential for long term telomere maintenance, it is therefore crucial for long-term survival 
of tumour cells and tumour progression.  Due to this high telomerase activity, cancer cells 
can almost be considered as immortal (not limited by Hayflick limit) thus avoiding 
apoptosis.24,25  Conversely ‘normal’ cells express little or no telomerase and generally 
have longer telomeres than tumour cells, making telomerase a relatively specific and 
pharmaceutically attractive anti-cancer target.,26 
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Despite intense academic and industrial efforts and innumerable in vitro and cell studies, 
no small-molecule telomerase inhibitors have to date emerged as fully approved 
pharmaceutical agents, although a number of vaccines and oligonucleosides are currently 
under investigation in clinical trials.27  This attrition has been largely attributed to 
insufficient understanding of human telomerase (h-telomerase) structure and mechanisms 
of interdiction in addition to further complexities presented by the enzymes dimeric 
composition.28  One significant obstacle has been the lack of sufficient quantities of stable 
and purified TERT, which has thwarted access to a functionally relevant X-ray crystal 
structure.   
 
Fig. 6. Pettus’ telomerase inhibitor development strategy 
Due to this purification problem, it was recently proposed jointly by the groups of Pettus 
and Reich that monomeric Tetrahymena telomerase (t-telomerase) may provide the most 
useful platform for inhibitor development.29  Said investigation screened spectrum 
representative telomerase inhibitors against both h-telomerase and t-telomerase to 
ascertain if inhibitor structure activity relationship (SAR) is conserved between enzymes. 
If successful, potential inhibitors could then be screened during early development against 
t-telomerase for practical reasons.  Second generation lead compounds could then be 
screened against h-telomerase, reducing the amount of biological labour involved in 
generating SAR data (Fig. 6). 
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 Table 2. Pettus and Reich’s SAR comparison study data 
  
Interestingly this hypothesis was quite effective for four of the six series of compounds 
tested and appears to show that t-TRAP assays (polymerase chain reaction based 
telomeric repeat amplification protocol) may allow for reasonable SAR predictions for 
telomerase inhibitors based upon a rubromycin scaffold (Entry 1, Table 2).  This study 
also reported that β-rubromycin did not exhibit any G-quadraplex stabilising effect during 
thermal melt analysis.  It therefore appears that the rubromycins do not inhibit telomerase 
through a G-quadruplex stabilization mechanism.  
 
 
  
Entry Inhibitor 
h-TRAP Maximal t-TRAP Maximal 
IC50 (µM) Inhibition IC50 (µM) Inhibition 
1 β-Rubromycin 1.53 ± 0.21 90% 0.81 ± 0.08 100% 
2 BIBR-1532 4.6 ± 0.48 100% > 200 NA 
3 THyF 0.25 ± 0.06 100% 0.62 ± 0.17 100% 
4 EGCG 1.18 ± 0.16 80% 0.37 ± 0.12 85% 
5 MST-312 12.8 ± 2.9 100% > 200 NA 
6 TMPyP 0.15 ± 0.01 100% 0.14 ± 0.014 100% 
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1.5 Rubromycin Biosynthesis 
Polyketides constitute a large, structurally diverse range of biologically active natural 
products.  The origin of this diversity is particularly intriguing as they are essentially 
polymeric structures of repeating acetate and propionate subunits.  In bacteria (i.e. 
rubromycin producing Streptomyces) the synthesis of secondary metabolites is usually 
controlled by remarkably versatile and amenable enzymatic clusters, known as type-II 
polyketide synthases (PKSs).   These clusters consist of several repeating domains, each 
with a role in either the functionalisation and/or chain elongation.    
 
Fig 7. Overall view of polyketide biosynthesis30 
This massive biological assembly line can essentially be considered as a two-stage 
process.  The initial biosynthetic sequence involves enzymes that are generally highly 
conserved between all type-II PKS systems.  The acetate-type molecular building blocks 
consumed by these massive polyenzymatic systems are generally in the form of acetyl-
coenzyme A (CoA) and malonyl-coenzyme A (MCoA) respectively.   
These subunits undergo chain elongation by repetitive decarboxylative Claisen thioester 
condensations between an activated acyl starter unit and a defined number of MCoA 
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derived extender units (pathway a, Fig. 7).  The resulting poly-β-oxoacyl-CoA chain, 
after optional β-keto processing (pathway b, Fig. 7) can then undergo regiospecific 
cyclisation by cyclases (CYC) to furnish the bare aromatic molecular polyketide skeleton. 
The biodiversity of these initial structures is surprisingly limited, which is a stark 
comparison to the plethora of intermediates that results from the subsequent tailoring 
stage carried out by a significantly larger and more diverse enzymatic family.  These are 
commonly referred to as tailoring enzymes and often responsible for pharmacophore 
installation.   
 
Scheme 2. Inferred PKS route from 13C labelling study 
Independent biosynthetic labelling studies using 1,2-13C acetic acid, have implied that 
both β-rubromycin (2) (from Streptomyces sp. A1)31 and the heliquinomycin aglycon 
(from Streptomyces sp. MJ929-SF2)32 incorporated 13 acetate units during polyketide 
biosynthesis, giving identical labelling patterns, inferring an unusually lengthy 
tridecaketide origin.  Upon further inspection of the gene cluster, the most likely PKS 
product appears to be a pradimicin-type intermediate (20). 
The precise post-PKS tailoring of (20) to afford the desired rubromycin skeletons is still a 
subject of discussion.  However, recent study by Li and Piel33 identified the type-II PKS 
gene cluster (grh cluster) that encodes for the biosynthesis of griseorhodin A (7) 
(from Streptomyces sp. JP95).  Further investigation of this unusually large 
oxidoreductase rich and diverse gene cluster shed further light on this pathway.34 
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Scheme 3. Inferred post-PKS biosynthetic tailoring 
One key enzyme identified was the flavin adenine dinucleotide (FAD) dependant 
oxidoreductase GrhO5, which upon removal generates the ‘unnatural’ antibiotic collione 
(21).  This enzyme was attributed to facilitate [6,6]-bis-benzannulated spiroketal 
formation, although the product of the immediate downstream GrhO1 enzyme could not 
be fully characterized.   
 
 
Scheme 4. Possible enzymatic installation of the spiroketal 
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The close protein homology of GrhO6 to oxidative enzymes, which may facilitate 
inferred Baeyer-Villiger type processes suggested related chemical functionality to this 
enzymatic class, inferring a possible enzymatic mechanism involving the monooxygenase 
unusually acting on the ester functionality over the ketone (Scheme 4, Route A). 
Conversely, carbon-bond cleavage could also be rationalized by enzymatic hydroxylation, 
promoting subsequent fragmentation before rearomatisation to the [5,6]-bis-
benzannulated spiroketal (Scheme 4, Route B). 
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Chapter 2: 
Rubromycin Model 
Systems 
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2.1 [5,6]-bis-Benzannulated Spiroketal Synthesis 
 
 
Fig. 8. Retrosynthetic analysis of [5,6]-bis-benzannulated spiroketals 
The key structural motif conserved throughout the natural rubromycins is the 
[5,6]-bis-benzannulated spiroketal, which forms the central scaffold.  Said spirocyclic 
core links the benzofuran and the benzopyran moieties via a central sp3 carbon atom 
(spiro carbon) such that the two cyclic ethereal oxygen atoms are orientated orthogonal to 
each other. 
Despite the attractive pharmacological potential of [5,6]-bis-benzannulated spiroketal 
(24), a general modular, robust and scalable methodology with broad substrate scope has 
to date proved elusive.  There have however been considerable and heroic efforts made by 
a number of research groups.  The main approaches considered (Strategies A-E, Fig. 8) 
have however yielded some interesting results and useful synthetic tools.  It is the aim of 
this chapter to describe each of these five strategies in turn, including their development 
and synthetic scope. It is the author’s intention to make a clear distinction between 
literature reports described both before the start (Chapter 2a), and during the course of 
this investigation (Chapter 2b). 
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Chapter 2a: 
Previous Model  
Studies  
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2.2 Greul and Brockmann Approaches (Strategies A and B) 
 
Scheme 5. Greul and Brockmann spiroketal synthesis 
The seminal publication in this field by Greul and Brockmann in 1971,35 outlined the first 
two strategies (Strategies A-B, Fig. 8) to the simple non-substituted 
[5,6]-bis-benzannulated spiroketal (24). The first of these, “strategy A” (Scheme 5) 
involves Lewis-acid promoted demethylation, of a bis-(o-methoxyphenyl)-substituted 
ketone (34) (prepared by aldol condensation followed by hydrogenation).  The naked 
phenoxide then undergoes Lewis-acid catalysed spirocyclization to form (24) in an 
extremely modest yield (2.4% over 3 steps).  This strategy shall from herein be referred to 
as spiroketalisation.  
 
Scheme 6. Greul and Brockmann spiroketal synthesis 
The alternative route “strategy B”, (Scheme 6) involves condensation of the o-methylated 
salicyl aldehyde (32) with a chloromethyl ketone (35), followed by subsequent 
Clemmenson reduction36 to give the 2-(2-aryl)ethylbenzofuran precursor (36).  This 
subsequently undergoes Lewis-acid promoted demethylation and cyclization to give the 
desired compound (24) in a slightly improved yield (4.2% over 3 steps).  This strategy 
shall herein be referred to as the 6-exo-trig spirocyclisation approach and shall be 
discussed later (Section 2.8).  
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2.3  de Koning Spiroketalisation Approach 
 
Scheme 7. de Koning spiroketal model system 
Surprisingly, no further synthetic efforts were observed in the literature until 1998 when 
de Koning and co-workers described a modification to Greul and Brockmann’s 
spiroketalisation procedure (Scheme 7).37,38  Their approach nicely showcased Varma and 
co-workers procedure for the solventless, microwave-assisted synthesis of nitroalkenes 
via a Henry reaction to couple the two fragments, providing (39) in 57% yield.39   
Subsequent exposure of (39) to Pearlman’s catalyst and catalytic HCl, under an 
atmosphere of hydrogen promoted spiroketal formation via a “Nef-type” process in a 
markedly improved 64% yield.  The authors initially suggested that the nitro group is 
reduced to afford enamine (41a), which under aqueous acidic conditions would hydrolyse 
to (40) and then cyclise to (42).b  Alternatively, it was suggested that the nitro group may 
be reduced to the unsaturated hydroxylamine (41b), which then tautomerises to an 
unsaturated oxime that again hydrolyses to (40) and cyclises under the acidic conditions. 
 
 
                                                 
b It was of note that in acidic solution sideproduct (40) slowly cyclised to (42). 
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2.4 Brimble’s Sonogashira Coupling/Spiroketalisation Approach 
 
 
Scheme 8. Brimble’s rubromycin model study 
In 2003 Brimble and co-workers further improved the efficiency of the spiroketalisation 
approach  (Scheme 7).40  Said methodology combines the effective use of a Sonogashira 
type coupling41 to prepare various aryl acetylene fragments (46).  These were converted 
to the cyclisation precursors (47) in two steps, namely full hydrogenation of the alkyne 
before subsequent oxidation of the resultant alcohol species using catalytic 
tetrapropylammonium perruthenate (TPAP) and N-methylmorpholine-N-oxide (NMO). 
Subsequent MOM-deprotection of both the γ- and δ-phenolic groups using 
bromotrimethylsilane facilitated spirocylization to give (48) in overall yields of 77-90%, a 
significant improvement on Greul and Brockmann’s pioneering efforts. 
 
 
Fig.  9. Additional spiroketal motifs generated by Brimble 
In a subsequent 2007 communication,42 Brimble et al. demonstrated that this 
methodology also has additional scope in synthetic chemistry by generating a small 
number of simple bis-benzannulated spiroketals with alternative aromatic motifs (Fig. 9). 
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2.5 Kozlowski’s Spiroketalisation  
 
Scheme 9. Synthesis of Kozlowski’s model precursor 
In 2006 the Kozlowski group demonstrated that a Brønstead-acid spiroketalisation could 
be used to construct a [5,6]-bis-benzannulated spiroketal with the desired oxidation 
pattern exhibited in pupuromycin (6).  This strategy featured a novel approach to 
precursor (55) generated via hydrogenation of the isoxazoline [3+2] cycloaddition 
product (54) formed between styrene (53) and nitroalkane (52) (Scheme 9).    
 
Scheme 10. Kozlowski’s model spiroketalization 
The key finding of this study, was however that exposing spiroketalisation precursor (55) 
to stepwise hydrogenation and Brønstead acid promoted spirocyclisation conditions 
facilitated the diastereo-enriched synthesis of spiroketal (56) (2:1 mixture).  This 
preference was rationalised by Kozlowski due to both the anomeric effect and a proposed 
hydrogen bond interaction in (56a) (Fig. 10). 
 
 
Fig.  10. Kozlowski’s rationalisation for diastereo-enrichment 
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2.6 Reißig’s Spiroketalisation 
 
Scheme 11. Synthesis of the prerequisite α,β-unsaturated ketone 
Contemporaneously to Kozlowski’s finding, Reißig and co-workers also reported 
[5,6]-bis-benzannulated spiroketal synthesis based around a similar Brønstead-acid 
promoted spiroketalisation.43  This approach differed from those outlined previously by 
employment of an α,β-unsaturated ketone spiroketalisation precursor (61).  Said species 
was generated from a Heck reaction between aryl iodide (60) and TES-protected 
α-hydroxy enone (59) (prepared in 3 steps from nucleophilic addition of lithiated 
methoxyallene (58) to benzaldehyde (57), followed by subsequent acid hydrolysis and 
silylation) (Scheme 11). 
 
 
Scheme 12. Thermodynamically controlled trans-selective spiroketalisation 
 
Upon subjection of (61) to hydrogenation conditions and subsequent exposure to catalytic 
amounts of acid promoted a diastereoselective spiroketalisation to afford trans-spiroketal 
(63) exclusively (Scheme 12).   
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2.7 Li and Xue’s Gold-Catalysed Spiroketalisation 
 
Scheme 13. Gold-catalysed route to spirocyclization precursor 
Shortly afterwards in 2007, Li and Zue demonstrated that a simple [5,6]-bis-
benzannulated spiroketal (24) could be generated from alkyne (65) and aryl iodides e.g. 
(64) (Scheme 13).44  These fragments were initially coupled using Sonogashira type 
methodology before basic acyl cleavage revealed the phenolic bis-aromatic alkyne 
spirocyclization precursor (66) similar to those employed by Brimble et al. (46).  The 
subsequent one-pot metal catalysed spiroketalization procedure is however a significantly 
more elegant model than Brimble's avoiding atom inefficient multi-step preparation of a 
prerequisite sp2 hybridised ketone.  The gold (I) catalyst in question [Ph3PAuCl/AgOTf 
(10 mol%)] was successfully employed at room temperature affording (24) in 62% yield 
after 48 hours (Scheme 14). 
 
  
Scheme 14. Gold-Catalysed Spirocyclization  
The proposed mechanism for this reaction involves co-ordination of the gold species to 
the alkyne and the ortho-phenol, which enhances the electrophilicity of the alkyne (66).  
The furan moiety is then believed to form first during a double intramolecular phenolic 
attack, generating the model spiroketal (24).  The active gold species is then believed to 
be simultaneously liberated however further mechanistic details are at the time of writing 
unknown and were only speculated upon by the authors. 
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2.8 Danishefsky’s 6-exo-trig Spirocyclisation Approach 
 
Scheme 15. Danishefsky’s synthesis of the spirocylisation precursor 
Building on the findings of Greul and Brockmann, Danishefsky and co-workers were, at 
the start of this investigation, the only group to optimise the 6-exo-trig spirocyclisation 
strategy towards [5,6]-bis-benzannulated spiroketals (Strategy B, Fig 8.).  This 
methodology was very effectively employed during the synthesis of their heliquinomycin 
(10) model system in 2001.45  In their approach the cyclisation precursor (67) was 
prepared by coupling of aldehyde (64) with 2-lithio-2,3-benzofuran, followed by benzyl 
protection of the free alcohol (66), before Brønsted acid-promoted deprotection of the 
methoxy methyl ester to furnish the prerequisite phenol (67) (Scheme 15).  
 
Scheme 16. Danishefsky’s model stereoselective spirocyclization  
Various unsuccessful attempts were made to cyclise (67) via face selective epoxidation of 
the furan, with the aim of promoting intramolecular nucleophilic attack from the phenol.  
After screening a variety of reagents to activate the benzofuran (Hg(II) salts, Pd, HCl, 
PhSeCl and I2) it was found that treatment with NBS generated bromonium ion (68) 
(Scheme 16).  Concomitant intramolecular nucleophilic attack of the phenol afforded the 
desired [5,6]-bis-benzannulated spiroketal (69) in good overall yield (85%).  This process 
was however somewhat complicated by non-regiospecific bromination of the benzopyran 
leading to a mixture of regioisomers (69a:69b; 5:4). 
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2.9 Kita’s Pummerer Approach (Strategy C) 
 
 
Scheme 17. Kita’s Pummerer reaction 
 
The third disconnection approach (Strategy C, Fig.8), was first made in 2007 by Kita and 
co-workers and was shown to be an effective, route to the [5,6]-bis-benzannulated 
spiroketal (81).46  The initial spiroketal (74) was prepared in one pot by a previously 
unknown aromatic Pummerer-type reaction between sulfoxide (70a) and 
2-methylenechroman (28) (Scheme 17) in the presence of trifluoroacetic anhydride 
(TFAA), before spiroketalization of the resultant oxonium ion proceeded with 
re-aromatisation of the nathalene to furnish (74) in 73% yield (10 mg isolated).  
 
 
 
Scheme 18. Kita’s construction of rubromycin model system 
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Serendipitously, whilst trying to derivatise (76) to the ortho-quinone species (78) by a 
second aromatic Pummer-type reaction using triflic anhydride, unexpected direct 
formation of the pentacyclic rubromycin model (81) was observed in 57% yield, in 
addition to (78; 27 %yield).   
 
During mechanistic investigation it was shown that treatment of (76) with trifluoroacetic 
anhydride (TFAA) afforded ortho-quinone (78) as a single product in 82% yield.  
Subsequent treatment of the ortho-quinone (78) with trifluoroacetic acid (TFA) afforded 
(81) via an unprecedented rearrangement in 87% yield (Scheme 18).  Kita and 
co-workers proposed that electron donation of the β-oxygen assists carbonyl protonation, 
thus promoting formal cleavage of the ketal, forming oxonium intermediate (80).  This 
then undergoes intramolecular cyclisation to form the pentacyclic model rubromycin core 
(81).  This strategy from herein shall be referred to as the Pummerer approach.   
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2.10 Pettus’ [3+2] Cycloaddition Strategy (Strategy D) 
 
Scheme 19. Pettus [3+2] model study 
 
A further novel approach was developed by Pettus and co-workers (Strategy D, Fig. 8) in 
2006 based around construction of a dihydrofuran via a [3+2] cycloaddition.47  Using 
Roy’s cerium ammonium nitrate (CAN) mediated conditions,48 they were able to promote 
a [3+2] cycloaddition between exo-enol ether (28) and 1,3-dicarbonyl carbene (29) 
oxidatively generated in situ (Scheme 19) from (82) in moderate yield (56%).  The 
resultant [5,6]-mono-benzannulated spiroketal (83) was then further aromatized using 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) to furnish the desired  
[5,6]-bis-benzannelated spiroketal (84) (64%).  This strategy from herein shall be referred 
to as the [3+2] cycloaddition approach. 
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2.11 hetero-Diels-Alder Approaches (Strategy E) 
 
Scheme 20. hDA approach to [5,6]-bis-benzannulated spiroketals 
The final strategy (Strategy E, Fig.8) towards [5,6]-bis-benzannulated spiroketals, that 
had been reported at the start of this investigation was to generate this interesting scaffold 
via a hetero-Diels-Alder (hDA) reaction (Scheme 20) between an exo-enol ether and an 
ortho-quinone methide (o-QM) such as (85) and (86) respectively. 
 
 
Scheme 21. Seminal hetero-Diels-Alder reaction 
Since the first report by Otto Diels and Kurt Alder’s of their famous [4+2] cycloaddition 
reaction first carried out over 80 years ago, this cycloaddition has proved to be an 
extremely popular49 and useful reaction in organic synthesis.50,51  An account of the 
incorporation of a oxygen atom in a [4+2] cycloaddition was reported two decades later 
by Gresham and Steadman (Scheme 21).52  Since then the scope of this reaction has been 
expanded to work effectively with both nitrogen53 and phosphorus.54 
 
 
Scheme 22. Frontier molecular orbital description of Diels-Alder cycloadditions 
Importantly, the reactivity of o-QMs (86) in [4+2] cycloaddtions are somewhat different 
in terms of frontier molecular orbital theory to the simple diene’s employed in Diels and 
Alder’s early work and can be best described as ‘inverse’ electron-demand hetero-Diels-
Alder reactions.  This is because it is the alkene component, which contributes an electron 
  
36 
 
pair from its HOMO to the LUMO of the electron rich 4π component to generate a new 
molecular orbital, which is the opposite to that observed during ‘normal’ Diels-Alder 
reactions (Scheme 26).   
 
2.12 ortho-Quinone Methides 
 
Scheme 23. Primary reaction modes of o-QMs 
ortho-Quinone methides (o-QMs) e.g. (86 and 92) are highly reactive, ephemeral 
intermediates that were first alluded to in 1907 by Fries.55  More recently in 2002, Amouri 
provided crystallographic evidence of o-QMs isolated as η4 π-complexes of Os, Rh and 
Ir.56  Despite their transient nature, there is an abundance of evidence for their function in 
a variety of biological systems and their use in organic synthesis is ever increasing, with a 
multitude of recent natural product syntheses being based on the formation of an 
o-QM.57,58 The transient nature of o-QMs is due to their propensity to undergo rapid 
rearomatisation either by Micheal addition of nucleophiles (Scheme 23, path a) or, often 
more usefully, by cycloaddition with 2π partners (path b) or via 
oxa-6π-electrocyclisation to give benzopyrans (path c).57,58   
 
Scheme 24. Dimer and trimer formation 
Surprisingly this rapid reactivity is often seen as a deterent to synthetic development in 
the field with the potential for dimer- and trimerisation a major stumbling block 
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(Scheme 24).59  To counteract this, the localized o-QM concentration is generally kept 
low to avoid dimerisation and/or it is common to employ an excess of the nucleophilic or 
dieneophilic components.  o-QMs can be generated via a broad range of chemically 
diverse methodologies (Scheme 25).   
 
Scheme 25. Overview of methods for forming o-QMs 
Typically, this process involves an elimination event of either a benzylic or phenolic 
substituent to generate a methylene or carbonyl functionality with concomitant 
dearomatisation.  Perhaps the most commonly encountered of these methods for o-QM 
generation is the elimination of a stable molecule (Scheme 25), typically a benzylic 
substituent to generate the methylene and α-carbonyl functionalities with concomitant 
dearomatisation. This process may be induced thermally (red pathways) including 
retro-dimerisation60; by addition of a nucleophile61, base62 or acid63  (blue pathways); 
tautomerisation, which may be induced thermally64 or photolytically65 (green pathways); 
via benzylic oxidation or oxidative Pd-catalysis66; Wittig methylenation67 of an ortho-
quinone or by aldol condensation.68  Many of these initiation methods have been applied 
in the synthesis of a variety of structurally challenging natural products.57 
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2.13 Serendipitous Synthesis of Spiroketals via a [4+2] Cycloaddition 
 
Scheme 26. Wilsons total synthesis of xyloketal D 
To the best of the author’s knowledge the first reported example of 
[5,6]-mono-benzannulated spiroketal generation occurring via an o-QM intermediate was 
published in 2004 by Wilson and co-workers during efforts towards the xyloketal family 
of natural products (Scheme 26).69  The o-QM was generated via thermolytic extrusion of 
N-methylmorpholine from (97), before in situ [4+2] cyclodaddion with (R)-4,5-dihydro-
2,3-dimethylfuran (98) furnished xyloketal D (99).  An intriguing observation in this 
reaction was the accompaniment of the [5,6]-mono-benzannulated spiroketal (100) as an 
unanticipated side product.   
 
Scheme 27. Baldwin’s total synthesis of alboatrin 
Contemporaneously to Wilson’s initial efforts Baldwin and co-workers reported a similar 
observation during the total synthesis of the phytotoxic natural product alboatrin 
(Scheme 27).70  o-QM generation was achieved upon heating acetate (101) in the 
presence of (±)-4,5-dihydro-2,4-dimethylfuran (±-98), which afforded the key alboatrin 
precursor (102) as the major product (63% yield) in addition to spiroketals (104) (25%), 
generated as a 3:2 mixture of diastereomers.   
 
 
Scheme 28. Acid promoted exo-enol isomerism 
  
39 
 
It is proposed that spiroketals (100 and 104) observed by the groups of Baldwin and 
Wilson both result from the cycloaddition of an intermediate o-QM with an exocyclic 
enol ether (106), which is generated via thermally reversible endo-enol isomerisation of 
dihydrofuran (98) (Scheme 28).  
2.14 Thermally Initiated hetero-Diels-Alder Approach to Spiroketals  
 
Scheme 29. Li and Xie’s synthesis of a [6,6]-bis-benzannulated spiroketal 
In 2006 Li and Xie demonstrated that the procedure developed by Baldwin and 
co-workers for o-QM generation could accommodate the use of 2-methylenebenzopyrans 
(Scheme 29).60b Cycloaddition to generate a handful of [6,6]-bis-benzannulated 
spiroketals such as (108) was achievable in reasonable yields (47-60%), though it was 
noted that this process could be improved by the addition of a Lewis acid such as TiCl4 to 
70-73%. 
 
Scheme 30. Formation of endo-enol ether 
Unfortunately, attempts to synthesise aromatic [5,6]-spiroketals using this procedure 
failed due to isomerisation of exo-enol ether (30) to the endo-form (110) (Scheme 30).  
This led them to investigate milder conditions to avoid this detrimental rearrangement. 
 
Scheme 31. Li and Xie’s spiroketal synthesis model 
In 2008, Li and Xie successfully adapted their previous [4+2] cycloaddition reaction60b of 
o-QMs generated from (112) as 4π components, towards use with stabilised vinyl 
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sulfoxides as 2π partners (111) to generate spiroketal motifs (Scheme 31).60c  As these 2π 
partners are far less susceptible to irreversible isomerisation to benzofurans, they were 
found to be stable enough to tolerate the high temperatures required for thermal extrusion 
of the acetate.  To the best of this author’s knowledge this is the first reported example of 
the intentional employment of hDA reaction to afford a [5,6]-bis-benzannulated 
spiroketal. Their results (Table 3) show an increased yield when the o-QM is brominated, 
(entry 5 vs. 2) presumably due to removal of electron-density from the LUMO by the 
inductive effect thus reducing the energy gap between the HOMO and LUMO.  This may 
be more apparent due to the inverse electron demand type nature of said [4+2] 
cycloaddition.   
 
Scheme 32. Resonance stabilisation exhibitied in Li and Xie’s vinyl sulfoxide 
The opposite effect (addition of an electron donating methoxy group) however appears to 
be less significant (entry 2 vs. 3).  This is presumably due to resonance-stabilisation of 
the carbonyl (Scheme 32), significantly decreasing the electron donating effect of the 
methyl ether with respect to delocalisation of electron density on the LUMO of the 
methylene functionality. 
 
Entry R1 R2 Yield (%) 
1 Me H 55
2 H H 58 
3 MeO H 62 
4 Me Br 76 
5 H Br 90 
6 MeO Br 86 
    
Table 3. Thermal [4+2] cycloaddition scope 
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Scheme 33. Further scope for Li and Xie’s [4+2] cycloaddition 
Following from the success of this strategy towards unsaturated pyrans, Li and Xie also 
showed that this strategy could be used to generate saturated [5,6]-bis-benzannulated 
spiroketals, however with a noticeable reduction in yield (Scheme 33). 
 
      
Scheme 34. Further uses of Bray’s hDA reaction 
In the same year, Bray has also demonstrated that [4+2] cycloaddition between an o-QM 
(31) generated in situ from 2-hydroxybenzyl acetate (118) (Scheme 34) in neat 
γ-methlene-γ-butrolactone (119) (which notably did not exhibit exo-enol isomerism under 
the acidic condtions at 100 oC) affording spiroketal (120).60d  Subsequent screening 
showed the reaction could also tolerate a range of both electron-rich and electron-
deficient o-QM species (Table 4).   
 
o-QM Precursor hDA Product 
Yield (%) 
R1 R2 R1 R2 
H H H H 84 
OAc H OAc H 76 
CO2Me H CO2Me H 79 
H Br H Br 80 
H OMe H OMe 75 
H NO2 H NO2 82 
 
Table 4. Bray’s [4+2] thermal cycloaddition products 
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2.15 Base Initiated hetero-Diels-Alder Approach to Spiroketals  
 
Scheme 35. Pettus’ base mediated [4+2] cycloaddition approach  
Building on these findings, Pettus and co-workers described a mild, base initiated [4+2] 
cycloaddition reaction in which o-QM (122) was generated using 1.0 equiv of tBuMgCl at 
−78 οC.71  Unfortunately exo-enol isomerism was also a significant even under these 
milder kinetic conditions, affording (123) in only 10% yield due to significant exo-enol 
isomerism (Scheme 35).   
 
Scheme 36. Pettus’ paecilospirone model system 
This effect was however significantly reduced when the using an exo-enol ether that 
cannot re-aromatise (Scheme 36).  This was achieved by functionalising the olefin with a 
n-pentyl moiety, which perhaps assists facial selectivity and ultimately furnished the 
diastereomerically enriched (8:1) paecilospirone model compound (126). 
ONC ONC O
R' OROBoc
OH
R'
RO
tBuMgCl, PhMe,
−
78 οC  
Benzyl alcohol Chroman spiroketal Yield 
(%) dr
a 
R R’ R R’ 
H Bn H OBn 61 3:1 
H Boc H Boc 77b 3.5:1 
Br Boc Br Boc 72 4.5:1 
b The combined yield of the two isomers 
 
Table 5. Pettus’ diastereoselective [4+2] cycloaddtion substrate scope 
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Fig. 11. Sterically driven face selectivity 
It is also of note that this methodology was developed alongside a diastereoselective 
[4+2] cycloaddition to generate a model system for the asymmetric synthesis of berkelic 
acid (Table 5).72,73  This strategy was successful by introduction of a diastereomerically 
pure exo-enol ether thus biasing the cycloaddition to favour one face preferentially (Fig. 
11). Unfortunately however an approach of this nature is inherently impossible with a 
benzofuran as required for a rubromycin approach. 
 
Scheme 37. Bray’s mild hDA procedure 
Contemporaneously to Pettus’s findings, Bray also demonstrated a base initiated, 
[5,6]-benzannulated spiroketal forming hDA reaction (Scheme 37).62d This 
transformation was achieved by deprotonating o-methylene-acetoxy-phenols such as 
(118) with a slight excess (1.04 equiv.) of iPrMgCl base at −78 οC to generate o-QM (31).  
Pre-formed exo-enols such as (127) were then added before warming the reaction mixture 
slowly to room temperature over 16 hours, which promoted a [4+2] cycloaddition to 
furnish the desired spiroketal (128a) in 76% overall yield. 
 
 
Scheme 38. Bray’s hDA procedure using 1.00 equiv. of iPrMgCl 
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Intriguingly, when 1.00 equivalent of iPrMgCl was used to initiate a hDA reaction 
between (118) and (129) a 6:1 product ratio of (130):(131) was obtained (Scheme 38). 
This is presumably from the hDA reaction of the endo-isomer, thus demonstrating the 
importance of 100% phenolic deprotonation before addition of the enol ether 
(See Scheme 37, 128b for comparison).  
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2.16  Brimble’s Radical Spirocylisation Approach 
 
Scheme 39. Brimble’s radical approach 
During the course of this investigation, there were also a number of reports from the 
aforementioned research groups, working towards a definitive, robust methodology 
suitable for the generation of all of these intriguing natural products and synthetic 
analogues.  The first of these was published in 2011 by Brimble and co-workers, in which 
they demonstrated that spiroketal formation can be facilitated using a photochemically 
initiated oxidative radical cyclisation (Scheme 39).74  Higher yields were generally 
observed for the formation of the 5,5-spiroketals (n = 1; 42-92%) relative to 
5,6-spiroketals (n = 2; 40-73%), which was attributed to intramolecular hydrogen 
abstraction proceeding through an unfavored seven-membered transition state (133, 
Scheme 39, n = 2,), when forming six-membered rings. 
 
2.17  Li and Xue’s Dual Pd(II)/Cu(II)-Catalyzed Spiroketalisation 
 
Scheme 40. Li and Xue’s Wacker spiroketalisation 
Shortly afterwards Li and Xue also published an adaptation of their previous 
gold-catalysed spiroketalisation of alkynes (Scheme 14), this process however 
differed in that spiroketalisation was promoted via a Pd(II)/Cu(II)-catalyzed 
chemoselective tandem aerobic cyclisation from phenolic olefins (Scheme 40). 75 
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Scheme 41. Proposed mechanism for tandem Wacker cyclisation and conjugate addition 
They propose that this transformation is achieved via palladium mediated 5-endo-trig ring 
closure to afford the initial benzofuran (based on isolation of the minor product), which 
then subsequently undergoes palladium promoted 6-exo-trig ring closure to give the 
desired motif upon protonation/extrusion of the palladium species (Scheme 41). The 
Wacker Cu(II) to Cu(I) redox cycle then re-oxidises the Pd(0) species back to Pd(II).  The 
reaction conditions allowed for spiroketal formation in reasonable isolated yields 
(36 to 71%), with more electron rich aromatics giving rise to higher yields, attributed to 
increased nucleophilicity of the phenols. 
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2.18  Li and Xue’s Fluoride Promoted 6-exo-trig Spirocyclisation 
 
Scheme 42.  Li and Xue’s spiroketalization conditions  
The following year, Li and Xue also reported a 6-exo-trig spirocyclisation approach that 
occurs via an apparent dual fluoride/hypoiodite promoted pathway (Scheme 42).76  There 
hypothesis was to generate a hypoiodite reagent in situ from mCPBA and TBAI to 
activate the benzofuranone enol tautomer (140) towards an unusual SN1 spiroketalisation.  
After screening the reaction conditions for additives to increase phenolic nucleophilicity it 
was observed that TBAF (2.0 equiv.) provides a remarkable increase in isolated yields (42 
to 89%; R and R’ = H; n =1).  From control experiments it is proposed that the fluoride 
component enhances nucleophilicity, via a proposed H-bonding interaction (141).  The 
iodide then eliminates to give an oxonium ion (142), which undergoes contemporaneous 
intramolecular nucleophilic attack, ultimately forming the spiroketal (Scheme 43). The 
reaction was reported to synthesise [5,5],[5,6] and [5,7]-motifs. 
 
 
Scheme 43. Proposed catalytic cycle 
  
49 
 
2.19  Li and Xue’s hetero-Diels-Alder Approach 
 
Scheme 44a. Xue’s copper catalysed cycloaddition cascade  
Later that year, Li and Xue also published a diastereoselective cycloaddition route to 
these moieties via a unique cascade process (Scheme 44a).77  This strategy revolves 
around the ability to convert an ortho-propenyl phenol into an exo-cyclic enol ether via a 
copper catalysed 5-exo-dig cyclisation and simultaneously form an o-QM thermally in 
one pot.  These reactive intermediates then combine via a hDA reaction with remarkable 
diastereoselectivitity.  This selectivity appears to arise from a proposed transition state 
involving a hydrogen-bonding interaction between 3’-hydroxy group and the carbonyl of 
the o-QM (Scheme 44b).  The scope of this reaction was also very good, tolerating a 
range of electron withdrawing and donating groups in generally good yields (62-90%) 
and excellent diastereoselectivities (>20:1). 
 
Scheme 44b. Proposed reaction mechanism 
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3.1 Introduction 
When it comes to Nature’s molecular architecture, the secondary metabolites with their 
eclectic myriad of designs, have perhaps been the most admired and sought-after targets 
for synthetic chemists.78  Although structural beauty and novelty are important reasons to 
synthesise natural products, biological activity is often the key driving force behind these 
projects.  This is of particularly importance for biologically active compounds that can 
only be isolated in minute quantities.  An ideal strategy in this field would be convergent, 
employ mild conditions and minimal use of cumbersome and atom inefficient protecting 
group chemistry. 
As the rubromycins have both structurally and biologically intriguing properties, it is of 
little surprise that a number of research groups have endeavoured to synthesize them in 
recent years.79 Although the five strategies outlined in chapter two had been reported at 
the start of this investigation, there was still very little known in terms of their robustness.  
This chapter will therefore outline the collective synthetic efforts from these research 
teams in applying their methodologies, to the synthetic challenge of the rubromycins and 
their analogues.  Again this chapter shall be divided into reports published before the 
outset of this investigation (Chapter 3a), and those reported during this study (Chapter 
3b). 
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3.2 Danishefsky’s Total Syntheses of Heliquinomycin Aglycone 
Scheme 45. Danishefsky’s failed spirocylisation 
In 2001 Danishefsky and co-workers reported the total synthesis of the helquinomycin 
aglycone (heliquinomycinone) (10).80  Building on their diastereoselective model system 
(Scheme 12), naphthofuran (146) was prepared as they envisaged that upon treatment 
with NBS, diastereoselective intramolecular cyclization could be achieved in the same 
fashion (Scheme 45).  Unfortunately, due to the electron-rich nature of the 
pentamethoxy-naphthalene ring, (147) could not be generated using NBS, or upon 
subjection of the material to a variety of other halogenating, epoxidising and bond-
activating metal-based reagents. 
 
Scheme 46. Danishefsky’s serendipidous generation of spirocylisation precursor (151) 
Successful oxidation of the targeted furan was however achieved using osmium tetroxide 
(Scheme 46) without compromising structural integrity, giving rise to a 1:1 mixture of 
inseperable diastereomers (149).  Serendipitous exposure of the benzylated 
diastereomeric products (150) to air in the presence of triethylamine/methanol (the author 
presumes during chromatography) lead to selective oxidation of the hydroxyl group on 
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the furan moiety.  Removal of the benzyl ether was subsequently achieved by 
hydrogenolysis to furnish the modified anomeric cyclisation precursor (151).   
 
Scheme 47. Danishefsky’s Mistunobu spirocylisation 
The desired cyclization could then finally be achieved under optimised Mitsunubu 
conditions (Scheme 47),81 affording a 1.2:1 mixture of spiroketals (152) and (153) (after 
desilylation) that could be separated cleanly.   
 
Scheme 48. Danishefsky’s completion of heliquinomycinone (11) 
Ketone (152) was then stereoselectively reduced using tetramethylammonium 
triacetoxyborohydride before subsequent treatment with BF·OEt2 promoted inversion of 
the dihydrofuranyl alcohol, required to furnish the correct stereochemistry of 
heliquinomycin-[5,6]-spiroketal core (Scheme 48).  The napthyl aglycone precursor (154) 
was then selectively oxidised to the desired methylated precursor (155) upon treatment 
with CAN.  The unnatural rubromycin analogue heliquinomycinone (11) was then 
furnished via regiospecific demethylation of the aryl-methoxy substituents of (155) using 
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the comparatively mild BBr3·Me2S complex at −78 οC in 52% yield.  Unfortunately, after 
several attempts this material could not be glycosyloated with a cymarose moiety to give 
the desired natural product (10). 
3.3 Reißig’s Cyclisation Approach 
 
Scheme 49. Generation of Reißig’s advanced model 
Building on their previous findings (Section 2.6) Reißig and co-workers subsequently 
demonstrated in 2006 that their methodology could tolerate functionalised napthzarin 
precursor (156) in an advanced model study to generate spiroketalisation precursor (159) 
Exposure of (159) to spiroketalisation conditions afforded a clean mixture of hydroxyl 
(160) and alkoxy (161) spiroketalsc as single diastereomers (Scheme 49).43  
 
Scheme 50. Reißig’s synthesis of dimethylated 3’-hydroxy-β-rubromycin (163) 
Surprisingly when advanced intermediate (162) was exposed to the identical conditions, a 
complex product mixture was produced, leading to isolation of the trans-dimethylated 
                                                 
c Generated from solvolytic displacement of the benzylic alcohol 
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3’-hydroxy-β-rubromycin (163) in markedly reduced yields (7%) (Scheme 50).82  Due to 
this markedly reduced level of product formation, it appears that electronic complications 
of the electron-rich naphthalene and the electron-deficient isocoumarin moieties are 
detrimental to rubromycin synthesis via an intramolecular cyclisation pathway. Reißig 
and co-workers hypothesised that electronically well-balanced aromatics would therefore 
be required to facilitate a successful Brønsted-acid promoted spiroketalisation. 
 
3.4 Kozlowski’s Attempted Synthesis of Pupuromycin 
 
Scheme 51. Kozlowski’s synthesis of advanced spirocyclization precursor (166) 
Also in 2006, Kozkolwski and co-workers demonstrated that their elegant [3+2]-
cyloaddition procedure (see section 2.5) could be employed to generate the desired 
pupuromycin spirocyclization precursor (166) in a relatively convergent manner (3 steps 
from naphthalene (164) and isocoumarin (165) precursors), (Scheme 51).  
 
 
Scheme 52. Kozlowski’s failed acid mediated spiroketalization 
Similar to Reißig’s findings, a Brønsted acid-promoted spiroketalisation reaction could 
not be achieved (Scheme 52).  To try and develop a more precise understanding of this 
chemistry they carried out a combinatorial screening study of isoxazoline spirocylisation 
precursors using conditions from their model study (Table 6). 
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Entry Isoxazoline Product Yield (%)
1 
 
  
72 
2 66 
3 
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Table 7.  Kozolwski’s combinatorial screening results 
 
Their results (Table 7) suggest that the nucleopilicity of the isocoumarin alcohol can be a 
critical hinderance to the desired approach (Scheme 53, Pathway A).  This appears to be 
due to the inductive effects of the two carbonyl substituents of the isocoumarin 
diminishing this phenolic nucleophilicity, such that the irreversible formation of the stable 
aromatic furan becomes the dominant pathway (Pathway B).  
 
Scheme 53. Electronic effects on spirocyclization 
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3.5 Kita Total Synthesis of γ-Rubromycin 
 
Scheme 54. Kita’s Pummerer key spiroketal formation step 
Having demonstrated a convergent methodology to furnish the model pentacyclic ketal 
(81) (Section 2.9), Kita et al. then began efforts towards the synthesis of γ-rubromycin (1) 
in 2007.83  Upon subjection of the advanced isocoumarin (176) and napthalene (175) 
precursors to the Tf2O promoted aromatic Pummerer-type reaction conditions, spiroketal 
product (178) was furnished as expected, in 39% yield (Scheme 54).d   
Subjection of the resultant spiroketal (177) to iPr2NH afforded the naked phenol, followed 
by oxidation using m-CPBA to furnish the pre-requisite sulfoxide reagent (178). 
Treatment with TFAA, promoted a second aromatic Pummerer-type reaction to form an 
ortho-quinone intermediate [analogous to (78) in the mechanism outlined in 
(Scheme 19)]. This in turn, linearly converted to the paraquinone species (179) with 
concomitant removal of the methoxymethyl (MOM) protecting group (Scheme 55). 
 
                                                 
d It should also be noted that based on Reiβig and Kozlowski’s earlier reports, Kita had postponed 
installation of the isocoumarin motif until after formation of the spiroketal. 
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Scheme 55. Kita’s total synthesis of γ-rubromycin (1) 
After MOM reprotection, quinone reduction and methylation the corresponding 
dihydroxyquinone dimethyl ether (181) could be generated before selective MOM 
deprotection and base-catalysed hydrolysis afforded the phenolic carboxylic acid (183) in 
good yield (88% over 2 steps).  [Co-(salen)2] catalysed oxidation of the naptholene 
afforded the desired paraquinone species (184) (84%), which upon subjection to Wong’s 
conditions84 facilitated conversion of the carboxylic acid moiety to the α-keto ester 
intermediate (185) before immediately cyclising to furnish the desired lactone (186). 
Regiospecific BBr3 deprotection of the methoxy substituents afforded the desired 
γ-rubromycin species (1) in <1% overall yield and marked the first reported chemical 
synthesis. 
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3.6  Project Aim 
At the start of this investigation into the rubromycins, the author (like many of the 
aforementioned research groups) was motivated by both the synthetic challenge of 
constructing the rubromycin scaffold, as well as the prospect of synthesising unnatural 
analogues possessing more “drug-like” physiochemical properties, to be employed as 
“tool” compounds for target validation of telomerase in the field of oncology.  
To explore either of these areas, development of a robust synthetic route towards these 
secondary metabolites was clearly of paramount importance.  To accomplish this, our 
approach embraced the philosophy that a synthetic route is of most use when it is 
convergent.85   
As the field of total synthesis is arguably the toughest test for newly developed synthetic 
methodology, this investigation hoped to explore both the strengths and limitations of 
Bray’s hDA methodology62d (Section 2.14) and further develop this chemistry towards 
the syntheses of the rubromycins.  It was anticipated that this procedure would have the 
major advantage, over strategies “A” and “B” (Fig. 5), of generating two C−C bonds in 
modular process.  It was also hoped that milder conditions than those used in strategies 
“C” and “D” (Fig.5) could also be employed, allowing for greater functional group 
tolerance.  
As developing the [4+2] cycloaddition step was the main objective central to these goals, 
γ−rubromycin (1) was chosen as the primary synthetic target, as a number of potentially 
useful late stage functional group modifications had already been described in the prior 
art by Kita (Scheme 55).83  
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3.7 Brimble’s Formal Synthesis of γ-Rubromycin 
 
 
Fig. 12.  Retrosynthetic analysis of isocoumarin precursor 
From the very outset of this investigation it was however very clear that we were not the 
only research group keen to improve on Kita’s procedure towards the rubromycins 
(Section 3.5).86  The first of these reports by Brimble, appeared in the literature almost 
immediately after this projects inception in 2009.  Drawing from the previous hypotheses 
generated by Reißig and Kozlowski that delicate electronic balancing of aromatic units 
should permit Brønsted acid-promoted spiroketalization, Brimble and co-workers, were 
convinced that spirocyclization would be possible only by paying deserved attention to 
the use of an appropriate isocoumarin ring precursor, due to its dual inductive and 
mesomeric properties (Fig. 12).  
 
Fig. 13. Brimble’s key intermediate 
In an attempt to overcome this significant hurdle in the synthesis of pentacyclic 
spiroketals, isocoumarin ring formation was as in Kita’s investigation noticeably 
postponed until after the key spiroketalisation step.  Their hypothesis was that this would 
significantly reduce the electron-withdrawing mesomeric effect of the eastern fragment 
and consequently increase the nucleophilicity of the phenol, thus encouraging the key 
acid-promoted spiroketalisation as previously demonstrated (Section 2.4) to give the key 
intermediate [5,6]-bis-benzannulated spiroketal (187) (Fig. 13). 
Having synthesised key advanced intermediates (188) and (190) Brimble and co-workers 
anticipated utilisation of the Sonogashira-acetylide methodology developed during their 
model study (Scheme 8) would facilitate a suitable spirocyclization precursor.  
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Unfortunately attempts to promote the lithium-mediated process were unsuccessful due to 
the formation of adduct (192) via aldol condensation of the methyl ether enolate (189) 
with aldehyde (188). 
 
Scheme 56. Adduct (192) formation by aldol condensation  
Due to this setback, Brimble consequently adjusted this strategy to avoid the lithium-
mediated process by using the acetylene (193) and iodide species (194) as Sonogashira 
coupling partners (Scheme 57).  The coupling was successful yielding the desired 
tricyclic acetylene (195) in 91% yield.e  Subsequent hydrogenation of the alkyne followed 
by oxidation of the alcohol using 2-iodoxybenzoic acid (IBX) afforded the desired 
spirocylisation precursor (196) in 95% yield (over 2 steps).  Spirocyclization was then 
successfully achieved using the conditions developed during previous model studies 
furnishing the desired 5,6-bis-benzannulated spiroketal (187) in 80% yield.  Kita’s 
advanced intermediate (186) was finally achieved by selective hydrolysis of the aliphatic 
ester to the carboxylic acid thus completing a formal synthesis of γ-rubromycin (1) in 17 
steps (equivalent to 1.4% yield of natural product 1).   
  
                                                 
e Non amine base (Cs2CO3) was used to minimise homo-coupling. 
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Scheme 57.  Brimbles syntheis of Kita’s Advanced intermediate (184) 
 
3.8 Pettus’ Total Synthesis of γ-Rubromycin 
Subsequently in 2010, during our ongoing synthetic efforts towards a modular approach 
to the rubromycins, Pettus and co-workers reported the first successful cycloaddition 
approach based around their previous model studies (section 2.10).  Having successfully 
generated reasonable quantities of both the desired quinone (197) and exo-enol ether 
(198), they demonstrated that these intermediates could indeed be coupled in the presence 
of CAN to give a 1:2 mixture of para- and  ortho-quinones (199) and (200) respectively 
(Scheme 58).   
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Scheme 58. Pettus [3+2] key cycloaddition step 
Fortuitously, deprotection and concomitant tautomerization of both individual isomers 
with BBr3 converged to the desired title compound (Scheme 59) in a total yield of 31.1% 
(over two steps) via a similar rearrangement described previously by Kita (Scheme 18), 
thus furnishing the title compound in 4.4% overall yield. 
 
 
Scheme 59. Pettus’ BBr3 promoted quinone tautomerization to γ-rubromycin (1) 
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3.9 Li and Xue’s Formal Synthesis of γ-Rubromycin 
 
Scheme 60. Xue and Li’s fragment γ-rubromycin coupling reactions 
In 2012, Li and Xue also managed to achieve a formal synthesis of γ-rubromycin (1) via 
their aforementioned fluoride promoted 6-exo-trig spirocyclisation approach 
(section 2.18).  This procedure was however less elegant than Pettus’ approach due to a 
lack of convergence, requiring five steps post fragment coupling to generate (187).  A 
further drawback was the rather protracted synthesis of the pre-requisite napthofuran 
ketone (201) or napthofuran (202) species. Union of the fragments could then be achieved 
via aldol condensation to furnish the key cyclisation precursor (203) (Scheme 60).   
 
 
Scheme 61. Xue and Li’s possible fragment coupling reactions 
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Subsequent hydrogenation and phenolic deprotection furnished naked phenol (204), 
before treatment with m-CPBA, TBAF and TBAI promoted the desired hypoiodide  
species facilitating spiroketalization in an impressive 88% yield at room temperature 
(Scheme 61).  The napthofuran ketone was then removed selectively in a stepwise 
reduction using NaBH4, then Et3SiH/TFA to afford Brimble’s key intermediate (187), 
thus completing a formal synthesis of γ-rubromycin (1) in a yield equivalent to 0.9-1.2% 
for (1)f.   
 
3.10 Li and Xue’s Total Synthesis of δ-Rubromycin 
 
Scheme 62. Xue and Li’s δ-rubromycin fragment coupling reactions 
Shortly afterwards, Li and Xue also successfully synthesised δ-rubromycin using a 
modified version of a transition-metal-catalysed cascade spiroketalization (Section 2.7).  
Advanced model alkyne was generated via a Sonogashira coupling between (206) and 
(207), before blanket EOM-deprotection furnished the prerequisite diol (209) (69% over 2 
steps).  However upon subjection of the intermediate, to the previously optimised 
conditions (Scheme 14) benzofuran formation was exclusively observed (95%) (Scheme 
62), which could only be further cyclised to the spiroketal in trace amounts upon 
treatment with AuCl, K2CO3 and CH3CN at 70 οC for 24 h.  
                                                 
f Yield calculated for (1) using literature yields for the final steps.  
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Scheme 63. Xue and Li’s transition metal catalysed spiroketalization, towards δ-rubromycin  
 
With the aim of circumventing benzofuran formation prior to nucleophilic attack of the 
isocoumarin phenolic oxygen atom, Xue and Li repeated the Sonogashira coupling with 
the unprotected phenol (211).  When the corresponding alkyne product (212) was exposed 
to a catalytic amount of AuCl and K2CO3, benzopyran (213) was generated in excellent 
yield (90%).  Exposure to AgOTf afforded the desired spiroketal (214) via a transition-
metal-catalysed spiroketalisation in 87% yield.  Although one, could envisage completion 
of δ−rubromycin from the resultant product via Kita’s protocol (Section 3.5, Scheme 55), 
attempts were then made towards a fully convergent approach using the fully elaborated 
isocoumarin. 
 
Unfortunately, upon repeating the Sonogashira coupling reaction with a fully elaborated 
isocoumarin a mixture of alkyne (218) and pyran (217) were observed. Interestingly the 
alkyne could not be cyclised using AuCl/K2CO3 as described previously (Scheme 64).  
However upon subjection of the alkyne to [PdCl2(PPh3)2], the pyran could be generated in 
89% yield. 
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Scheme 64. Xue and Li’s palladium catalysed Sonagashira/pyran formation procedure 
Subsequent removal of the MOM ether revealed the naked phenol, which underwent 
concomitant spiroketalization via a 5-endo-trig ring closure to furnish the desired 
spiroketal (219). Gratifyingly upon treatment of the resultant spiroketal with BBr3 
regioselective demethylation could be achieved to furnish δ-rubromycin (5) in an 
impressive 8.7% overall yield (Scheme 65). 
 
 
Scheme 65. Xue and Li’s synthesis of δ-rubromycin (5) 
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Chapter 4: 
Results & Discussion 
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4.1 - Retrosynthetic Analysis 
 
Fig. 14. Retrosynthetic analysis of key intermediate (220) 
Retrosynthetic disconnection of two carbon-carbon bonds of γ-rubromycin (1), proposed 
for a [4+2] cycloaddition reaction affords exo-enol ether (221) and o-QM (222).  It was 
therefore anticipated that if the mild inverse electron-demand hDA conditions could 
tolerate the electronics of these moieties, then an convergent synthesis amenable to 
analogue development may be possible.   
It was however, clear from the outset that due to the formation of the spiroketal at a very 
late stage, this strategy was to carry a certain degree of risk.  An additional concern for 
this strategy was that a [4+2] cycloaddition, had never, to the author’s knowledge, been 
achieved with such an electron-deficient o-QM. 
Fortunately, due to the great volume of work previously undertaken in this key research 
area, several routes to various isocoumarin and napthazarin subunits of the rubromycin 
family had been previously reported (see Section 3).  This information was extremely 
valuable as an efficient and reproducible route to these subunits was thought to be an 
essential requirement for this strategy to be effective. 
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Napthazarin 
Synthesis 
 
“Architecture starts when you carefully put two bricks together. There it begins” 
 
Ludwig “Mies” van der Rohe (1886 –1969),  
German Architect  
 
  
73 
 
4.2 Danishefsky’s Napthazarin Synthesis 
As the benzofuran moiety, is also a fundamental pre-requisite in the 6-exo-trig 
spirocyclisation approach, Danishefsky’s synthethesis of heliquinomycinone (Section 
3.2) offered by far the most suitable shortcut to the carbon skeleton of the 2π partner 
(221).  This approach is based around a modification of Perry’s strategy towards the 
synthesis of 2-ethylfuranapthoquinones.45,80,87   
In addition to the strong homology with the anticipated 2π hDA component (221), the 
synthesis of this moiety was also reportedly achieved in a very  respectable overall yield 
of 30%, with reasonable accessibility from commercially available bromo-veratraldehyde 
(224) making it a logical starting point (Scheme 66).  
OMe
BrMeO
OH
OMe
BrMeO
OMe
OMe
CNMeO
OMe
OMe
MeO
OMe
O
OMe
MeO
OMe
HO2C
O
O
OMe
MeO
OMe
O
OMe
OOOMe
OMe
BrMeO
O
a, b c d
e
f
(224) (225) (226) (227)
(228)(229)(230)
g
a. mCPBA, H2O/CH2Cl2, , 16 h; b. MeOH, conc. HCl, r.t. 30 min, (70% over 2 steps);
c. Acetone, K2CO3, Dimethylsulfate, r.t. 12 h, (93%); d. DMF, Cu(I)CN, , 16 h (98%);
e. 3-furoic acid, THF, n-BuLi, 78 C, 2 h, then (227) (92%); f. H2SO4, 3 days, (88%);
g. Na2S2O4, TBAB, KOH, dimethylsulfate, THF/H2O (50%)  
Scheme 66. Danishefsky’synthesis of the napthazaring 
In this strategy, key nitrile88 (227) was provided using Rizzacasa’s synthesis, from 
benzaldehyde (224) via Daykin oxidation, followed by methylation of the resultant 
phenol using Me2SO4 to give trimethoxy-protected aryl bromide (226).  This was 
ultimately converted to (227) using the Rosenmund-van Baun cyanation in 65% yield 
over three steps.  Subsequent nucleophilic addition of the dianion of 3-furoic acid to 
                                                 
g Yields quoted in brackets represent reported literature values. 
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nitrile88 followed by aqueous work-up afforded furoic acid (228), which when subjected 
to strong acidic conditions underwent an intramolecular Friedel Crafts type cyclisation to 
afford7 quinone (229).  This was subsequently reduced and methylated in a one pot 
procedure to furnish the desired napthofuran (230) as a pale yellow solid. 
 
 
Entry Oxidant Solvent Temp (οC) 
Yield (%) 
R = CHO 
(224)
R = OH 
(225) 
R = CO2H 
(224a)
1 mCPBA (1.49 equiv) CH2Cl2 40 76-99 0-19 0 
2 mCPBA (1.49 equiv) CHCl3 62 66-88 5-34 0 
3 H2O2 (20 equiv.) 1 M NaOH 100 95 3 0 
4 H2O2 (20 equiv.) 5 M NaOH 100 86 12 0 
5 MMPP (1.0 equiv) 89 MeOH rt 0 0 99.5 
6 mCPBA
i. 
(1.49 equiv) CHCl3 62 5-19 65-88 0 
i. Commercial bromovetraldehyde (225) further purified by silica gel chromatography prior to use 
Table 8. Optimisation of the Dakin reaction 
In the author’s hands the first step, the Baeyer-Villiger reaction initially proved low-
yielding and unreliable (entries 1 and 2; Table 8) relative to literature reports (70-
82%).90,91  Clearly this was undesirable for the initial step of a natural product synthesis, 
therefore an short optimisation study was carried out using common, readily available 
per-acids.  Upon purification of the reaction mixtures by silica gel chromatography of the 
crude reaction mixtures the author was surprised to observe that the recovered starting 
material was isolated as a “brilliant white” solid rather than luminous canary yellow as 
supplied.  The origin of this extreme colour was not detectable by 1H NMR or GC/MS nor 
was there any available data from known contaminants listed by the supplier.  Even more 
surprising was that subjection of “brilliant white” aldehyde (224) to the original reaction 
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conditions, yields increased up to and in excess of those reported in the literature on a 
4.5 g scale (entry 6, Table 8).   
 
Scheme 67. Scale-up of key nitrile 
Thankfully, methylation of the resultant phenol and subsequent SNAr with CuCN in DMF 
proceeded without incident on 9.5 g scale (Scheme 67) to give the nitrile (227) in slightly 
improved yield (97%, over 2 steps).  Unfortunately, further problems were encountered 
with regard to the nucleophilic addition of dianion of 3-furoic acid to nitrile (227).   
OMe
CNMeO
OMe
OMe
MeO
OMe
O
HO2C
O
(227) (228)
OMe
MeO
OMe
O
HO2C
O
(228)
a, c b, c
ai. 3-furoic acid, THF, 78 C; ii. n-BuLi (2.2 equiv.), 78 C, 2 h; iii. (227) 78 C to r.t., 16 h;
bi. 3-furoic acid, THF, 78 C; ii. t-BuLi (2.2 equiv.), 78 C, 2 h; iii. (227) 78 C to r.t., 16 h;
c. 1M HCl, 2 h, r.t.;  
Scheme 68. Nucleophilic addition of dianion of 3-furoic acid to nitrile (227) 
In the author’s hands, the initial reaction conditions delivered no conversion to the 
expected ketone (228).  A small aliquot of the n-BuLi and 3-furoic acid mixture was 
therefore removed under nitrogen and injected directly into CD3OD and the resultant 
mixture was subsequently analysed by 1H NMR.  This experiment indicated that there 
was no detectable deuteration at the 2-position of the furan at −78οC in the author’s 
hands.  This problem was therefore overcome by increasing the strength of the base from 
n-BuLi (pKa ≈ 50) to t-BuLi to (pKa ≈ 55), which after acidic work-up furnished the 
desired carboxylic acid (228) in ca 99% yield. 
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Scheme 69. Completion of Danishefsky’s napthofuran 
Gratifyingly, treatment of the resultant carboxylic acid with neat H2SO4 for 3 days 
facilitated the desired intramolecular Friedel-Crafts cyclisation as described by 
Danishefsky affording quinone (229) in 96 % yield (lit. 88%).3  Upon subjection of the 
quinone (229) to the one pot reduction/methylation conditions we found that our intial 
product recovery to be very poor (5-20%).  However by thouroughly deoxygenating the 
solution with argon for 1 h prior to addition of the Na2S2O4 appeared to help stabilise the 
reactive radical species, furnishing (231) in yields of (40-55%) as a pale yellow solid on a 
100 mg scale, however in the author’s hands these yields could not be achieved on a 
larger scale. 
 
Scheme 70. Reichwagen’s Zn SET quinone reduction. 
Having established that Danishefsky’s route to quinone (229) was reproducible and 
scalable in the author’s hands, the low yields and unpredictable nature of the existing one-
pot quinone reduction/methylation procedure made it rather unattractive.  Upon 
inspection of the literature, the procedure that initially appeared most attractive was the 
seemingly underutilised Reichwagen’s Zn SET quinone reduction (Scheme 70).92 
 
Scheme 71. Attempted Reichwagen’s procedure. 
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Unfortunately in the author’s hands, when this protocol was applied to the more electron-
rich trimethoxy-napthoquinone (229), only unreacted starting material was recovered. No 
reaction could be initiated by heating the ultrasonic bath to 80 οC, activating the Zn with 
acid, thoroughly degassing the solution or any combination of these.   
 
4.3 Alternative Napthazarin Synthesis 
Due to erratic yields in the late stage reduction strategy, combined with the high cost of 
the bromovetraldehyde starting material and alternative shorter and more scalable 
synthesis of a suitable 2π partner was investigated.  Key areas identified for optimisation 
were cost/synthesis of the aryl-nitrile, usefulness of the intermediates in model 
cycloadditions and improving the napthoquinone reduction.  
 
Scheme 72. Kita’s late stage oxidation 
Interestingly, upon re-examination of the literature it was noticed that a late stage 
oxidation of advanced intermediate (183) by Kita had been achieved in 84% yield 
(Scheme 72).  It was therefore anticipated that the commercially available and more 
affordable 3,5-dimethoxybenzonitrile (£917.10 mol−1 vs £6151.26 mol−1)h could be 
employed in a similar approach, thus removing a net 3 synthetic steps, significant material 
costs and the risks involved in handling CuCN in DMF. 
O
O
MeO
OMe
OMeO
OMe
CN
a,b
MeO
OMe
O
O
HO2C
c,d f
MeO
OMe
O
OMe
OMe
a. 3-furoic acid, t-BuLi, 78 C; b. HCl(aq.) (90% over 2 steps); c. (COCl)2, cat. DMF; d. AlCl3, CH2Cl2 (88% over 2 steps);
e. H2SO4, rt, 3 days (86%); fi. NaS2O4 ,TBAF, HF/H2O; ii. KOH/H2O (slurry); iii. Me2SO4 (64%).
(234) (235) (236) (237)
or e
 
Scheme 73. Synthesis of tetramethoxy-napthazarin (237) 
                                                 
h Prices based on 25g and 5g bottles from www.sigmaaldrich.com on 26/01/2014 
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Gratifyingly applyinging Danishefskys’ quinone synthesis protocol to (234) was 
remarkably straightforward and (236) could be generated in 77% over 3 steps (a,b,e 
Scheme 73).  The Friedel-Crafts reaction could also be facilitated in comparible yield by 
derivatising (235) to the corresponding acid chloride before promoting cyclisation upon 
addition of AlCl3 (c,d, Scheme 73).  Subjection of (236) to the afformentioned one pot 
reduction/methylation proceeded in an increased yield (relative to Scheme 69) of 64%, 
presumably due to the decreased electron density of the aromatic moiety. 
4.4 Methylene Installation Strategies 
 
Scheme 74. Retrosynthetic analysis of the 2π component 
Having established two potential napthazarin syntheses, synthetic efforts were then 
directed towards installation of the essential benzofuryl-methylene to generate the key 2π 
component (Scheme 74).  As little work had been conducted into this area, it was difficult 
to asses the ease of this transformation and thus methylene installation was modelled 
using benzofuran (243). 
 
Scheme 75. Proposed methylene installation strategies 
As the 2-position of benzofurans is known to be the most acidic site (pKa = 33.2; THF)93 a 
deprotonation/electrophilic trapping methodology was envisaged.  The most promising 
route selected was based around Molander and co-workers extremely rapid and high 
yielding procedure for the oxidation of organotrifluoroborates using Oxone.94,95  This was 
of particular interest as they were able to convert functionalised benzofuran (243) to 
benzofuranones in 71% overall yield without the requirement of silica gel 
chromatography (Scheme 76).  
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Scheme 76. Molander’s oxidative lactone formation 
The reaction conditions reported also appeared to tolerate aryl methyl ethers when used to 
convert aryltrifluoroborates to phenols (Scheme 77).  This was reported to occur without 
any side reactions and thus presented itself to be the ideal oxidation protocol to generate 
the fully functionalised benzofuranone. 
 
Scheme 77. Methyl ether functional group tolerance of Molander’s oxidation 
Gratifyingly, the author found Molander’s reports to be very easily reproduced on the first 
attempt, furnishing (242) in 29% overall yield from benzofuran.  With this material in 
hand, the lactone was exposed to the Tebbe reagent, before treatment with aqueous NaOH 
generated a green solution, as described by Grubbs.  Analysis of the solution by 1H NMR 
in 0.1 M NaOD, in D2O indicated 78% conversion to (241) based on integration of the 
methylene signals 3.97 ppm (2H, 78 %, 241): 3.69 ppm  (2H, 22 %, 242) and the presence 
of two new broad CH signals at 4.92-4.81 ppm (1H, 78%) and 4.40-4.26 ppm (1H, 
78%).96  
 
 
Scheme 78. In house synthesis of exo-enol ether (241) 
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Having replicated the protocols of Molander and Grubbs, it was anticipated that this 
olefin installation strategy could be applied to generate either olefin (238) or (239) 
from napthazarin (237) or (230). However as conditions to generate ortho-quinone 
methide (222) had not yet been established, the author believed that it would be 
prudent not to commit samples of (237) or (230) towards this strategy until this 
challenge had been overcome.  It was hoped that this cautious approach would 
maximise the probability of developing practical conditions that would be compatible 
with both the generation and coupling of these two reactive subunits. 
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Isocoumarin 
Synthesis 
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4.5 Isocoumarin Moiety 
Unlike the napthazarin, with one clear starting point, there have been several routes to the 
isocoumarin moieties of the rubromycin family similar to our requirements.  Of these 
methodologies many have been surprisingly lengthy for a planar, bicyclic moiety.  This 
has mostly been due to the various oxidation states within this structure.  At the outset of 
our investigation, there appeared to be a handful of literature preparations amenable to 
synthesis of the 4π component (222).   
4.6 Kozlowski’s Isocoumarin  
 
Scheme 80. Kozlowski's isocoumarin synthesis 
During a large body of work in this field Kozlowki’s reported the most unique 
isocoumarin preparation in 2001, as it is the only method not based around a vanillin-like 
starting material.97  This methodology initially employs high-pressure bis-carboxylation 
of catchecol (247) and the resultant dicarboxylated product subsequently underwent two 
step methylation to afford dimethyl 2,3-dimethoxyterepthalate (248).  As direct 
electrophilic iodination of the electron defiecient arene was not viable, mono-iodination 
was accomplished via a three-step procedure.  This was accomplished via sequential 
nitration of the aromatic, which was subsequently regiospecifically reduced to the 
corresponding aniline, before eventual iodination under Sandmeyer conditions to furnish 
(249) in 86 % yield over 3 steps. 
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Regiospecific saponification of the least hindered methyl ester was achieved using LiOH 
in THF:H2O before chemoselective reduction of the resultant carboxylic acid and 
subsequent protection of the corresponding alcohol as a silyl ether (251).  Once 
sufficiently protected, Heck coupling could be achieved with methyl enol ether (252) 
giving (252) in 21.5% yieldi (over 10 steps), thus setting up for acid-promoted 
intramolecular condensation to afford benzyl alcohol (254) in 17.9% overall yield 
(17.9%). 
While this route appears to have the advantage that conversion of the silyl protected 
carboxylic acid to the corresponding acetyl ester type o-QM precursor, this route is 
however long-winded and requires high pressure apparatus not available to the author.  
The Heck coupling was also later described as “not reproducible” by the same research 
group in 2010,98 citing dehalogenation as a significant problem and was thus discounted 
by the author as a suitable starting point.   
 
4.7 Behar’s Isocoumarin 
 
Scheme 81. Behar’s isocoumarin synthesis 
A more concise isocoumarin synthesis was outlined by the Behar group.99  The main 
advantage of this route is that opianic acid starting material (255) is commercially 
available, allowing a significant reduction in the number of steps towards the isocoumarin 
scaffold.  Unfortunately progress on the isocoumarin moiety (258) initially proved 
problematic due to the author’s inability to reproduce these results (Scheme 81).   
                                                 
iThere was a notable recovery of (251) (23%) for this step. 
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They reported a route to condensate (256), using what would appear a rather facile 
reaction, proceeding simply by deprotonation of opianic acid using NaH at 23 oC, 
followed by nucleophilic addition to diethyl bromomalonate, before intramolecular 
cyclisation.  However in the author’s hands, it was not possible to isolate the 
corresponding cyclised condensate (256) but it is believed based upon 1H NMR evidence 
(shift in malonate 1H signal from 4.83 to 5.81 ppm indicative of a deshielding effect) that 
an open-chain form (259) was the major product generated. 
 
Fig. 15. Proposed open-chain form of the condensate 
The reaction was extensively screened against a variety of temperatures (−78 οC to 130 
οC), bases (NaH, K2CO3, Na2CO3, DBU, Et3N) and solvents (THF, DMPU, DMF, Et3N,) 
however the desired cyclic species could not be generated efficiently via this method.  
Unfortunately this species could not be cyclized thermally and/or upon subjection to acid 
(various mixtures of H2SO4, HCl, AcOH, H2O, PTSA, NH4Cl).   
 
 
Fig. 16. Behar’s 1H NMR assignments 
Upon further scrutiny of Behar’s experimental procedure it was noticed that the 1H NMR 
dataj generated for the intermediates (256) and (257) did not appear to correspond to the 
structures proposed (Fig. 16) casting further doubt in the author’s mind, regarding the 
synthetic utility of this protocol.  
                                                 
j No spectra available in Behar’s publication for comparison 
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Scheme 82. Anticipated metal coumarinate formation 
Metal alkoxide or hydroxide type base cyclisation of the condensate was considered, 
however this was not attempted due the known instability of isocoumarin lactones 
towards ring opening to form metal coumarinates in the presence of dilute hydroxide 
(Scheme 82), which can be difficult to eliminate entirely from alkoxide reagents, even 
when freshly prepared.100  
 
4.8  Chatterjea’s Isocoumarin 
 
Scheme 83. Chatterjea’s synthesis of the isocoumarin moiety 
When delving deeper into the Behar groups report, it was found that the carboxylic acid 
(257) had been synthesised in 1965 by Chatterjea et al.101 using conditions outlined above 
(Scheme 83).  In the author’s hand’s formation of (257) initially proved elusive after 
several attempts.  This initial failure to replicate these results was attributed to the 
possible presence of trace amounts of NaOH in solution (caused by trace amounts of 
water in equilibrium with Na2CO3) causing a ring opening effect as described previously 
(Scheme 82).  This problem was overcome partially by thorough distillation and 
purification of the reagents, in combination with addition of activated molecular 3Å 
sieves to the reaction mixture, facilitating product formation but in erratic yields 
(10 to 65%).  
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Scheme 84. Revised synthesis of the isocoumarin moiety 
Gratifyingly, the methyl ester could also be synthesised in an excellent yield (97%) by 
performing a Fisher-Speir esterification, refluxing the carboxylic acid in methanol in the 
presence of catalytic sulphuric acid. It was also found that this transformation could also 
be accomplished upon treatment of carboxylic acid (257) with 
diazo(trimethylsilyl)methane afforded the corresponding methylester (258) cleanly and in 
excellent yield (99%).   
 
Fig. 17.1H NMR data for Chattejea’s methlyated isocoumarin (250) 
It was however found that the literature 1H NMR data for (258) given in the two known 
preparations (by the Danishefsky and Behar research groups) to be somewhat unusual as 
neither appeared to correspond with our findings (Fig. 17).  The key differences are that 
Danishefsky’s data does not provide evidence to suggest the presence of the styrenyl 1H 
signal (7.37 ppm) and that Behar’s assignment of the aromatic 1H signal as a quartet and 
therefore two chemically equivalent nuclei would appear erroneous to the author.  An X-
ray crystal structure (Fig. 18) for the author’s sample was therefore obtained so as to 
confirm it to be the desired methyl ester (258).   
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Fig. 18. X-Ray crystal structure of methlyated isocoumarin (258) 
 
4.9  Reißig’s Isocoumarin 
 
 
Scheme 85. Reißig’s attempted halogenations 
 
The fourth and ultimately more flexible, and reliable synthetic route explored was that 
reported by Reißig and co-workers, during their synthetic efforts towards the 
rubromycins.102,103  Their initial approach aimed to selectively deprotect (258) with 0.3 
equiv of BBr3 (i.e. 0.9 equiv. of bromide) at −78 οC (pathway ai., Scheme 85).  They had 
then envisaged that allylation of the phenol (261), followed by a Claisen rearrangement to 
permit functionalisation at the 6-position.  Unfortunately for the advancement of this 
methodology it was found by both the Reißig group and in the author’s handsk that the 
8-methoxy group was selectively attacked, presumably due to complexation between the 
Lewis acid and the neighbouring carbonyl functionality (pathway aii., Scheme 85).   
Their second approach to functionalise the 6-position was via bromination with NBS 
(pathway bi., Scheme 85).  Unfortunately for the advancement of this methodology it 
                                                 
k Reaction was repeated due to lack of previous supporting information available 
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was found by both the Reißig group and in the author’s hands that bromination occurred 
exclusively at the 5-position (pathway bii., Scheme 85).  In light of this evidence and in 
the absence of a selective enzymatic operation to facilitate this transformation, they 
developed a novel concise method more amenable to encompassing chemical diversity 
(Scheme 86).   
 
Scheme 86. Reißig revised synthesis of the isocoumarin moiety 
This was accomplished by ortho-lithiation of protected vanillin derivative (266) before 
treating with excess methyl chloroformate, prior to one-pot double deprotection using KF 
under acidic, aqueous conditions to furnish esterified vanillin (267) in 46% yield over 5 
steps.  Regiospecific iodination was then achieved using the slightly unusual 
tetramethylammonium dichloroiodate reagent as a extremely mild and synthetically 
useful source of electrophilic iodine.  The resultant halobenzaldehyde (268) was then 
olefinated using a Horner-Wadsworth-Emmons reaction using methyl 
(dimethylphosphono)methoxyacetate (269)l affording (270).  Cyclisation was 
subsequently achieved via Brønstead acid-promoted lactone formation in a mixture of 
refluxing aqueous HBr and methanol, furnishing the desired iodoisocoumarin (271) as a 
precipitate in 19-23% yield over 8 steps.   
  
                                                 
l Literature appears to indicate phosphonate production to be the limiting scalability factor. 
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Scheme 87. Envisaged fuctionalisation of Reßigs iodo-isocoumarin (271) 
Despite the increased number of synthetic steps, this route therefore appeared to offer 
significant advantages over those previously outlined, with regard to a scalable and 
effective rubromycin synthesis.  Firstly, vanillin (265) is a significantly more economical 
starting material (£7.02 mol-1)m than the more specialist opianic acid (255) reagent 
(£2240.63 mol-1).n  Secondly, the iodinated product (271) has greater homology with the 
required o-QM precursor (272), as the desired and synthetically difficult 7-hydroxy-8-
methoxy oxidation pattern (Scheme 87) is already ‘pre-installed’ in the starting material 
(265), which is also available in bulk quantities.   
 
Scheme 88. Scale-up of acetal synthesis 
This route was explored to assess its reproducibility, scalability ease of use and scope for 
derivatisation.  Initial results (Scheme 88) were very promising, in the author’s hands 
Reißig’s route to (266) was found to be a high yielding (96-98% observed, 97% reported) 
and highly scalable (carried out on 1 to 50 g scale, 7.56 g reported).  The acetal 
protection, again proved to be very effective and scalable (from 926 mg reported to 80 g 
in 91% overall yield).o  The 3-step conversion of (266) to the corresponding ester (267) 
also proved to be highly reproducible in the author’s hands.  However the undesirable 
yields reported (58%) and observed (55-60%) in the author’s hand appears to be the result 
                                                 
m Price based upon 2kg bottle from www.sigmaaldrich.com on 03/07/2010 
n Price based upon 5g bottle from www.alfa.com on 03/07/2010 
o Dry loading sample onto SiO2 must be done below 30 οC to afford degradation. 
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of poor conversion (ca 55-63% calculated by 1H NMR of the crude reaction mixture) to 
the corresponding TBS/acetal protected methyl ester (266c) rather than the harsh 
deprotection conditions as one may have anticipated.  It was therefore proposed that poor 
lithiation of (266) may be limiting product formation. 
 
Entry RLi Equiv. Solvent Conditions Yield 
1 n-BuLi, TMEDA 2.3 Et2O 0 oC, 2 h 16% 
2 n-BuLi, 1.2 C6H12 r.t., 3 h 40% 
3 n-BuLi, 3.0 C6H12 r.t., 3 h 29% 
4 t-BuLi, 1.2 C6H12 r.t., 3 h 20% 
5 n-BuLi, 1.2 C6H12 0 oC, 5.5 h 56% 
 
Table 9. Reißig’s optimization study 
When looking at previous results (Table 9) by Reißig and co-workers it appears, rather 
unsurprisingly, that lithiation is inversely proportional to temperature over longer reaction 
times.  Interestingly the use of cyclohexane as a non-coordinating solvent appears to 
significantly improve yields relative to Et2O.  The author assumes that as the acetal is 
only weekly ortho-directing that cyclohexane is an ideal solvent to enhance selective 
ortho-lithiation.   
The main drawback of using this solvent however is that it has a melting point of 4-7 oC.  
In an attempt to decrease the freezing point of the solvent, without making the reaction 
mixture more polar, a reverse addition protocol (ie adding the arene to a solution of pre-
cooled n-BuLi in hexanes/C6H10) was investigated (Table 10).  It was found that using 
this protocol, maintaining the external cooling bath at −1 οC was the lowest temperature 
the reaction mixture would stir easily and would not be succeptible to freezing due to the 
standard error in the cooling unit apparatus.  This temperature could however be 
decreased to −6 οC after addition of (266) to the reaction mixture. 
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Entry Temp (οC) Time (h) n-BuLi (equiv.) Solvent 
Conversion 
(%) 
1 −1 2 1.2 C6H12 56 
2 −1 20 1.2 C6H12 61 
3 −1 20 2.0 C6H12 58 
4 −6i. 10 1.2 C6H12 84 
5 −6i. 20 1.2 C6H12 80 
6 −6i. 20 2.0 C6H12 79 
i. External cooling bath was reduced from −1 to −6 οC after addition of (266) 
Table 10. Deuteration study of (266) 
Interestingly decreasing the temperature to −6  οC facilitated a significant increase in 
lithiation  (entries 2 vs entry 5, Table 10).  It also appeared that increasing the amount of 
n-BuLi had little effect on the overall conversion and that leaving the reaction mixture for 
longer than 10 hours had no appreciable effect upon the yield.  These optimised 
conditions for lithiation (entry 4, Table 10) were then applied to (266) using Reiβig’s 
conditions for the electrophilic quench (entry 4, Table 11). Unfortunately, the author was 
surprised to find that the reaction actually occurred in a slightly reduced yield (50% vs 
56%) than described in the literature.  As this electrophilic quench with ClCO2Me was 
achieved in a significantly lower level of conversion to that previously described using 
D2O (entry 4, Table 10), this step required further optimisation.  Thankfully, after a short 
optimisation study, it was found that increasing the amount of ClCO2Me and maintaining 
the reaction temperature at 10 οC, yields could be improved to 72% overall (entry 7, 
Table 11). 
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Entry Temp (οC) Time (h) i. ClCO2Me (equiv.) Solvent 
Conversion 
(%) 
1 −6 24 1.94 C6H12 36 
2 −6  to 0 24 1.94 C6H12 48 
3 −6 to 10 24 1.94 C6H12 56 
4 −6 to 25 24 1.94 C6H12 50 
5 −6 to 10 24 1.0 C6H12 32 
6 −6 to 10 24 2.0 C6H12 57 
7 −6 to 10 24 3.0 C6H12 72 
8 −6 to 10 24 4.0 C6H12 64 
i. Reaction mixture was allowed to warm passively from −6 οC to the defined reaction temperature 
(over ca 30 min) and held at the that temperature for the time stated below. 
Table 11. Esterification of (257) 
 
Scheme 89. Synthesis of Iodophenol (259) 
The author was pleased to find that dual deprotection proceded as described (Scheme 89), 
however yields initially appeared variable (45-50%) between reactions, however with 
close monitoring of the reaction by TLC analysis, yields were increased and more 
consistent (65-70%).  The author was also pleased to observe that iodination to (268) 
could be carried out quantitatively, without any side reaction at the C-5 positions upon 
using an excess of Me4NICl2 . 
 
Scheme 90. Synthesis of phosphonate (266) 
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Synthesis of phosphonate (269) also proceed without incident on 20 g scale.p This was 
achieved by radical bromination of methyl methoxyacetate (273) to give the 
corresponding bromide (274).  This was then purified by distillation under reduced 
pressure before dropwise addition of trimethyl phosphite to the resultant oil.  After 
heating the mixture for 16 h, phosphonate was then purified via distillation under reduced 
pressure to give phosphonate (269) in 75% yield over 2 steps. 
 
Scheme 91. Horner-Wadsworth-Emmons olefination of Iodophenol (270) 
Upon close inspection of the described Horner-Wadsworth-Emmons olefination 
procedure towards iodostyrene (270) it was of slight surprise to the author that only 2.0 
equiv. of NaHMDS was added to the reaction mixture to deprotonate both phenol (268; 
1.0 equiv.) and phosphonate (269; 1.22 equiv.).  The author wondered, if a slight excess 
(2.4 equiv.) of NaHMDS was added to ensure quantitative deprotonation perhaps 
olefination could be carried out quantitatively (Scheme 91).  Unfortunately, this only 
facilitated a marginal increase in yield (86% vs 82%).q 
 
Scheme 92. Proposed chemioselective deprotection of acetal (266c) 
It was therefore hypothesized that if chemoselective deprotection of the acetal 
(Scheme 92) was carried out prior to olefination, perhaps this transformation could be 
                                                 
p Due to the extremely exothermic nature of this reaction, this reaction could not safely be carried out 
on a larger scale. 
q When the analogous Wittig olefination was attempted the reaction afforded a complex mixture of 
products and therefore was discarded as a viable alternative. 
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achieved quantitatively.  To assses this phenol (267) was converted to the novel silyl ether 
(275) and subjected to previous olefination conditions (Scheme 93).   
 
Scheme 93. Horner-Wadsworth-Emmons olefination of (276) 
The author was pleased to find that olefination could be achieved to furnish the novel 
olefin (276) in 96.2% overall yield upon removal of the acidic phenolic proton from 
the reaction.  The (E:Z) ratio was also more favourable (1:5 vs 7:13) than Reißig’s 
protocol for isocoumarin formation.  It was therefore deamed worthwhile to 
investigate a selective acetal deprotection approach.  Towards this goal, all relevant 
cyclic acetal deprotection reactions outlined in “Protective Groups in Organic 
Synthesis, Third Edition”104 in addition to treatment of (266c) with a range of 
Brønsted–acids on a 25 mg scale, but unfortunately selective protection could not be 
achieved.  Interestingly, during this screening, the author was rather surprised to 
discover a novel procedure for the chemoselective deptotection of the phenolic silyl 
ether.  This was achieved upon heating a solution of (266c) in DMSO/H2O to reflux to 
give the novel phenol (266a) in 99.1% isolated yield (Scheme 94).105 
 
Scheme 94. Chemioselective phenolic deprotection of silyl ether (266c) 
Upon re-examination of the literature it appeared that since the publication of this 
textbook, there was a report in 2002 by Mohan and co-workers that Bi(OTf)3.3H2O can be 
used as a mild reagent towards the deprotection of acetals in THF/H2O.106  A second 
screening was therefore carried out using all the available metal triflates, present in the 
laboratory.   
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Entry Lewis Acid Conversion (%) Yield (%) 
1 Y(OTf)3 0 0 
2 Sc(OTf)3 0 0 
3 In(OTf)3 0 0 
4 Zn(OTf)2 0 0 
5 TMSOTf 85 78 
6 Sn(OTf)2 74 65 
Table 12. Development of a selective deprotection protocol 
Gratifyingly, both TMSOTf and Sn(OTf)2 were found to facilitate the desired acetal 
hydrolysis, while leaving the silyl ether relatively untouched [less than 2-3% hydrolysis in 
both instances (entries 5 and 6, Table 12)]. 
 
Scheme 95. Selective deprotection of the acetal 
After further optimisation of the reaction conditions it was found that the reaction could 
essentially be conducted in a manner analogous to a titration (Scheme 95).  A slight 
excess of TMSOTf (1.05 equiv.) was added to a solution of the acetal in anhydrous THF 
at −5 οC, water (10-13 equiv.) was then added dropwise over 90 min until TLC analysis 
indicates consumption of the starting material.  The reaction was robust and reliable 
enough to be carried out on multi-gram scale in excellent isolated yields (92%)r and the 
material isolated was identical to that synthesized via TBS protection of (267) 
(Scheme 93). 
                                                 
r Without careful monitoring of the reaction by TLC analysis, yields were reduced due to the formation 
of (258) 
  
96 
 
 
Scheme 96 – Deprotection and iodination of of (276) 
Gratifyingly, removal of the silyl ether and subsequent iodination could be achieved in 
excellent overall yield (97 % over 2 steps).  This procedure was also interesting as it 
allowed us to explore the synthetic utility of (270) and the novel intermediate (277).  Said 
intermediates were then exposed to Brønstead-acid promoted lactonisation conditions 
(Table 13) used previously by the groups of Reißig103 (entries 1 and 4), Danishefsky45,80 
(entries 2 and 5) and Kozlowski98 (entries 3 and 6) during their total synthesis 
investigations (Section 3a).  In the author’s hands, Danishefsky’s approach (entry 5, 
Table 13) was found to be preferencial for the synthesis of Reißig’s isocoumarin (271) 
and that Kozlowski’s procedure (entry 2, Table 13) appears to to be most favourable for 
the synthesis of the novel isocoumarin (278). 
 
 
Entry R = Acid Solvent Yield (%) 
1 H HBr (47% aq.) MeOH 64 
2 H H2SO4 (3N) MeOH 85 
3 H PTSA PhMe 94 
4 I HBr (47% aq.) MeOH 68 
5 I H2SO4 (3N) MeOH 83 
6 I PTSA PhMe 75 
Table 13. Summary of isocoumarin formation 
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4.10 Acetate Installation Strategies 
 
Scheme 97. Overview of acetate installation approaches 
With meaningful quantities of various isocoumarins and isocoumarin precursors in hand, 
the next key step was how to install an acetate functional group ortho to the phenol.  Due 
to an entirely different ‘endgame’ to previous strategies a great deal of modification was 
necessary to install the acetyl leaving group on the methylene carbon ortho to the phenol.  
The three general strategies towards this installation considered were; transition metal 
catalysed cross-coupling with an acyl-containing organometallic or equivalent synthon 
(pathway a, Scheme 91), direct formylation (pathway b), and Claisen rearrangement 
twinned with periodate cleavage (pathway c).s 
  
                                                 
s In the interest of completeness, lithium-halogen exchange followed by an electrophilic quench with 
DMF was also  attempted, however it was found that methyl ester cleavage ensued even at reaction 
times of less than 10 seconds at −78 οC. 
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4.11 Claisen Strategy 
Scheme 98. Danishefsky’s periodate cleavage 
Due to previous observations by Danishefsky and co-workers (Scheme 98), it appears 
that allylated isocoumarins undergo sequential periodate cleavage to give benzaldehydes 
and not acetaldehyde products as one might expect.  Although there were no reported 
conditions or yieldt for this transformation, we anticipated that if successful this would 
provide a very straightforward route to benzaldehyde (282).  It was anticipated that said 
ortho-formylated phenol could subsequently be reduced and acetylated to give the desired 
o-QM precursor (272). 
 
Scheme 99. Attempted Claisen approach to salicaldehyde 
Allylation of (271) could be achieved using allyl bromide and Hünigs base in DMF at 
80 °C (Scheme 99) and subsequent Claisen rearrangement could be carried out at 210 °C 
under microwave irradiation in PhCl to gave the allyl isocoumarin (279) in 90% overall 
yield.  Unfortunately, the attempted one-pot periodate cleavage of (279) gave an 
extremely polar (Rf = 0.0; 100% EtOAc), clear, colourless oil, which was insoluble in 
deuterated chloroform, dichloromethane, water, methanol, acetonitrile, toluene and 
dimethyl sulfoxide, thus making it rather synthetically impractical and thus was not 
analysed further. It was therefore anticipated that by carrying out acetylation prior to 
periodate cleavage, the resultant products would be more soluble.  Unfortunately after 
extensive efforts acetylation of (279) could not be achieved (Table 14). 
                                                 
t It is therefore not known if the SEM protecting groups survive this procedure. 
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Entry Base Electrophile Solvent Temp. (οC) Yield (%) 
1 NEt3 AcCl i. CH2Cl2 25 0 
2 K2CO3 AcCl i. DMF 80 0 
3 K2CO3 AcCl/NaI i. DMF 80 0 
4 NEtiPr2 AcCl DMF 80 0 
5 NEtiPr2 AcBr DMF 150 0 
6 NEtiPr2 AcBr DMA 165 0 
7 NEtiPr2 Ac2O DMA 165 0 
8 NEtiPr2 Ac2O DMA 165 0 
9 NEtiPr2 Ac2O Ac2O 25 0 
10 NEtiPr2 Ac2O Ac2O 140 0 
11 NaHMDS AcBr DMF −40 0 
12 NaHMDS Ac2O DMF −40 0 
13 - Ac2O Ac2O 25-165 0 
14 - Ac2O AcOH (5% H2SO4) 25-165 0 
i. DMAP (0.25 equiv.) added 
Table 14. Attempted acetylation of (279) 
Due to repeated failures to synthesise (281), attempts were then made to try and bring the 
olefin into conjugation with the aromatic moiety.  It was hoped that perhaps this 
compound may be more soluble and that potential mixtures of compounds recovered from 
periodate cleavage may be less complicated.   
 
Scheme 100. RhCl3 conjugation approach to styrene (282) 
It was therefore of great satisfaction that alkene (279) could be brought into conjugation 
upon treatment with catalytic RhCl3 (Scheme 100), to generate novel styrene in a 19:1 
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inseperable mixture of (282):(279).107  It was then hoped that, either acetylation or OsO4 
dihydroxylation of (282) followed by periodate cleavage may be accomplished.   
 
Scheme 101. Attempts to functionalise (282) 
Unfortunately subsequent synthetic efforts both via stepwise and one-pot dihydroxylation 
and periodate cleaveage also gave a clear colourless oil with the same insoluble properties 
previously seen (Scheme 99) and acetylation could not be achieved after numerous 
attempts (Scheme 101), thus this strategy was abandoned. 
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4.12 Direct Formylation Strategy 
 
 
Scheme 102. Direct formylation approaches attempted on (255), (270) and (271) by author 
 
Despite a sizeable amount of literature precedent regarding direct formylation reactions 
ortho to a phenol, finding a suitable reaction to accomplish this initially proved to be 
extremely fruitless.  This difficulty is reflected in the literature, with only a limited 
number of examples reported with electronically neutral and electronically deficient 
aromatics.   
 
Fig. 19. Electronic characteristics of advanced intermediates 
This presented us with an increased level of difficulty due to the ‘electronically 
schizophrenic’ nature of our functionalised vanillin derivatives (Fig. 19).  Of all of the 
reactions attempted (summarised in Scheme 102)108,109 the only methodology that proved 
successful in all cases was via a simple Mannich reaction with the preformed imminium 
salt of morpholine and paraformaldehyde in acetic acid (see overleaf). 
 
Scheme 103. Model acetylation 
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When this procedure98 was initially tested on vanillin, the author was delighted to 
discover the major reactio product was ortho-benzyl ether (285) and not morpholine (284) 
as anticipated (Scheme 103).  
 
 
Scheme 104. Mechanistic proposal for acetate formation 
It was proposed that after formation of the Mannich product (284), morpholine is then 
eliminated from the conjugate acid (286), generating o-QM (287) in situ, in a similar 
fashion to that described by Wilson (Scheme 26).69  The reactive intermediate was then 
quenched by nucleophilic addition from the solvent to complete this intriguing novel 
transformation (Scheme 104).u 
 
Scheme 105. Model acetylation 
It was therefore proposed that if the reaction was carried out in a solution of acetic acid 
that perhaps the ortho-acetate could be generated via the same novel reaction mode 
(Scheme 105).  Gratifyingly, this o-QM pathway furnished the desired product (289) in 
slightly increased yield (35%), perhaps due to the increased ability of AcOH to protonate 
the morpholine leaving group. 
  
                                                 
u Repeating the reaction in the absence of morpholine or paraformaldehyde lead to 0% conversion of 
(288), inferring the initial formation of morpholine (284) and morpholinium (286). 
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Entry Phenol Yield (%) 
1 
 
(267) 0 
2 (277) 60-70 
3 (278) 0 
 
Table 15. Scope of the Mannich protocol 
In the author’s hands, when either benzaldehyde (267) or isocoumarin (278) were 
subjected to the reaction conditions, neither of the corresponding Mannich or benzyl 
acetate products were observed (entries 1 and 3, Table 15).  This was believed to be due 
to reduced nucleophilicity of the π-system, thus demonstrating the high energetic barriers 
towards electrophilic aromatic substitution.  The electron donation contribution of the 
conjugated methoxy group of styrene (277), appears to offer sufficient contribution to 
subtly overcome this nucleophilicity problem (entry 2, Table 15).   
 
Entry X- Solvent Temp. (οC) Yield (%) 
1 AcO- AcOH 70 60-70 
2 AcO- AcOH 90 84 
3 AcO- AcOH 130 99.9 
4 AcO- AcOH 150 97 
5 Cl- MeCN 90 79 
6 Cl- MeCN 130 90 
7 Cl- MeCN 150 91 
 
Table 16. Optimization of benzylic functionalisation 
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Gratifyingly, overall yield of (290) could be increased to 99.8% upon increasing the 
temperature to 130 οC, although the author was surprised to see no evidence of o-QM 
formation at 150 οC (entries 4 and 7, Table 16). It was therefore our hypothesis that 
functional group interconversion to the acetate could potentially lower the activation 
energy of o-QM formation, based on comparison of their conjugate acids (pKa values in 
H2O for AcOH = 4.75110 and N-methylmorpholine = 7.80).111  
 
Entry Nucleophile Solvent Temperature (οC) Yield (%) 
1 AcOH AcOH 150 0 
2 NaOAc AcOH 150 0 
3 NaOAc MeCN 130 0 
4 KOAc MeCN 130 0 
5 CsOAc MeCN 130 0 
6 NaOAc EtOH 110 0 
7 KOAc EtOH 110 0 
8 NaOAc PhMe 160 0 
9 KOAc PhMe 160 0 
10 CsOAc PhMe 160 0 
 
Table 17. Attempted acetate installationv 
Several attempts were then made to try and perform an isohypsic conversion of the 
morpholine functionality to an acetate via an o-QM analogous to (Scheme 105).  
Unfortunately after several attempts a transformation of this nature could not be achieved 
(Table 17). 
 
                                                 
v Phenol  (277) (10 mg,  25.37 µmol, 1.0 equiv.) was dissolved in specified solvent (0.3 mL) at room 
temperature in a CEM microwave vial under an atmosphere of argon before addition of the specified 
nucleophile (0.51 mmol, 20.0 equiv.) and the resultant suspension was heated for 16 h. Temperatures 
reported are that of the external heating block. 
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Scheme 106. Kozlowski’s acetate installation 
Interestingly, upon re-examination of the literature it was discovered that a similar 
transformation to that attempted in (Table 17) had been achieved by Kozlowski 
(Scheme 106).98  In their report, phenol (292) was dissolved in Ac2O and heated at 
140 οC to promote the isohypsic functional group interconversion of the morpholine to an 
acetate. The author presumes that this occurs via an o-QM intermediate, with thermal 
extrusion of acyl morpholine, before contemporaneous acetylation of the resultant phenol 
to give diacetate (293). 
 
Scheme 107. Formation of the diacetate 
As Kozlowski’s procedure appeared to offer an extremely straightforward and high 
yielding approach for acetate installation the reaction was probed for synthetic utility.99  
Upon subjection of (290) to the conditions outlined by Kozlowski, the author was 
delighted to observe formation of the corresponding diacetate (294) in 84% yield. With 
meaningful quantities of this material in hand, we then attempted to chemoselectively 
remove either one or both of the acetyl esters. 
 
Scheme 108. Attempted hydrolysis of (294) under basic conditions 
Diacetate (294) was then treated with NaOMe (2.0 equiv.), in anhydrous methanol at 0 οC 
until TLC analysis indicated consumption of the starting material (Scheme 108).112  
Unfortunately upon further inspection the reaction appears to afford a mixture of 
hydrolysis products, although it is difficult to know if this hydrolysis occurs during the 
reaction or upon addition of a Brønstead acid to neutralise any alkoxides present.  No 
improvement in product recovery was exhibited using a variety of aqueous and anhydrous 
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acids for this purpose (HCl, NH4Cl, AcOH, PTSA, citric acid or camphorsulfonic acid), 
so the approach was abandoned. 
 
Scheme 109. Attempted hydrolysis of (287) under acidic conditions 
The analogous reaction was attempted under acidic conditions using anhydrous HCl in 
MeOH at 0 οC. After 20 minutes TLC analysis indicated complete consumption of the 
starting material and the reaction mixture was passed through a short plug of alumina and 
concentrated under reduced pressure.  Unfortunately GC/MS and 1H NMR analysis of the 
reaction mixture appeared to indicate mixtures of demthylated products.  To ascertain the 
relative rates of hydrolysis, the reaction was carried out in deuterated methanol in a 
Young’s tube at 25 oC (Figure 20). Unfortunately from the results of this experiment it 
appears that the methyl ester hydrolysis occurs at a comparative rate to that of the acetyl 
group and that this was not a viable approach.w 
 
 
 
Figure 20. 1H NMR hydrolysis experiment 
                                                 
w Product mixtures analysed by ESI and GC/MS appeared to show minimal deuterium incorporation. 
Z-(2 × OAc) Z-(4 × OMe) 
AcOH 
E-(2 × OAc) E-(4 × OMe) 
HCl, d4-MeOH
(295)(294)
OMe
AcO CO2MeOMe
CO2Me
OMe
HO CO2Me
OMe
CO2Me
HOAcO
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Scheme 110. Attempted hydrolysis of (287) via an o-QM 
Another o-QM approach similar to (Scheme 104) was also considered.  In this approach 
the diacetate was heated in distilled deionised water for 16 hours at a range of 
temperatures (50-150 οC) (Scheme 110).x  Unfortunately only mixtures of hydrolysis 
products similar to those isolated previously (Schemes 108 and 109) and hydrolysis 
approaches were abandoned, in favour of exploring the potential of (290) as an o-QM 
precursor. 
Although this was not the desired transformation the author has initially envisaged, it is 
known from the work of Wilson and co-workers benzylic morpholine substituents can be 
employed as effective leaving groups to generate an o-QM (Scheme 26).69   
4.13 Cross-Coupling Strategy 
 
Scheme 111. Reißig’s isocoumarin cross-coupling reaction 
Due to the precedent by Reißig and co-workers that iodide installation ortho to the phenol 
of the desired isocoumarin followed by palladium catalysed cross-coupling is not only 
possible but also facile and high yielding (Scheme 111), this seemed like an atom 
efficient method of vinyl installation for an envisaged selective olefin oxidation. 
 
                                                 
x Diacetate (294) (10 mg, 24.38 µmol) was dissolved in H2O (0.2 mL) at room temperature in a CEM 
microwave vial and heated at the desired temperature for 16 h.  Temperatures reported are that of the 
external heating block. 
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Scheme 112. Overview of initial cross-coupling reactions explored 
From a model study (Scheme 112)113 it was found that Suzuki coupling was capable of 
facilitating this transformation, however this was only possible when the phenol was 
protected as a silyl ether, which was quantitatively cleaved in the reaction, perhaps in a 
concerted elimination event inferred from the TLC and GC/MS analysis. 
 
Scheme 113. Model Suzuki conditions 
With vinylation conditions from our model system in hand, coupled with the observation 
that the solubility of advanced intermediates decrease significantly upon annulation to the 
isocoumarin, iodophenol (270) was investigated for synthetic utilty.  Gratifyingly upon 
conversion of phenol (270) to the perquisite novel silyl ether, diastereomers (303a) and 
(303b) could be separated via silica gel chromatography (Scheme 114).y 
 
 
Scheme 114. Silyl ether protection of (270) 
                                                 
y Stereochemical assignment inferred from 1H NMR spectra was confirmed via X-ray crystallography. 
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Scheme 115. Vinyl installation  
Gratifyingly, upon subjection of (303a) to the aforementioned Suzuki reaction conditions 
(Scheme 115), formation of the desired ortho-vinylic phenol (304) proceded without 
incedent in excellent yield (91-99%).  Unfortunately, using Upjohn114, Poli115 and 
Sharpless asymmetric dihydroxylation116 conditions, vinyl-selective dihydroxylation 
could not be achieved (Scheme 116), and thus upon in situ treatment with sodium 
periodate resulted in the dialdehyde (305).z 
 
Scheme 116. Attempted selective olefin oxidation 
Having established a cross-coupling route towards benzaldehyde formation via the 
aforementioned route would not tolerate olefin (304), our attention then turned towards 
Brimble’s formal synthesis product (184; Scheme 57).  It was anticipated that removing 
the olefin and therefore late stage dihydroxylation competition, this would allow for the 
key acetate product to finally be generated.  
 
Scheme 117. Brimble’s synthesis of iodophenol (309) 
During the synthesis of advanced intermediate (190, Scheme 56), Brimble reported that 
iodophenol (309) could be generated in 5 steps from commercially available and 
                                                 
z Background reaction was ran osmium free with sodium periodate, confirmed no olefinic oxidizing 
side-reactions were occurring during this step. 
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inexpensive guaiacol in 25% overall yield.  Frustratingly, no supporting information 
regarding the synthesis or charecterisation of intermediates (307-300) was reported in 
Brimble’s manuscript and so had to be investigated by the author.   
 
Scheme 118. Synthesis of bromide (307) 
Fortunately in 2012 Kan and co-workers117 published a scalable and high yielding 
procedure for the synthesis of (306a), which could be replicated in the author’s hands on 
50 g scale.  The resultant phenol, could then be protected as the corresponding methyl 
ethyl ether (307) using either Hünigs base (87.7%) or K2CO3 (81.2%).aa   
 
Scheme 119. Synthesis of unsaturated diester (308) 
Unfortunately replication of the following step initially proved more challenging as the 
reaction conditions were simply described as “LDA, THF, 0 οC, 0.5 h, then dimethyl 
malonate, 0 οC, then [(307)], THF, 0 οC”.  After a number of attempts the author found 
that when using freshly distilled solvents and reagents, the reaction could be replicated in 
a reproducible (79.2 to 81.4%) manner by deprotonation of dimethyl malonate (1.2 
equiv.) with LDA (2.4 equiv.) at 0 οC over 30 minutes, before dropwise addition of a 
solution of (307) (1.0 equiv.) in THF over ten minutes (Scheme 119).  The reaction 
mixture was then held at 0 oC for a further 30 minutes, before quenching the reaction with 
MeOH in attempt to limit the formation of the ethyl ester (310). 
                                                 
aa Telescoping of this procedure could also be achieved by filtering the reaction mixture after 
bromination in 71.1% overall yield.  
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Scheme 120. Deprotection and Iodination 
Gratifyingly, deprotection of the phenol (308) could be achieved quantititatively and 
iodination could be achieved in 91.7% yield using K2CO3 in place of NaHCO3, and not 
allowing the reaction temperature to rise above 5 oC, thus avoiding degradation of the 
starting material. 
 
Scheme 121. TBS protection and vinyl installation 
Gratifyingly, after silyl deprotection of (309), the resultant iodide (311) could be 
converted to novel styrene (312) via the previously established Suzuki conditions 
(Scheme 121).  It was then found that using Ac2O in pyridine was the preferred method 
of acyl protection, to furnish the desired novel styrene (313) in up to 86.9% overall yield 
(three steps).   
 
Scheme 122.  Attempted periodate cleavage 
Unfortunately, after several attempts using Upjohn, Poli, and Sharpless asymmetric 
dihydroxylation conditions, followed by treatment with NaIO4 (1.0 equiv.), compound 
(314) could not be isolated cleanly due to various over oxidation and degradation 
products.  Due to the author’s inability to generate the fully elaborated acetate initially 
envisaged (272) in combination with pressure on this projects timeline, attempts were 
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then focussed upon investigating the employment of morpholine (290) in a similar 
fashion to that described in (Scheme 26). 
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hetero-Diels-Alder 
Approaches 
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4.14 Morpholine hetero-Diels-Alder Strategy 
 
Scheme 123. hDA reaction of morpholinium salt  
Encouragingly an initial proof of concept reaction using conditions outlined by Wilson 
(Scheme 123) showed that the advanced morpholine intermediate (290) can form an 
o-QM, which undergoes [4+2] cycloaddition using DHF as a simple 2π component at 
130 οC to give the novel furan (316) as the major product in 65% isolated yield.  It was 
therefore anticipated that with further optimisation this reaction could be undertaken 
using a base mediated approach under kinetic conditions. 
 
Scheme 124. Attempted base initiated hDA 
Frustratingly no reaction was observed when the morpholium species was warmed in the 
presence of DHF and iPrMgCl from −78 οC to r.t. and subsequent heating resulted in a 
complex mixture (Scheme 124).  Clearly in this case methyl morpholine was not a 
suitable leaving group for application in a low-temperature initiation approach.   
 
Scheme 125. Attempted spiroketal formation  
In an attempt to generate a spiroketal via this protocol, the thermal protocol was repeated 
using γ-methlene-γ-butrolactone118 in a protocol analogous to earlier reports by Bray 
(Scheme 34).  Unfortunately attempting the reaction at a range of temperatures (50 to 
130 oC) and reaction times (8 to 48 h), just resulted in complex mixtures (Scheme 125), 
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which contained no indicative signs of product formation, so this approach was 
abandoned.  Following on from this, attempts to convert the quaternary ammonium salt 
(315) to an acetate in a similar fashion to previous attempts (Table 17), furnished a 
similar outcome (Table 18).  
 
 
 
Table 18. Attempted acetate installationbb 
 
As a considerable amount of the starting material had been generated it was envisaged 
that perhaps the strategy could be adapted towards a thermally stable 2π partner. The 
most thermodynamically stable benzofuran previously reported to undergo hDA reactions 
with o-QMs are those described by Xie and Li (Scheme 31).  It was therefore hoped that 
                                                 
bb Phenol  (290) (10 mg,  25.37 µmol, 1.0 equiv.) was dissolved in specified solvent (0.3 mL) at room 
temperature in a CEM microwave vial under an atmosphere of argon before addition of an electrophile 
(25.11 µmol, 0.99 equiv.) at 0 oC.  The reaction mixture was allowed to warm up to r.t. and was stirred 
for a further 3 h, before addition of the specified nucleophile (0.51 mmol, 20.0 equiv.) and the resultant 
suspension was heated for 16 h. Temperatures reported are that of the external heating block. 
Entry Electrophile Nucleophile Solvent Temp. (οC) Yield (%) 
1 MeI NaOAc PhMe 130 0 
2 MeI KOAc PhMe 130 0 
3 MeI CsOAc PhMe 130 0 
4 MeI NaOAc PhMe 150 0 
5 MeI KOAc PhMe 150 0 
6 MeI CsOAc PhMe 150 0 
7 (CF3CO)2O CsOAc PhMe 150 0 
8 Tf2O CsOAc PhMe 150 0 
9 AcCl CsOAc PhMe 150 0 
10 BnBr CsOAc PhMe 150 0 
11 MeI NaOAc MeCN 130 0 
12 MeI KOAc MeCN 130 0 
13 MeI CsOAc MeCN 130 0 
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subjection of (315) to conditions outlined in Xie and Li’s reports would allow for the 
generation of the unsaturated spiroketal (319). 
 
 Scheme 126. Overview of attempts to employ a sulfoxide as an electrophile 
Unfortunately initial attempts towards this goal (entry 1, Table 19), did not appear to be 
successful with respect to generation of a spiroketal, with no representative signals 
present during NMR analysis of the resultant mixture (Figure 21).  
 
Figure 21. Crude 1H and 13C NMR analysis from the reaction described in (Scheme 127) 
Unfortunately, increasing the amount of the sulfoxide (318) had no affect of the overall 
result of this protocol (entries 2 and 3, Table 19), even when leaving the reaction for 39 
hours.  As Li and Xue’s procedure was described at 110 οC, it was proposed that above 
this temperature the sulfoxide may be unstable and therefore degrade before it could react 
with the o-QM.  However, when the reaction was repeated at this temperature (entries 4 
and 5), no product was detected after 16 or 39 hours. 
OMe
OMe
O
O
OMe
O
MeO
O
O
Representative
Spiro-Carbon
C13 δ ~ 109 ppm
H
Representative
Terminal Styrene
H1 δ ~ 5.7 ppm
J ~ 10 Hz
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Table 19. Attempted unsaturated spiroketal formation  
To try and attenuate the risk that the morpholine wasn’t sufficiently alkylated, the 
temperature of the initial alkylation step was increased to 40 οC after warming to r.t. but 
again, this could not promote product formation (entry 6).  Similar results, were also 
achieved using an excess of alkylating agent, at r.t. for 24 hours (entries 7 and 8).   
The reaction was also attempted using the amino and thioether intermediates used to 
synthesise (318) (entries 9 and 10), however this avenue of investigation was equally 
unsuccessful.  It was then proposed that perhaps a more electron withdrawing 
quaternising agent would lower the activation energy of the o-QM initiation and promote 
Entry 
2π component     Electrophile 
t1 (h) T1 (οC) t2 (h) 
T2 
(οC) 
Conversion 
(%) R = equiv. E+ = equiv. 
1 SOPh 1.0 MeI 0.99 2.0 0 to rt 16 130 0 
2 SOPh 5.0 MeI 0.99 2.0 0 to rt 39 130 0 
3 SOPh 10.0 MeI 0.99 2.0 0 to rt 39 130 0 
4 SOPh 10.0 MeI 0.99 2.0 0 to rt 16 110 0 
5 SOPh 10.0 MeI 0.99 2.0 0 to rt 39 110 0 
6 SOPh 10.0 MeI 0.99 2.0 0 to 40 39 110 0 
7 SOPh 10.0 MeI 1.05 24.0 0 to rt 39 130 0 
8 SOPh 10.0 MeI 1.30 24.0 0 to rt 39 130 0 
9 SPh 10.0 MeI 0.99 2.0 0 to rt 39 110 0 
10 NMe2 10.0 MeI 0.99 2.0 0 to rt 39 110 0 
11 SOPh 10.0 (CF3CO)2O 1.05 3.0 0 to rt 39 110 0 
12 SOPh 10.0 Tf2O 1.05 3.0 0 to rt 39 110 0 
13 SOPh 10.0 AcCl 1.05 5.0 0 to rt 39 110 0 
14 SOPh 10.0 BnBr 1.05 4.5 0 to rt 39 110 0 
15 SOPh 10.0 pNO2BnCl 1.05 8.5 0 to rt 39 110 0 
16 SOPh 10.0 pNO2BnCl+NaI 1.05 6.0 0 to rt 39 110 0 
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product formation.  Unfortunately, our results did not reflect this hypothesis 
(entries 11-16). 
 
Fig. 21. Model substrates screened 
Due to the persistently unsuccessful nature of these protocols, it was hoped that perhaps 
by comparing the reactivity of some model compounds (Fig. 21), a more synthetically 
useful reaction could be uncovered in order to facilitate the synthesis of γ-rubromycin 
(Table 20).  In this study phenols (320; R = Morpholine), (321; R = NBn2) and 
(322; R = OAc)cc were compaired to establish their relative reactivity rates and to see if 
the conditions for o-QM formation could be carried out in a milder fashion. 
Initially, the model phenols were then subjected to the hDA conditions 
(entries 1-3, Table 20) previously used to generate benzopyran (316; Scheme 123).  
Unfortunately, under these conditions both of the benzylamines (320) and (321) 
performed markedly worse than acetate (322).   
It was again proposed that perhaps a more electron withdrawing quaternising agent would 
lower the activation energy of the o-QM initiation and increase yields but again, our 
results did not reflect this hypothesis (entries 4-7).  Having no encouragement for this 
strategy, our attention was then turned towards concentrating the reaction mixture, in the 
hope that the 2π component would become more accessible to the reactive intermediate.   
 
 
 
                                                 
cc Compound was synthesised previously by Dr. C.D. Bray as part of a different investigation. 
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Table 20. Optimisation of hDA conditions 
Gratifyingly, upon removal of the toluene after quaternisation, the reaction was found to 
proceed in comparible yields to that previously observed using the acetate (entries 3, 8 
and 9).  This trend was also observed when the reaction temperature was lowered to 
110 οC, however product conversion was markedly reduced (entries 10-12). 
                                                 
dd Solvent was removed under reduced pressure at r.t  prior to addition of DHF. 
ee Reaction mixture was heated in a microwave . 
Entry Electrophile Phenol Solvent Temp. (οC) Yield (%) 
1 MeI 320 PhMe 130 50 
2 MeI 321 PhMe 130 51 
3 - 322 PhMe 130 67 
4 Tf2O 320 PhMe 130 36 
5 Tf2O 321 PhMe 130 48 
6 (CF3CO)2O 320 PhMe 130 39 
7 (CF3CO)2O 321 PhMe 130 45 
8 MeI 320 PhMedd 130 66 
9 MeI 321 PhMe23 130 68 
10 MeI 320 PhMe23 110 48 
11 MeI 321 PhMe23 110 52 
12 - 322 - 110 56 
13 MeI 320 PhMe23 130ee 67 
14 MeI 321 PhMe23 13030 71 
15 - 322 - 13030 85 
16 - 320 - 13030 79 
17 - 321 - 13030 82 
18 - 320 - 11030 58 
19 - 321 - 11030 63 
20 - 320 - 15030 42 
21 - 321 - 15030 37 
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Interestingly, upon repeating the reaction in a microwave reactor at 130 οC yields could 
be meaningfully increased for the acetate but not for the quaternised benzylamines 
(entries 13-15).   
Rather surprisingly, when the reaction was repeated without a quaternising agent, the 
reaction proceeded in an increased and comparible yield to that acetate (entries 15-17).  It 
also appeared that this temperature was reasonably optimised for this transformation, as 
yields were significantly reduced by decreasing (entries 18-19) and increasing 
(entries 20-21) the temperature by 20 οC. 
 
Scheme 127. Potential mechanisms of o-QM formation 
Although this reaction has not been investigated mechanistically, it is proposed that 
perhaps the phenolic proton migrates onto the nitrogen atom in a concerted elimination 
reaction, which is supported by the deshielded nature of the 1H NMR signals around 
10.2 ppm (pathway A, Scheme 127).  The alternative hypothesis (pathway B), may be 
that DHF is functioning as the quaterising agent, and the reaction proceeds via a similar 
pathway to those seen previously. 
 
Scheme 128. Microwave assisted hDA reaction  
Although these reaction conditions (Table 20, entry 16) didn’t appear to be much milder, 
repeating the protocol with phenol (290), the desired product was furnished in slightly 
improved overall yield (70%) and perhaps more importantly, purification via silca gel 
chromatography was significantly more facile.  
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Scheme 129. Microwave assisted spiroketal formation 
 
Upon subjection of phenol (290) to the same reaction conditions using γ-methlene-γ-
butyrolactone as the solvent, it was with great delight that spiroketal (317) was isolated in 
64% overall yield.  This was a significant step forward in the persuit of a modular 
approach to the rubromycins and synthetic analogues via a hetero-Diels-Alder 
methodology.  
 
Scheme 130. Attempted microwave assisted bis-benzannulated spiroketal formation 
Unfortunately, upon resubjection of the sulfoxide (318) to the reaction conditions, it was 
not possible to generate a bis-benzannulated [5,6]-spiroketal via this approach 
(Scheme 130).  For this reaction to prove suitable for the synthesis fully elaborated 
rubromycins, a great deal of optimisation is still required, to reduce the initiation 
temperature of o-QM formation.   
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Summary & 
Conclusions 
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4.15 Summary and Conclusion 
Scheme 131. Proposed synthesis of γ-rubromycin 
At the outset of this project, our aim was to try and establish a general, robust method of 
synthesising the rubromycins via a [4+2] cycloaddition (Scheme 131).  Although 
γ-rubromycin and heliquinomycinone had been synthesised previously by Kita45 and 
Danishefsky109 respectively, there was still ample scope for development of a definitive, 
modular approach to these highly intriguing molecular scaffolds. 
Our motivations to develop this methodology were twofold: firstly to investigate the 
synthetic utility of Bray’s [4+2] cycloaddition chemistry, and secondly to provide a 
modular approach to unnatural rubromycin analogues to elevate their status as potential 
medicinal chemistry lead compounds. 
 
Scheme 131. Proposed methylene installation 
Preliminary investigations allowed us to generate the desired napthazarin subunits 
(Scheme 69 and 73), and having replicated the literature results of Molander and Grubbs 
(Scheme 78), this appeared to be a promising strategy to synthesise the desired exo-enol 
ethers (238) and (239) (Scheme 132).  However, the author believed that it would be 
prudent not to commit samples of (230) or (237) to this methelene installation strategy 
until conditions for generating the key electron deficient o-QM (222) were established.  
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This strategy would offer the advantage of allowing us to establish whether or not this 
reactive 2π species would need to be stabilised in some way (e.g. 221; R’ = SOPh) to 
tolerate said o-QM generation conditions. 
 
Scheme 132. Adaptation of the strategy towards morpholine leaving groups 
In our attempts to achieve this goal, a number of synthetic routes towards the key o-QM 
precursor (272) were explored.  Although a number of novel isocoumarins, and 
isocoumarin synthons (326) could be generated, unfortunately these could not be 
converted into (272) as anticipated.  Fortunately, the author was able to build upon the 
work of Wilson86 and substitute the benzylic acetate leaving group with the more 
synthetically accessible morpholine (290) (Scheme 132). 
 
Scheme 133. Synthetic utility of morpholinium (315) in Bray’s base and thermally initiated 
methodologies 
Although, this compound had no synthetic utility under Bray’s base-initiated conditions, 
gratifyingly under thermal conditions, o-QM (323) could be generated and trapped 
reliably by [4+2] cycloaddition with DHF (Scheme 133).  This was a key achievement 
for this project as to the author’s knowledge, a [4+2] cycloaddition had never been 
achieved with such an electron-deficient o-QM (Scheme 124). 
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Scheme 134. Scope of the microwave promoted hDA reaction  
Building on this methodology, the author also discovered that upon irradiation in a 
microwave reactor, that morpholine (290) could be converted into o-QM (327) without 
the need to alkylate the amine (Scheme 128).  This is to the author’s knowledge, the first 
example of such a transformation, however a precise mechanism is currently unknown at 
this time. 
Frustratingly, despite numerous attempts, this protocol could not be adapted towards the 
synthesis of a [5,6]-bis-benzannualted spiroketal during the course of this investigation 
(Scheme 134).  However, after further optimisation of the reaction conditions, [4+2] 
cycloaddition between o-QM (323) and γ-methylene-γ-butyrolactone (119) could be 
achieved, affording spiroketal (317) (Scheme 130).   
Although this reaction could not be achieved at low temperature as originally envisaged, 
this study does provide a proof of concept that synthetic rubromycin analogues such as 
(317) can be generated using this novel microwave promoted [4+2] cycloaddition.  It is 
hoped that with further development, this may prove to be a viable strategy for the 
synthesis of the rubromycins and other synthetic analogues. 
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4.16 Future Work 
 
Scheme 135. Adapted [4+2] strategy towards the rubromycins 
To adapt this microwave promoted cycloaddition protocol, towards this projects ultimate 
goal of synthesising members of the rubromycin family, it is proposed that investigation 
of more thermally stable 2π components may hold the key to achieving this 
transformation. 
One particularly attractive strategy would be to generate both the 2π and 4π components 
in situ by adapting Li and Xue’s recently developed copper catalysed [4+2] system 
(Scheme 44a and 44b) to the author’s microwave promoted [4+2] approach 
(Scheme 135). 
 
Scheme 136. Exploration of microwave promoted [4+2] strategy to generate synthetic 
rubromycins with improved physicochemical properties  
 
It is also of note that installation and elimination of the benzylic morpholine to 
generate an o-QM requires less synthetic steps compaired with all other benzylic 
leaving groupinstallation/elimination strategies (Scheme 25).  As this approach also 
appears to be more toleratant to electron defiecient phenols, this protocol may prove 
to be a useful general tool for the construction of [5,6]-benzannulated spiroketals in 
two steps from commercially available phenols and exo-enol ethers (Scheme 136). 
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Chapter 5: 
Experimental 
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5.1 Experimental 
I. General Information: Unless otherwise stated, commercially available reagents were 
used as supplied.  All reactions requiring anhydrous conditions were conducted in flame-
dried apparatus under an inert atmosphere of nitrogen or argon.  Microwave heating was 
conducted in 10 mL thick walled microwave vials (microwave) fitted with crimp top 
Teflon seals.  Analytical thin-layer chromatography (TLC) was performed on silica gel 
plates (0.25 mm) precoated with a fluorescent indicator. Standard flash chromatography 
procedures were performed using Kieselgel 60 (40-63 μm) or with a Varian Superflash 
automated purification system.  Petroleum refers to the fraction boiling between 40-60 oC.  
Infrared spectra were recorded in the range 4000-600 cm-1, using a Bruker Tensor 37 
FTIR machine equipped with a PIKE MIRacle ATR accessory.  IR signals are reported in 
wavenumbers (cm-1) and signal intensity is subjectively denoted br = broad, brs = broad 
(strong), brm = broad (medium) s = strong, m = medium and w = weak.   
Both 1H and 13C NMR spectra were recorded using either a Bruker AV400 NMR or 
AV600 spectrometer.  Chemical shifts δ are reported in ppm (relative to δH CHCl3 (7.27) 
and δC CDCl3 (77.0) unless otherwise stated) and multiplicity of signals denoted: s = 
singlet, d = doublet, t = triplet, q = quartet, and m = multiplet respectively with coupling 
constants (J) reported in hertz (Hz).  Structural interpretations and assignments were 
made based upon COSY, HMQC, HMBC, DEPT 135, DEPT 90 and NOESY 
experiments and denoted as follows: (1H NMR) ArCH = aryl proton, Me = CH3 of a 
methy group, MeO = CH3 of methoxy group, CO2Me = CH3 of methylester, CO2H = H of 
carboxylic acid, OH = H of alcohol, CHa=CHb or CH=Cquat = single alkenyl proton, CHO 
= aldehyde proton, SiMe2tBu = 2 × Me groups of TBS, SiMe2tBu = tBu group of TBS, 
NCH2 = methylene protons attached to a nitrogen atom, OCH2 = methylene protons 
attached to an oxygen atom; (13C NMR) COMe = C atom bearing a methoxy group, 
COMe = C atom of methoxy group, COH = C atom bearing an alcohol group, CBr = C 
atom bearing a bromine atom, CCN=C atom bearing a nitile goup, CCN = C atom of 
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nitrile group, C=O= carbonyl, ArCH = aryl C bearing a hydrogen atom, Cquat. = 
quaternary cabon, ArCquat.=  quaternary aromatic cabon, ArCCquat. = quaternary carbon 
fused to aryl ring, CH2 = methylene carbon, CH3 = methyl carbon, CO2H = C atom of 
caroboxylic acid, CO2Me = C atom of methyl ester (C=O), CO2Me = C atom of methyl 
ester (CH3), CHa=CHb or CH=Cquat.= alkenyl cabon. 
GC/MS spectra were recorded using an Agilent 6890gc and 5973 msd instrument.  High 
resolution mass spectra (HRMS) were obtained by the EPSRC National Mass Service 
(Swansea) using a double focussing mass spectrometer (Finnigan MAT 95 XP). 
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II. Experimental Procedures and Compound Characterisation 
5-Bromo-3,4-dimethoxyphenol (225).90  m-Chloroperbenzoic acid 
(4.75 g, 27.5 mmol, 1.5 equiv.) was added in one portion to a solution of 
5-bromo-3,4-dimethoxybenzaldehyde  (224) (4.50 g, 18.4 mmol, 
1.0 equiv.) in CH2Cl2/H2O (68 : 2 mL) before heating to reflux for 
16 hours.  The reaction mixture was carefully added to vigorously stirred sat. aq. NaHCO3 
solution (30 mL) and stirring was continued for 30 minutes before extracting the aqueous 
layer with CH2Cl2.  The combined organic phases were successively washed with sat. aq. 
NaHCO3 solution (30 mL), and sat. aq. Na2S2O5 solution (30 mL) (test for peroxides 
negative) and sat. aq. NaCl solution (30 mL).  The organic phase was dried over MgSO4, 
before concentrating to a crude tan oily solid under reduced pressure.   
The residue was dissolved in MeOH (10 mL) before addition of 6M HCl (10 mL) and the 
mixture was stirred at r.t. for 30 minutes.  The MeOH was then removed under reduced 
pressure and the remaining aqueous solution was extracted with Et2O (3 × 150 mL).  The 
combined organic layers were dried over MgSO4 before concentrating to an off-white 
solid under reduced pressure.  The title compound was then purified using flash 
chromatography (EtOAc:Petroleum; 1:4) to afford the title compound (225) as a white 
solid (3.75 g, 16.2 mmol, 88%).   
mp = 97-98 oC; Rf = 0.19 (EtOAc:Petroleum;1:4); νmax (film)/cm-1 3286br (OH), 2947w 
and 2933w (CH), 2836w (CH3), 1608m and 1578m (C=C);  1H NMR (400 MHz, 
d6-acetone) δ =  8.42 (brs, 1H, OH), 6.59 (d, J = 2.7 Hz, 1H, ArCH), 6.50 (d, J = 2.7 Hz, 
1H, ArCH), 3.80 (s, 3H, OMe), 3.68 (s, 3H, OMe); 13C NMR (100.0 MHz, d6-acetone) 
δ = 155.2 (COMe), 155.2 (COMe), 140.5 (COH), 117.6 (CBr), 110.9 (ArCH), 101.3 
(ArCH), 60.5 (OMe), 56.2 (OMe); HRMS (EI) calcd for [C8H8O379Br]- 230.9662 and 
[C8H8O381Br]- 232.9642; found 230.9664 and 232.9638 [M−H]−; spectroscopic data is in 
agreement with that previously reported.90 
OMe
Br
OH
MeO
(225)
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OMe
Br
OMe
MeO
(227)
3-Bromo-4,5-dimethoxybenzoic acid (224a).To a pre-cooled (0 oC, 
external) solution of 5-bromo-3,4-dimethoxybenzaldehyde (224) 
(980 mg, 4.0 mmol, 1.0 equiv.) in MeOH (25 mL) was slowly added 
80% magnesium bis(monoperoxyphthalate) hexahydrate 
(2.48 g, 4.0 mmol, 1.0 equiv.) at -5 οC.  The mixture was allowed to gradually warm to 
r.t. and stirred for 16 h.  The crude mixture was then diluted with Et2O (200 mL) and 
washed with H2O (100 mL).  The layers were then separated and the aqueous layer was 
extracted again further Et2O (200 mL) and the combined organics were dried over 
MgSO4, filtered and concentrated under reduced pressure to afford the title compound as 
a white solid (1.04 g, quant.). 
m.p. 176-178 οC; Rf = 0.44 (EtOAc:MeOH; 9:1); νmax (film)/cm-1 2969br (OH), 2642w, 
2605w and 2513w (CH), 1732w (O-CO), 1682s (C=O), 1589m, 1565m and 1490m 
(C=C); 1H NMR (400 MHz, d6-DMSO) δ = 13.19 (brs, 1H, CO2H), 7.70 (s, 1H, ArCH), 
7.59 (s, 1H, ArCH), 3.89 (s, 3H, OMe), 3.82 (s, 3H, OMe); 13C NMR (100.0 MHz, 
d6-DMSO) δ = 165.6 (CO2H), 152.1 (COMe), 149.3 (COMe), 127.7 (CCO2H), 125.3 
(ArCH), 116.9 (CBr), 113.0 (ArCH), 60.2 (OMe), 56.1 (OMe); HRMS (EI) calcd for 
[C9H8O479Br]- 258.9611 and [C9H8O481Br]- 260.9592; found 258.9608 and 260.9583 
[M−H]−. 
2,3,5-Trimethoxybromobenzene (226).91  A solution of 5-bromo-3,4-
dimethoxyphenol (225) (5.30 g, 22.8 mmol, 1.0 equiv.) in anhydrous 
acetone (150 mL) was treated with anhydrous K2CO3 
(6.3 g, 45.5 mmol, 2.00 equiv.) and Me2SO4 (6.35 g, 50.4 mmol, 
1.1 equiv.) under nitrogen.  After 12 h stirring at r.t. under nitrogen, the reaction mixture 
was diluted with ice-cold distilled water (250 mL), concentrated under reduced pressure 
to one-third volume and extracted with EtOAc (3 × 50 mL).  The organic extracts were 
washed with water and sat. aq. NaCl solution (30 mL) and dried over MgSO4 before 
concentration under reduced pressure to afford a yellow oil that was purified using flash 
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chromatography (EtOAc:Petroleum; 1:4) to afford the title compound as a pale-yellow oil 
(5.55 g, 22.6 mmol, 99%). 
Rf = 0.28 (EtOAc:Petroleum,1:4); νmax (film)/cm-1 3000w, 2960w and 2937w (CH), 
2835w (CH3), 1599m, 1570m and 1489m (C=C); 1H NMR (400 MHz, CDCl3) δ = 6.63 
(d, J = 2.5 Hz, 1H, ArCH), 6.44 (d, J = 2.5 Hz, 1H, ArCH), 3.83 (s, 3H, OMe), 3.80 
(s, 3H, OMe), 3.76 (s, 3H, OMe); 13C NMR (100.0 MHz, CDCl3) δ = 156.4 (COMe), 
153.9 (COMe), 140.6 (COMe), 117.3 (CBr), 107.9 (ArCH), 99.9 (ArCH), 60.5 (OMe), 
55.6 (OMe), 55.6 (OMe);  GCMS (CI) calcd for [C9H1279BrO3]+ 247 and [C9H1281BrO3]+ 
249; found = 247 and 249 [M+H]+; spectroscopic data is in agreement with that 
previously reported.91 
2,3,5-Trimethoxybenzonitrile (227).88  To a solution of stirred, 2,3,5-
trimethoxybromobenzene (226) (9.5 g, 38.5 mmol, 1.0 equiv.) in 
anhydrous DMF (150 mL) was added copper(I) cyanide (7.2 g, 80.4, 
2.1 equiv.) at r t. and the reaction mixture was heated to reflux, under 
nitrogen with for 16 hours.  The solution was allowed to cool to r.t. before being poured 
into a solution of excess aqueous EDTA and stirred for 2 h.  The product was then 
extracted with ethyl acetate before concentrating under reduced pressure to afford a 
brown solid.  Purification of the crude material was achieved using flash chromatography 
(EtOAc:Petroleum, 1:4) to give the title compound as an off-white crystalline solid 
(7.3 g, 37.7 mmol, 98%). 
mp 61-63 oC, [lit. 61-62.5 oC)]; Rf = 0.38 (EtOAc:Petroleum; 1:4); νmax (film)/cm-1 
3106w, 3006w and 2952w (CH), 2844w (OCH3), 2233m (CN), 1593m and 1590m 
(C=C); 1H NMR (400 MHz, CDCl3) δ = 6.65 (1H, J = 2.6 Hz, ArCH), 
6.48 (1H, J = 2.6 Hz, ArCH), 3.89 (s, 3H, OMe), 3.81 (s, 3H, OMe), 3.78 (s, 3H, OMe); 
13C NMR (100.0 MHz, CDCl3) δ = 156.1 (COMe), 153.6 (COMe), 146.36 (COMe), 
116.3(CCN), 106.8 (CCN), 105.8 (ArCH), 105.7 (ArCH) 61.9 (OMe), 56.0 (OMe), 55.9 
(OMe); HRMS (CI) calcd for [C10H12O3N]+ 194.0812; found 194.0810 [M+H]+; 
spectroscopic data is in agreement with that previously reported.88 
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 8-Hydroxy-5,7-dimethoxynaptho[2,3-b]furan-4,9-dione (229).45,80  
To a stirred solution of 3-furoic acid (260 mg, 2.3 mmol, 1.0 equiv.) 
in anhydrous THF (15 mL) at −78 οC was added t-butyllithium 
(3.2 mL, 5.1 mmol, 2.2 equiv., 1.6 M in hexanes) dropwise.  The 
solution was stirred for 2 h at −78 οC, then a solution of nitrile (227) (500 mg, 2.6 mmol, 
1.1 equiv. in 5 mL THF) was added dropwise.  The reaction mixture was allowed to warm 
slowly from −78 οC to r.t. over 6 hours and the mixture was then stirred at r.t. for 12 h, 
before quenching by a slow addition of H2O (20 mL).  The mixture was extracted with 
Et2O (2 × 30 mL) and the dark brown aqueous layer was acidified to pH 1 with 1M HCl, 
stirred for 2 h, then extracted with EtOAc (3 × 30  mL).  The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure to afford the 
furan (228) (700 mg, 2.3 mmol, quant.) as a dark brown solid.  The compound was 
carried forward without further purification. 
Furan (228) was then stirred in 98% sulfuric acid (8 mL) for 3 days at r.t. before carefully 
pouring the dark red mixture onto ice (50 g).  The warmed mixture was extracted with 9:1 
CH2Cl2/MeOH (200 mL) and the organic layer was separated, dried over MgSO4, filtered 
and concentrated under reduced pressure.  The crude compound was purified by flash 
chromatography (EtOAc:Petroleum; 5:2) to afford the title compound (229) as a 
“haem-red” solid (603 mg, 2.2 mmol, 96% over 2 steps). 
 
mp = 87-88 oC; Rf = 0.15 (EtOAc:Petroleum; 5:2); νmax (film)/cm-1 3194w and 2943w 
(CH), 2361br (OHconj), 1640s (C=O), 1479 (C=C); 1H NMR (400 MHz, CDCl3)  
δ = 13.19 (s, 1H, OH), 7.75 (d, J = 1.8 Hz, 1H, OCHa=CHb), 6.97 (d, J = 1.8 Hz, 1H, 
OCHa=CHb), 6.74 (s, 1H, ArCH), 4.02 (s, 3H, OMe), 4.01 (s, 3H, OMe); 13C NMR 
(100.0 MHz, CDCl3) δ = 178.6 (C=O), 177.7 (C=O), 156.7 (Cquat.), 155.9 (COMe), 150.2 
(OCHa=CHb), 149.9 (COMe), 149.4 (COH), 133.7 (Cquat.), 114.9 (ArCCquat.), 111.4 
(ArCCquat.), 109.5 (OCHa=CHb), 102.8 (ArCH), 57.0 (OMe), 56.4 (OMe); HRMS (CI) 
calcd for [C14H11O6]+ 275.0556; found 275.0547 [M+H]+; spectroscopic data is in 
agreement with that previously reported.45,80 
O
O
OH
MeO O
OMe
(229)
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4,5,7,8,9-Pentamethoxynaphtho[2,3-b]furan (230).45,80 To a 
solution of quinone (229) (97 mg, 0.35 mmol, 1.0 equiv.) in THF 
(1.8 mL) and H2O (1.1 mL) were added TBAB (23 mg, 0.07 mmol, 
0.2 equiv.) and Na2S2O4 (85% wt., 400 mg, 1.72 mmol, 4.9 equiv.).  
The mixture was stirred for 15 min, then KOH (430 mg, 7.7 mmol, 22.0 equiv.) was 
added to the clear solution and the resultant red/purple solution was stirred for 20 min.  
Me2SO4 (290 μL, 3.15 mmol, 9.0 equiv.) was added and the solution was stirred for a 
further 2 h before addition of 10% aq. ammonium hydroxide solution (4.0 mL).  The 
orange/yellow solution was stirred for a further 16 h at r.t., diluted with H2O (20 mL) and 
extracted with EtOAc (3 × 50 mL).  The combined organic layers were collected and 
dried over MgSO4 before concentrating under reduced pressure.  The crude product was 
then purified using flash chromatography (EtOAc:Petroleum, 1:2 → 1:1) to provide the 
title compound as a pale yellow solid (61 mg, 0.19 mmol, 55% yield). 
mp = 71-73 oC; Rf = 0.30 (EtOAc:Petroleum, 1:1);  νmax (film)/cm-1 2935w and 2837w 
(CH), 1487m and 1450m (C=C); 1H NMR (400 MHz, CDCl3) δ = 7.59 (d, J = 2.4 Hz, 
1H, OCHa=CHb), 6.94 (d, J = 2.4 Hz, 1H, OCHa=CHb), 6.66 (s, 1H, ArCH), 4.06 
(s, 3H, OMe), 4.02, (s, 3H, OMe), 4.01 (s, 3H, OMe), 3.96 (s, 3H, OMe), 3.89 
(s, 3H, OMe); 13C NMR (100.0 MHz, CDCl3) δ = 153.6 (ArCquat.), 148.4 (COMe), 147.2 
(COMe), 145.5 (OCHa=CHb), 145.3 (COMe), 136.7 (ArCquat.), 134.8 (ArCquat.), 123.5 
(COMe), 120.8 (COMe), 114.8 (ArCquat.), 104.4 (OCHa=CHb), 95.4 (ArCH), 62.8 (OMe), 
62.7 (OMe), 61.9 (OMe), 57.1 (OMe), 56.8 (OMe); HRMS (CI) calcd for [C17H18O6]+ = 
318.1103; found 318.1114 [M+H]+; spectroscopic data is in agreement with that 
previously reported.45,80 
 
2-(3,5-Dimethoxybenzoyl)furan-3-carboxylic acid (235).  To a 
stirred solution of 3-furoic acid (300 mg, 2.7 mmol, 1.0 equiv.) in 
anhydrous THF (15 mL) −78 οC was added t-butyllithium (1.6 M in 
hexanes, 3.6 mL, 5.8 mmol, 2.2 equiv.) dropwise.  The solution was 
stirred for 2 h at −78 οC, then a solution of 3,5-dimethoxybenzonitrile (480 mg, 2.94 
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mmol, 1.1 equiv. in 20 mL THF) was added dropwise.  The reaction mixture was allowed 
to warm from −78 οC to r.t. over 6 hours and the mixture was stirred for 16 h, before 
quenching the reaction by slow addition of H2O (40 mL).  The mixture was extracted with 
Et2O (2 × 60 mL) and the dark brown aqueous layer was acidified to pH 1 with 1M HCl, 
stirred for 2 h, then extracted with EtOAc (3 × 50 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated under reduced pressure before purification 
via silica gel chromatography (100% EtOAc)  afforded the title compound as a yellow 
solid (670 mg, 2.4 mmol, 90% yield). 
mp = 78-79 οC; νmax (film)/cm-1 2942br (O-H), 1640s (C=O), 1457m and 1483m (C=C); 
1H NMR (400 MHz, CDCl3) δ = 7.72 (d, J = 1.6 Hz, 1H, OHC=CHR); 7.30-7.28 
(m, 3H, 1 × OCHa=CHb, 2 × ArCH), 6.78 (dd, J = 2.2, 1.3 Hz, 1H, ArCH), 3.88 
(s, 6H, 2 × OMe); 13C NMR (100.0 MHz, CDCl3) δ = 185.8 (C=O), 160.8 (2 × COMe), 
160.6 (CO2H), 149.1 (Cquat.), 146.4 (OCHa=CHb), 136.3 (ArCquat.), 130.6 (Cquat.), 117.2 
(OCHa=CHb), 108.7 (2 × ArCH), 106.8 (ArCH), 55.8 (2 × OMe); GCMS (CI) calcd for 
[C14H13O6]+ 277; found  277 [M+H]+. 
5,7-Dimethoxynaphtho[2,3-b]furan-4,9-dione (236).  Method A: 
Carboxylic acid (235) (200 mg, 0.7 mmol, 1.0 equiv.) was dissolved 
in oxalyl chloride (2.0 mL, 23.6 mmol, 32.8 equiv.) at −5 οC before 
addition of DMF (50 µL, 0.65 µmol, 0.1 mol%) liberating fumes of 
HCl gas.  After 2 h the reaction mixture had stopped fuming and was concentrated under 
reduced pressure, without exposure of the flask to air to give a bright yellow solid, which 
was subsequently dissolved in CH2Cl2 (25 mL).  After cooling the reaction mixture to −5 
οC, AlCl3 (140 mg, 1.08 mmol, 1.5 equiv.) was slowly added over 10 minutes and the 
reaction mixture was warmed slowly to r.t. over 3 h.  The reaction mixture was then 
cooled to −5 οC, before the reaction mixture was carefully quenched by slow addition of 
ice (15 g) and sat. aq. NH4Cl solution (10 mL) before extracting with CH2Cl2 
(3 × 40 mL).  The crude compound was purified by flash chromatography 
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(EtOAc:Petroleum; 5:2) to afford the title compound  as an orange solid 
(163 mg, 0.63 mmol, 88%).   
Method B: Furan (235) (200 mg, 0.72 mmol) was stirred in 98% sulfuric acid (5 mL) for 
3 days at r.t.  before carefully being poured onto ice (20 g).  The mixture was extracted 
with 9:1 CH2Cl2/MeOH (70 mL) and the organic layer was separated, dried over MgSO4, 
filtered and concentrated under reduced pressure.  The crude compound was purified by 
flash chromatography (EtOAc:Petroleum; 5:2) to afford the title compound as an orange 
solid (160 mg, 0.62 mmol, 86%).  
mp = 97-98 oC; Rf = 0.28 (EtOAc:Petroleum; 5:2); νmax (film)/cm-1 3193w, 2953w and 
2942w (CH), 1640s (C=O), 1454m and 1476m (C=C); 1H NMR (400 MHz, CDCl3)  
δ = 7.65 (d, J = 2.0 Hz, 1H, ArCH), 7.36 (d, J = 2.4 Hz, 1H, OCHa=CHb), 6.88 (d, J = 2.0 
Hz, 1H, ArCH), 6.68 (d, J = 2.4 Hz, 1H, OCHa=CHb), 3.92 (s, 3H, OMe), 3.90 
(s, 3H, OMe); 13C NMR (100.0 MHz, CDCl3) δ = 178.3 (C=O), 178.1 (C=O), 155.4 
(Cquat.), 152.1 (OCHa=CHb), 149.6 (COMe), 148.2 (COMe), 131.0 (Cquat.), 130.7 
(ArCquat.), 110.1 (OCHa=CHb), 108.1 (ArCCquat.), 105.8 (ArCH), 103.2 (ArCH), 56.2 
(OMe) 55.1; HRMS calcd for [C14H11O5]+ 259.0601; found [M+H]+ 259.0605. 
4,5,7,9-Tetramethoxynaphtho[2,3-b]furan (237).  To a solution 
of quinone (236) (200 mg, 0.69 mmol, 1.0 equiv.) in THF (3.0 mL) 
and H2O (2.0 mL) were added TBAB (44 mg, 0.14 mmol, 0.2 
equiv.) and 85% wt. Na2S2O4 (790 mg, 3.40 mmol, 4.9 equiv.).  The 
mixture was stirred for 15 min, before addition of KOH (850 mg, 15.18 mmol, 22.0 
equiv.) was added to the clear solution and the resultant red/purple solution was stirred for 
20 min before addition of Me2SO4 (0.59 mL, 6.21 mmol, 9.0 equiv.).  The solution was 
stirred for a further 2 h before addition of 10% ammonium hydroxide (8.0 mL) and the 
orange/yellow solution was stirred for a further 16 h at r.t.  The mixture was diluted with 
H2O (20 mL) and extracted with EtOAc (3 × 75  mL).  The combined organic layers were 
collected and dried over MgSO4 before concentrating under reduced pressure.  The crude 
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product was then purified using flash chromatography (EtOAc:Petroleum, 1:2 → 1:1) to 
provide the title compound as an orange solid (127 mg, 0.44 mmol, 64% yield). 
mp = 86-88 oC; Rf = 0.36 (EtOAc:Petroleum, 1:1);  νmax (film)/cm-1 2935w, 2867w and 
2837w (CH), 1504w, 1486m and 1444m (C=C); 1H NMR (400 MHz, CDCl3) δ = 7.56 
(d, J = 2.3 Hz, 1H, OCHa=CHb), 7.16 (d, J = 2.3 Hz, 1H, ArCH), 6.96 (d, J = 2.3 Hz, 1H, 
OCHa=CHb), 6.48 (d, J = 2.3 Hz, 1H, ArCH), 4.25 (s, 3H, OMe), 4.00, (s, 3H, OMe), 
3.95 (s, 6H, 2 × OMe); 13C NMR (100.0 MHz, CDCl3) δ = 157.7 (COMe), 157.2 
(COMe), 144.7 (OCHa=CHb), 144.5 (COMe), 144.3 (COMe), 134.2 (ArCquat.), 128.2 
(ArCquat.), 120.7 (ArCquat.), 113.5 (ArCquat), 104.5 (OCHa=CHb), 97.7 (ArCH), 91.9 
(ArCH), 62.9 (OMe), 60.8 (OMe), 56.1 (OMe), 55.3 (OMe); GCMS (CI) = 289 
[C16H17O5]+; found 289 [M+H]+. 
 
7,8-Dimethoxy-1-oxo-1H-isochromene-3-carboxylic acid 
(257)99,101  Freshly distilled diethylbromomalonate (0.71 mL, 
4.2 mmol, 1.0 equiv.) was added via syringe to a suspension of 
opianic acidff (255) (0.9 g, 4.3 mmol, 1.0 equiv.) and anhydrous K2CO3 (1.5 g, 10.9 mmol, 
2.6 equiv.) in freshly distilled but-2-one containing activated 4Å molecular sieves at 
reflux and heating was continued for a further 3 hours.  The solvent was then removed 
under reduced pressure and the crude oily residue was treated with water (5 mL) and 
extracted with ether (2 × 10 mL) and the combined organics were concentrated under 
reduced pressure.  The crude residue was subsequently dissolved in a 1:1 mixture of 
glacial AcOH:23% aq. HCl (10 mL) and refluxed for 1 h.  The mixture was allowed to 
cool to 40 oC and was treated with cold EtOAc (10 mL) causing the title compound to 
precipitate as a pale green solid.  The product was collected by filtration and dried in an 
oven at 60 oC (0.67 g, 2.7 mmol, 65%). 
                                                 
ff Purification of the commercially available opianic acid was achieved by flash 
chromatography (EtOAc:Petroleum) before removing the residual solvent in vacuo. 
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mp = 263-264 oC [lit. 261 oC]; νmax (film)/cm-1 3100-2600br (OH), 1755s and 1685s 
(C=O, ester), 1634m (C=C), 1590m (CO-O), 1562m and 1494m (C=C);  1H NMR (400 
MHz, d6-DMSO) δ = 13.63 (brs, 1H, CO2H), 7.68 (d, J = 8.8 Hz, 1H, ArCH), 7.63 
(d, J = 8.8 Hz, 1H, ArCH), 7.56 (s, 1H, CH=Cquat.), 3.82 (s, 3H, OMe), 3.80 (s, 3H, OMe); 
13C NMR (100.0 MHz, d6-DMSO) δ = 161.2 (CO2H), 157.0 (ArCCO2), 154.5 (COMe), 
149.9 (COMe), 141.2 (CH=Cquat.), 128.7 (ArCquat.), 124.6 (ArCH), 120.3 (ArCH), 116.0 
(ArCquat.), 112.0 (CH=Cquat.), 60.9 (OMe), 56.4 (OMe); HRMS (EI) calcd for [C12H9O4]- 
249.0405; found 249.0399 [M−H]−; spectroscopic data differs to that previously reported 
as discussed on pages 85-86.99,101 
Methyl 7,8-dimethoxy-1-oxo-1H-isochromene-3-carboxylate 
(258).99,101  Method A: To a solution of carboxylic acid (257) 
(100 mg, 0.4 mmol, 1.0 equiv.) in anhydrous CH2Cl2 (5 mL) was 
added a 2M solution of trimethylsilyldiazomethane in Et2O (0.30 
mL, 0.6 mmol, 1.5 equiv.) dropwise at r.t.  The brilliant yellow solution was stirred at r.t. 
for 5 min before it was subsequently treated with dropwise addition of glacial AcOH until 
returning to a clear solution (ca 0.3 mL).  The reaction mixture was then concentrated 
under reduced pressure to afford the title compound (250) as an off-white solid (104 mg, 
0.4 mmol, 99%). 
Method B:  To a solution of carboxylic acid (257) (100 mg, 0.40 mmol, 1.0 equiv.) in 
MeOH (10mL) was added cat. 98% H2SO4 (ca. 100 µl) and the reaction mixture was 
refluxed for 24 h.  The reaction mixture was then concentrated under reduced pressure to 
afford the title compound (249) as a pale yellow solid (102 mg, 0.4 mmol, 97%). 
mp 172-173 oC [lit. 174-176 oC]; νmax (film)/cm-11744m and 1716s (C=O, ester), 1590w 
(CO-O), 1560w, 1497m and 1438m (C=C); 1H NMR (600 MHz, CDCl3) δ = 7.36 
(d, J = 8.4, 1H, ArCH), 7.35 (s, 1H, CH=Cquat.), 7.30 (d, J = 8.4 Hz, 1H, ArCH), 3.97 
(s, 3H, OMe), 3.96 (s, 3H, OMe), 3.93 (s, 3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) 
δ = 161.1 (CO2Me), 157.3 (ArCCO2), 155.2 (COMe), 151.6 (COMe), 141.5 (CH=Cquat.), 
129.1 (ArCquat.), 124.0 (ArCH), 119.5 (ArCH), 117.1 (ArCquat.), 112.5 (CH=Cquat.), 61.8 
O
OMe
MeO
O
CO2Me
(258)
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(OMe), 56.7 (OMe), 52.9 (CO2Me); HRMS (EI) calcd for [C13H12O6Na]+ 287.0532; 
found 287.0536 [M+H]+; spectroscopic data differs to that previously reported as 
discussed on pages 85-86.99,101 
 
Empirical formula              C13 H12 O6 
Formula weight            264.23 
Temperature    120 K 
Wavelength    0.71073 Å 
Crystal system    Monoclinic 
Space group    -P 2yn  
Unit cell dimensions   a =  3.8703(2)Å a = 90ο  
b =  19.8892(14)Å b = 96.022(4)ο 
c = 15.1977(9)  g = 90ο 
Volume                        1163.42(12)Å3 
Z                4 
Density    1.509 Mg/m3 
Absorption coefficient   0.121 mm-1 
F(000)     552 
Crystal size    0.18 × 0.07 × 0.06 mm3 
Theta range for data collection  0.979 to 0.993o 
Index ranges    4<=h<=5, −25<=k<=25, −18<=l<=19 
Reflections collected   20129  
Independent reflections  2631 [R(int) = 0.0986] 
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Completeness to theta  = 25.00o 98.2% 
Absorption correction   Multiscan 
Refinement method   Full-matrix least-squares on F2 
Data/restraints/parameters  2631/ 0/175 
Goodness-of-fit F2   1.026 
Final R indices [I.2sigma(I)]  R1 = 0.0647, wR2 = 0.1214 
R indices (all data)   R1 = 0.1193, wR2 = 0.1411 
Largest diff. peak and hole  0.187 and -0.273 e.Å-3 
4-(tert-Butyldimethylsilyl)oxy)-3-methoxybenzaldehyde (265a).103  
Et3N (70 mL, 502 mmol, 1.5 equiv.) was added at r.t. to a mixture of 
vanillin (50 g, 329 mmol, 1.0 equiv.), TBSCl (54.4 g, 361 mmol, 1.1 
equiv.) and DMAP (0.1 g, 0.8 mmol, 0.25 mol %) in CH2Cl2 (750 mL).  
After stirring at r.t. for 24 h, the organic layers were washed with sat. aq. NH4Cl solution 
(2 × 500 mL).  The separated organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to a brown oil.  Flash chromatography 
(EtOAc:Petroleum, 1:3) afforded the title compound (265a) as a yellow oil (84.3 g, 317 
mmol, 96%). 
Rf = 0.65 (EtOAc:Petroleum, 1:3); νmax (film)/cm-1 2958w and 2930w (C-H), 2857w 
(OCH3), 1696s (C=O, aldehyde), 1593m (C=C), 1284m (SiMe2), 1033m (Si-O), and 
838m (SiMe2); 1H NMR (400 MHz, CDCl3)  δ = 9.85 (s, 1H, CHO), 7.40 (d, J = 1.8 Hz, 
1H, ArCH), 7.36 (dd, J = 8.0 Hz, 1.8 Hz, 1H, ArCH), 6.96 (d, J = 8.0 Hz, 1H, ArCH), 
3.87 (s, 3H, OMe), 1.00  (s, 9H, SiMe2tBu), 0.19 (s, 6H, SiMe2tBu); 13C NMR (100.0 
MHz)  δ = 191.1 (CHO), 151.8 (COMe), 151.5 (COTBS), 131.1 (CCHO), 126.3 (ArCH), 
120.9 (ArCH), 110.3 (ArCH), 55.6 (OMe), 25.7 (SiC(CH3)3), 18.7 (SiC(CH3)3), −4.4 
(SiMe2); HRMS (CI) calc for [C14H23O3Si]+ 267.1412; found 267.1411 [M+H]+; 
spectroscopic data is in agreement with that previously reported.103 
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(4-(1,3-Dioxan-2-yl)-2-methoxyphenoxy)(tert-butyl)dimethylsilane 
(266).103 4-(tert-Butyldimethylsilyl)oxy)3-methoxybenzaldehyde 
(265a) (80 g,  246 mmol, 1.0 equiv.) was dissolved in CH2Cl2 
(210 mL), before addition of 1,3-propanediol (82 mL, 1.14 mol, 4.6 
equiv.), trimethyl orthoformate (49 mL, 477 mmol, 1.9 equiv.) and n-Bu4NBr3 (7.6 g,  
24.2 mmol, 0.01 equiv.) were added and the resultant mixture was stirred at r.t. for 2.5 
days.  Sat. aq. Na2CO3 solution (250 mL) and H2O (250 mL) were added and the layers 
were separated.  The aqueous layer was then extracted with CH2Cl2 (200 mL) and the 
combined organic were dried over MgSO4 and filtered before concentrating under 
reduced pressure.  The crude oil was then purified by flash chromatography (EtOAc:n-
hexane, 1:19) furnishing the title compound (266) as colourless oil (71.7 g, 22.1 mmol, 
90%). 
Rf = 0.64 (EtOAc:Petroleum, 1:19); νmax (film)/cm-1 2955w and 2929w (CH), 2855w 
(OCH3), 1282m (SiMe2), 1123m (SiO) and 838m (SiMe2); 1H NMR (400 MHz, CDCl3)  δ 
= 7.03 (d, J = 1.7 Hz, 1H, ArCH),  6.93 (dd, J = 8.2, 1.7 Hz, 1H, ArCH), 6.83 (d, J = 
8.1 Hz, 1H, ArCH), 5.44 (s, 1H, HCO2), 4.23 (dd, J = 11.2, 5.0 Hz, 2H, 2 × OCHa,Hb), 
3.96-3.86 (m, 2H, 2 × OCHa,Hb), 3.82 (s, 3H, ArOMe), 2.08-2.22 (m, 1H, OCH2CHa,Hb), 
1.39 (m, 1H, OCH2CHa,Hb), 0.99 (s, 9H, SiMe2t-Bu), 0.16 (s, 6H, SiMe2t-Bu); 
13C NMR (100.0 MHz)  δ = 151.1 (COMe), 145.6 (COTBS), 132.6 (CCHO2), 120.8 
(ArCH), 118.8 (ArCH), 109.8 (ArCH), 101.9 (CCHO2), 67.6 (2 × OCH2CH2), 55.6 
(OMe), 25.9 (SiC(CH3)3), 25.9 (2 × OCH2CH2), 18.6 (SiC(CH3)3), −4.5 (SiMe2); HRMS 
(CI) calcd for [C17H29O4Si]+ 325.1826; found 325.1830 [M+H]+; spectroscopic data is in 
agreement with that previously reported.103 
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Representative procedure for deuteration of (266). 
n-Butyllithum (0.25 mL, 0.6 mmol, 2.0 equiv., 2.5 M in hexanes) was added to anhydrous 
cyclohexane (5.0 mL) at 2 οC and the resultant mixture was further cooled to −1 οC 
(external).  Acetal (266) (100 mg, 0.3 mmol, 1.0 equiv.) was added and the reaction was 
further cooled to −6 οC and allowed to stir at that temperature for 20 h, at which point 0.2 
mL of the reaction mixture was removed via syringe and added to a 5 mL round bottom 
flask containing CD3OD (3 mL) under an atmosphere of argon at room temperature.  
After 30 minutes a 1H NMR was recorded to determine conversion of starting material 
upon integration of the signals highlighted overleaf (84%). 
 
Methyl 3-((tert-butyldimethylsilyl)oxy)-6-(1,3-dioxan-2-yl)-2-
methoxybenzoate (266c).103   n-Butyllithum (59 mL, 146 mmol, 
2.5 M in hexanes, 1.2 equiv.) was added to a solution of acetal 
(266) (39 g, 120 mmol, 1.0 equiv.) in anhydrous cyclohexane (750 
mL) at 0 οC.  The mixture was allowed to warm to r.t. and stirred for 4.5 h before 
2 × ArCH (d-257)
ArCH(OR)2 (d-257)
ArCH(OR)2 (257)3 × ArCH (257)
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recooling the solution to 0 οC.  The reactive mixture was quenched by addition of methyl 
chloroformate (31 mL, 401 mmol, 3.3 equiv.) dropwise.  The reaction was allowed to 
warm slowly to r.t. and stirring was continued for a further 16 h.  The reaction mixture 
was quenched with sat. aq. Na2CO3 solution (200 mL), the layers were separated and the 
aqueous layer was extracted with Et2O (3 × 400 mL) and the combined organics were 
dried over MgSO4 and concentrated under reduced pressure before purifying the crude 
product by column chromatography (EtOAc:n-Hexane, 1:5).  The title compound was 
furnished as clear colourless solid (33.1 g, 86.6 mmol, 72%). 
mp. 74-76 οC; [lit. 76-78 οC]; Rf = 0.51 (EtOAc:n-Hexane 1:5); νmax (film)/cm-1 2951w 
and 2930w (CH), 2857w (OCH3), 1724s (C=O, ester), 1599w (CO-O), 1492w, 1453w 
and 1437w (C=C), 1271s (SiMe2), 1143m (SiO) and 838s (SiMe2); 1H NMR (400 MHz, 
CDCl3) δ = 7.23 (d, 1H, J = 8.6 Hz, ArCH), 6.87 (d, 1H, J = 8.6 Hz, ArCH), 5.55 (s, 1H, 
CHO2), 4.21 (dd, J = 11.3, 1.2, 2H, 2 × OCHa,Hb), 3.95-3.86 (m, 2H, 2 × ROCHa,Hb), 
3.89 (s, 3H, OMe), 3.81 (s, 3H, CO2Me), 2.21-2.08 (m, 1H, OCH2CHa,Hb) 1.43-1.35 (m, 
1H, OCH2CHa,Hb), 0.99 (s, 9H, SiMe2t-Bu), 0.16 (s, 6H, SiMe2t-Bu); 13C NMR (100.0 
MHz)  δ = 167.9 (CO2Me), 149.3 (COMe), 148.3 (COTBS), 129.6 (CCHO2), 127.9 
(CCO2Me), 122.2 (ArCH), 122.0 (ArCH), 99.2 (CCHO2), 67.4 (2 × OCH2CH2), 61.4 
(OMe), 52.2 (CO2Me), 25.8 (SiC(CH3)3), 25.7 (OCH2CH2), 18.5 (SiC(CH3)3), −4.7 
(SiMe2);  HRMS (CI) calcd for [C19H31O6Si]+ 383.1885; found 383.1884 [M+H]+; 
spectroscopic data is in agreement with that previously reported.103 
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Empirical formula              C19 H30 O6 Si 
Formula weight            382.52 
Temperature    100(2) K 
Wavelength    0.71073 Å 
Crystal system    Monoclinic 
Space group    -P 2ybc 
Unit cell dimensions   a =  14.6051(10)Å a = 90ο 
b =  15.8731(11)Å b = 97.9860(10)ο 
c = 8.9463(6)Å g = 90ο 
Volume                        2053.9(2) Å3 
Z                4 
Density    1.237 Mg/m3 
Absorption coefficient   0.145 mm-1 
F(000)     824 
Crystal size    0.40 × 0.10 × 0.10 mm3 
Theta range for data collection  2.57 to 34.99ο 
Index ranges    −23<=h<=23, 25−<=k<=24, −14<=l<=7 
Reflections collected   8987 
Independent reflections  43509 [R(int) = 0.0304] 
Completeness to theta = 25.00ο 99.3% 
Absorption correction   Multiscan 
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Refinement method   Full-matrix least-squares on F2 
Data/restraints/parameters  8987/0/242 
Goodness-of-fit F2   1.025 
Final R indices [I.2sigma(I)]  R1 = 0.0421, wR2 = 0.1192 
R indices (all data)   R1 = 0.0590, wR2 = 0.1329 
Largest diff. peak and hole  1.474 and -0.383e.Å-3 
Methyl 6-formyl-3-hydroxy-2-methoxybenzoate (267).103  Acetal 
(266c) (5.0 g, 13.1 mmol, 1.0 equiv.) was dissolved in THF (100 
mL) in a PTFE bottle before addition of conc. aq.HCl (37%, 16 mL), 
KF (2.8 g, 48.4 mmol, 3.7 equiv.) and H2O (20 mL) and the mixture 
was stirred at r.t. for 9 h.  The layers were then separated and the aqueous layer was 
extracted with CH2Cl2 (3 × 80 mL).  The combined organics were dried over MgSO4 and 
concentrated under reduced pressure.  Silica gel chromatography (EtOAc:Petroleum; 2:3) 
afforded the title compound as a light pink solid (1.92 g, 9.1 mmol, 70%). 
mp = 101-103 οC; [lit. 106 οC]; Rf = 0.42 (EtOAc:Petroleum 2:3); νmax (film)/cm-1 3147br 
(OH), 3010w, 2975w, 2847w (C-H), 1742m (C=O, ester) 1661s (C=O, aldehyde), 1597m, 
1560m, 1505m (C=C); 1H NMR (400 MHz, CDCl3) δ = 9.81 (s, 1H, CHO), 7.57 (d, J = 
7.9 Hz, 1H, ArCH), 7.13 (d, J = 7.9 Hz, 1H, ArCH), 6.42 (s, 1H, OH), 4.00 (s, 3H, OMe), 
3.92 (s, 3H, CO2Me); 13C NMR (100.0 MHz)  δ = 189.2 (CHO), 167.1 (CO2Me), 154.5 
(ArCOH), 144.5 (COMe), 130.1 (CCHO), 127.6 (ArCH), 127.2 (ArCH), 116.7 
(CCO2Me), 62.7 (OMe), 53.2 (CO2Me); GCMS (CI) calcd for [C10H9O5]- 209; found 209 
[M−H]−; spectroscopic data is in agreement with that previously reported.103 
Methyl 6-formyl-3-hydroxy-4-iodo-2-methoxybenzoate (268).103   
To a solution of phenol (267) (1.2 g, 5.7 mmol, 1.0 equiv.) in 
CH2Cl2 (25 mL) was added tetramethylammonium dichloroiodate119 
(1.86 g, 6.9 mmol, 1.2 equiv.) and NaHCO3 (1.1 g, 12.6 mmol, 2.2 
equiv.) at 0 οC and the reaction was allowed to stir at r.t. for 4 h.  The reaction mixture 
was then re-cooled to 0 οC before addition of aq. HCl solution (1M, 20 mL) and CH2Cl2 
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(25 mL) and the organics were then washed with sat. aq. Na2S2O3 solution (30 mL).  The 
organics were dried over MgSO4 and concentrated under reduced pressure before silica 
gel chromatography (EtOAc:Petroleum; 3:1) afforded the title compound as a yellow oil, 
which solidified to give a faintly yellow solid upon storage (1.90 g, 5.7 mmol, 99%) at 
3 οC for 30 min. 
mp = 37-39 οC; Rf = 0.81(EtOAc:Petroleum 3:1); νmax (film)/cm-1 3315br (OH), 3017w, 
2978w and 2846w (CH), 1739m (C=O, ester), 1678s (C=O, carbonyl), 1570m, 1491m 
and 1471m (C=C); 1H NMR (400 MHz, CDCl3) δ = 9.76 (s, 1H, CHO), 7.98 (s, 1H, 
ArCH), 3.99 (s, 3H, OMe), 3.93 (s, 3H, CO2Me); 13C NMR (100.0 MHz)  δ = 187.8 
(CHO), 166.3 (CO2Me), 154.5 (COH), 143.8 (COMe), 138.3 (ArCH), 128.2 (CCHO), 
128.0 (CCO2Me), 84.0 (CI), 62.7 (OMe), 53.3 (CO2Me); GCMS (CI) calcd for 
[C10H8IO5]-  335; found 335 [M−H]−; spectroscopic data is in agreement with that 
previously reported.103 
Methyl bromomethoxyacetate (274).120  **Caution, this reaction is 
extremely exothermic, take care to heat the reaction gently, in a vessel 
no smaller than 2 litres with extremely efficient vapour cooling.** Methyl 
methoxyacetate (20.0 g, 192 mmol, 1.0 equiv.) was dissolved in CCl4 (250 mL), before 
addition of NBS (34.2 g, 192 mmol, 1.0 equiv) and benzoyl peroxide (75% in H2O) (400 
mg, 1.2 mmol, 0.6 mol. %) and the mixture was gently heated to 77 oC over 6 hours so as 
to control the potentially explosive reaction.  The reaction was stirred at 77 oC for a 
further 16 hours and the mixture was then filtered and concentrated under reduced 
pressure to afford the title compound (274) as a brown oil (26.3 g, 144 mmol, 75%).  A 
sample of the resultant residue was then distilled under reduced pressure 
(43-45 oC/0.1 mbar) to afford the title compound as clear, pale yellow oil and the 
remainder was carried forward without further purification.   
νmax (film)/cm-1 2957w (CH3), 2843w (CH3), 1747s (C=O), 1378m (CO2C-H3); 
1H NMR (400 MHz, CDCl3) δ = 6.01 (s, 1H, CH), 3.85 (s, 3H, OMe) 3.58 
(s, 3H, CO2Me); 13C NMR (100.0 MHz)  δ = 166.0 (CO2Me), 83.2 (CBr), 58.9 (OMe), 
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53.4 (CO2Me); GCMS (CI) = 182 [C4H779BrO3]+ and 184 [C4H781BrO3]+; found 182 and 
184; spectroscopic data is in agreement with that previously reported.121 
Methyl (Dimethylphosphono)methoxyacetate (269).121  **Caution, 
this reaction is extremely exothermic, take care to add the 
trimethyl phosphite dropwise at r.t.** To a 100 ml round bottomed 
flask fitted with an air condenser was added crude methyl bromomethoxyacetate (26.3 g, 
144 mmol, 1.0 equiv.) was carefully added trimethyl phosphite (18 mL, 153 mmol, 1.1 
equiv.) dropwise at r.t. and the resultant, gently bubbling mixture was stirred at r.t for 20 
min before heating to 185 oC for 5 hours.  The cooled reaction mixture was then distilled 
under reduced pressure (111-112 oC/0.1 mbar) to afford the title compound (269) as a 
clear, colourless oil (30.5 g, 144 mmol, 99%). 
νmax (film)/cm-1 2900w (CO2C-H3), 2853w and 2849w (OCH3), 1750s (C=O), 1262s 
(P=O); 1H NMR (400 MHz, CDCl3) δ = 4.25 (d, J = 19.5 Hz, 1H, PCH), 3.86 (d, J = 5.2 
Hz, 3H, POMe), 3.84 (s, 3H, OMe), 3.83 (d, J = 5.2 Hz, 3H, POMe), 3.52 (d, J = 0.5 Hz,  
3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) δ = 167.3 (CO2Me), 78.8 (d, J = 158.3 Hz, 
(PCH), 60.3(d, J = 12.9 Hz, COMe), 54.2 (d, J = 8.0 Hz, POMe), 54.1 (d, J = 8.0 Hz, 
POMe), 52.8 (CO2Me); 31P (161.9, MHz, CDCl3) δ = 16.3 (P=O); HRMS (CI) calcd for 
[C6H14O6P]+ 213.0528;  found 213.0519 [M+H]+; spectroscopic data is in agreement with 
that previously reported.122 
Methyl 6-(1,3-dioxan-2-yl)-3-hydroxy-2-methoxybenzoate (266a).  
Method A: To a solution of silyl ether (266c) (70 mg, 0.22 mmol, 
1.0 equiv.) in DMSO (1.4 mL, 19.7 mmol, 90 equiv.) and H2O (79 µl, 
4.4 mmol, 20 equiv.) was heated at 170 οC for 2 h.  The reaction 
mixture was cooled to r.t. diluted with Et2O (10 mL) and washed with sat. aq. NaCl 
solution (5 × 6 mL), dried over MgSO4, and concentrated under reduced pressure.  
Purification of the crude reaction mixture by silica gel chromatography 
(EtOAc:Petroleum; 1:3) afford the title compound as a white solid (58 mg, 0.22 mmol, 
99%).   
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Method B: To a solution of silyl ether (266c) (500 mg, 1.3 mmol, 1.0 equiv.) in THF (10 
mL) was added 1M TBAF in THF (1.4 mL, 1.4 mmol 1.1 equiv.) and stirred at r.t. for 60 
min before addition of saturated aq. NH4Cl (10 mL).  The mixture was extracted with 
Et2O (3 × 35 mL), dried over MgSO4 before concentrating under reduced pressure before 
silica gel chromatography (EtOAc:Petroleum; 1:3) afforded the title compound as a white 
solid (344 mg, 1.3 mmol., 98%).   
mp = 174-176 οC; Rf = 0.21 (EtOAc:Petroleum;1:3); νmax (film)/cm-1 3214br (-OH), 
3006w, 2987w and 2924w (CH), 2857w (OCH3), 1699s (C=O), 1587m (C=C); 1H NMR 
(400 MHz, CDCl3) δ = 7.31 (dd, 1H, J = 8.5, 0.5 Hz, ArCH), 7.00 (d, 1H, J = 8.5 Hz, 
ArCH), 5.70 (brs, 1H, OH), 5.58 (s, 1H, CHO2), 4.22 (ddd, J = 11.9, 5.0, 1.3 Hz, 2H, 2 × 
OCHa,HbCH2), 3.92 (s, 3H, OMe), 3.91 (ddd, J = 12.3, 2.5, 1.3 Hz, 2H, 2 × 
ROCHa,HbCH2), 3.85 (s, 3H, CO2Me), 2.16 (dddd, J = 17.4, 13.2, 12.3, 5.0Hz, 1H, 
OCH2CHa,Hb), 1.41 (dddd, J = 13.5, 4.0, 2.5 Hz, 1.3 Hz, 1H, OCH2CHa,Hb); 
13C NMR (100.0 MHz)  δ = 167.5 (CO2Me), 149.2 (COH), 144.3 (COMe), 129.0 
(CCHO2), 126.0 (CCO2Me), 122.9 (ArCH), 116.9 (ArCH), 99.1 (CCHO2), 67.5 (2 × 
OCH2CH2), 62.6 (OMe), 52.5 (CO2Me), 25.7 (OCH2CH2);  HRMS (CI) calcd for 
[C13H17O6]+ 269.1020; found 269.1023 [M+H]+. 
Methyl 3-((tert-butyldimethylsilyl)oxy)-6-formyl-2-
methoxybenzoate (275).  Method A: Et3N (0.07 mL, 0.50 mmol, 
1.5 equiv.) was added at r.t. to a mixture of phenol (267) (69 mg, 
0.33 mmol, 1.0 equiv.), TBSCl (54.3 mg, 0.36 mmol, 1.1 equiv.) 
and DMAP (2 mg, 0.01 mmol, 5 mol %) in CH2Cl2 (1.0 mL).  After stirring at r.t. for 
24 h, the reaction was diluted with CH2Cl2 (10 mL) and washed with sat. aq. NH4Cl 
solution (2 × 5 mL).  The organic layer was separated, dried over MgSO4, filtered and 
concentrated under reduced pressure to a pale yellow/brown oil.  Flash chromatography 
(EtOAc:Petroleum, 1:3) afforded the title compound (268) as a pale yellow oil  (102 mg, 
0.31 mmol, 95%). 
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Method B: To a solution of acetal (266c) (16.9 g, 44.2 mmol, 1.0 equiv.) in reagent grade 
THF (1.5 L) at −5 οC was added TMSOTf (8.4 mL, 46.4 mmol, 1.05 equiv.) dropwise and 
left to stir at that temperature for 15 minutes.  H2O (8.8 mL, 488.9 mmol, 11.1 equiv.) 
was then added dropwise to the reaction over 180 min (at which time TLC analysis 
indicated complete consumption of the starting material) before diluting the reaction 
mixture with EtOAc (1.5 L).  Saturated aq. Na2CO3 solution (1.5 L) was then added to the 
solution.  The organics were then separated before further extraction of the aqueous layer 
with EtOAc (1.5 L) and the combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure at 30 οC.  The resultant brown oil was then purified 
by flash chromatography on silica gel (EtOAc:Petroleum, 1:5) to afford the title 
compound as a pale yellow oil (13.2 g, 92%). 
Rf = 0.41 (EtOAc:Petroleum, 1:5); νmax (film)/cm-1 2952w and 2933w (CH), 2859w 
(OCH3), 1737s (C=O, ester), 1695s (C=O, aldehyde), 1584m (CO-O), 1264s and 834s 
(SiMe2) and 1138m (SiO); 1H NMR (400 MHz, CDCl3) δ = 9.82 (s, 1H, CHO), 7.52 
(d, 1H, J = 8.5, ArCH), 7.00 (d, 1H, J = 8.5, ArCH), 3.97 (s, 3H, OMe), 3.85 
(s, 3H, CO2Me), 1.02 (s, 9H, SiMe2t-Bu), 0.25 (s, 6H, SiMe2t-Bu); 13C NMR (100.0 
MHz) δ = 189.0 (CHO),  167.1 (CO2Me), 154.8 (COMe), 148.9 (COTBS), 130.3 
(CCHO), 128.9 (ArCH), 127.7 (CCO2Me), 121.9 (ArCH), 61.8 (OMe), 52.9 (CO2Me), 
25.7 (SiC(CH3)3), 18.4 (SiC(CH3)3), −4.3 (SiMe2);  HRMS (CI) calcd for [C16H25O5Si]+ 
324.1466; found 325.1467 [M+H]+. 
(E/Z)-Methyl-3-((tert-butyldimethylsilyl)oxy)-6-(2,3-
dimethoxy-3-oxoprop-1-en-1-yl)-2-methoxybenzoate (276).  
To a solution of phosphonate (269) (3.5 g, 16.5 mmol, 1.3 
equiv.) in THF (40 mL) was added NaHMDS (2 M in THF, 
8.6 mL, 17.1 mmol, 1.35 equiv.) dropwise at −78 οC over 10 minutes before stirring at 
this temperature for 20 minutes.  A solution of aldehyde (275) (4.1g, 12.7 mmol, 1.0 
equiv.) in THF (20 mL) was added dropwise and the reaction mixture was allowed to 
O
CO2MeTBSO
CO2Me
OMe
(276)
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warm slowly warm to r.t.and stirred for 16 h.  A saturated solution of aq. NH4Cl (45 mL) 
was introduced and the crude mixture was extracted with Et2O (3 × 50 mL).  The 
combined organics were dried over MgSO4 and concentrated under reduced pressure to 
afford the title compound (5.0 g, 12.2 mmol, 96%) of as an inseparable  mixture of (E:Z; 
1:5) isomers respectively as a pale yellow oil.  Stereochemical assignments were made on 
the basis of NOESY experiments and correllation of chemical shifts of closely related 
literature compounds.103 
Rf = 0.28 (EtOAc;Petroleum 1:19); νmax (film)/cm-1 2953w and 2931w (CH), 2858w 
(OCH3), 1722s (C=O, ester), 1636w (C=C, conj), 1590m (CO-O), 1484m (C=C), 1236s 
and 836s (SiMe2) and 1138m (SiO); HRMS (CI) calcd for [C19H28O7N1Si1]+ 428.2099; 
found [M+NH4]+ 428.099; (Z)-isomer: 1H NMR (400 MHz, CDCl3) δ 7.80 (d, 1H,  J = 
8.63, ArCH), 6.91 (d, 1H,  J = 8.63, ArCH), 6.83 (s, 1H, HC=Cquat.), 3.95 (s, 3H, OMe), 
3.83 (s, 3H, OMe), 3.82 (s, 3H, CO2Me), 3.73 (s, 3H, CO2Me), 1.02 (s, 9H, SiMe2t-Bu), 
0.22 (s, 6H, SiMe2t-Bu); 13C NMR (100.0 MHz, CDCl3) δ 167.7 (CO2Me), 164.6 
(CO2Me), 149.3 (COMe), 148.1 (ArCquat.), 145.6 (COTBS), 130.6 (ArCquat.), 126.3 
(ArCH), 124.3 (HC=Cquat.), 122.3 (ArCH), 119.4 (HC=Cquat.), 61.3 (OMe), 59.3 (OMe), 
52.4 (CO2Me), 52.2 (CO2Me), 29.5 (SiC(CH3)3), 18.2 (SiC(CH3)3), −4.49 (SiMe2); 
(E)-isomer: 1H NMR (400 MHz, CDCl3) δ = 6.84-6.79 (m, 2H, 2 × ArCH), 6.11 (s, 
1H, HC=Cquat.), 3.85 (s, 3H, OMe), 3.82 (s, 3H, OMe), 3.69 (s, 3H, CO2Me), 3.60 (s, 3H, 
CO2Me), 1.00 (s, 9H, SiMe2t-Bu), 0.19 (s, 6H, SiMe2t-Bu); 13C NMR (100.0 MHz, 
CDCl3) δ 167.8 (CO2Me), 163.9 (CO2Me), 148.3 (COMe), 147.9 (ArCquat.), 147.9 
(COTBS), 128.9 (ArCquat.), 126.5 (HC=Cquat.), 125.2 (ArCH), 122.1 (ArCH), 107.0 
(HC=Cquat.), 61.3 (OMe), 56.0 (OMe), 52.1 (CO2Me), 52.0 (CO2Me), 25.7 (SiC(CH3)3), 
18.2 (SiC(CH3)3), -4.6 (SiMe2).  
Methyl 6-(2,3-dimethoxy-3-oxoprop-1-en-1-yl)-3-hydroxy-2-
methoxybenzoate (277).  To a solution of (276) (340 mg, 0.82 
mmol, 1.0 equiv.) in THF (3.5 mL) was added 1M TBAF in 
THF (1.05 mL, 1.05 mmol 1.28 equiv.) and stirred at r.t. for 30 
min before addition of sat. aq. NH4Cl solution (5 mL).  The mixture was extracted with 
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Et2O (3 × 20 mL), dried over MgSO4 before concentrating under reduced pressure to 
afford the title compound (E:Z; 1:5) as a yellow oil that could be further purified using 
coloumn chromatography (EtOAc:Petroleum, 1:3) to give a pale yellow oil (238 mg, 
97%).  Stereochemical assignments were made on the basis of NOESY experiments and 
correllation of chemical shifts of closely related literature compounds.103 
Rf = 0.23 (EtOAc:Petroleum 1:8); νmax (film)/cm-1 3283br (OH), 2998w and 2939w (CH), 
2834w (OCH3), 1730s and 1701s (C=O, ester), 1629 (C=C, conj.) 1573m (C=C), 1275s 
and 1063 (C-O-CH3); HRMS (CI) calcd for [C14H17O7]+ 297.0972; found 297.0696 
[M+H]+; (Z)-isomer: 1H NMR (400 MHz, CDCl3) δ 7.81 (d, 1H, J = 7.50, ArCH), 7.03 
(d, 1H, J = 7.5, ArCH), 6.88 (s, 1H, HC=Cquat.) 5.89 (brs, 1H, OH), 3.97 (s, 3H, OMe), 
3.86 (s, 3H, OMe), 3.83 (s, 3H, CO2Me), 3.71 (s, 3H, CO2Me); 13C NMR (100.0 MHz, 
CDCl3) δ 167.8 (CO2Me), 165.2 (CO2Me), 149.7 (COH), 146.0 (COMe), 127.6 (ArCH), 
124.2 (HC=Cquat.), 120.0 (ArCH), 117.8 (HC=Cquat.), 62.9 (OMe), 59.9 (OMe), 53.2 
(CO2Me), 52.7 (CO2Me); (E)-isomer: 1H NMR (400 MHz, CDCl3) δ 6.85-6.78 (m, 2H, 
ArCH), 6.12 (s, 1H, HC=Cquat.), 5.85 (brs, 1H, OH), 3.87 (s, 3H,OMe), 3.84 (s, 3H, 
OMe), 3.70 (s, 3H, CO2Me), 3.61 (s, 3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) δ 
167.8 (CO2Me), 164.1 (CO2Me), 148.2 (COH), 147.0 (COMe), 128.76 (ArCquat.), 128.2 
(CH=Cquat.), 125.7 (ArCH), 122.7 (ArCH), 107.1 (HC=Cquat.), 63.0 (OMe), 56.3 (OMe), 
52.4 (CO2Me), 52.0 (CO2Me). 
Methyl 7-hydroxy-8-methoxy-1-oxo-1H-isochromene-3-
carboxylate (278).  Method A: A solution of (277) (100 mg, 
0.34 mmol) dissolved in a 1:1 mixture of MeOH:HBr (37%) was 
heated to 95 oC in a sealed microwave vial for 12 h before slowly cooling to −25 οC.  The 
resultant creamy precipitate was filtered and washed with cold Et2O (15 mL).  The mother 
liquors were then diluted with H2O (10 mL) before further extraction with EtOAc (3 × 15 
mL), the organics were then concentrated under reduced pressure to give a mixture of 
white solid in a pale yellow oil.  The subsequent oil/solid mixture was washed with cold 
Et2O (15 mL) and the combined solids were further purified via column chromatography 
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(EtOAc: Petroleum 4:1) to afford the title compound as a pale white solid (55 mg, 0.22 
mmol, 64%). 
Method B: A solution of (277) (100 mg, 0.34 mmol) dissolved in a 2:1 mixture of 
MeOH:3N H2SO4 (2 mL) was heated to 95 oC in a sealed microwave vial for 4 h before 
slowly cooling to −25 οC.  The resultant creamy precipitate was filtered and washed with 
cold Et2O (15 mL).  The mother liquors were then diluted with H2O (10 mL) before 
further extraction with EtOAc (3 × 15 mL), the organics were then concentrated under 
reduced pressure to give a mixture of white solid in a pale yellow oil.  The subsequent 
oil/solid mixture was washed with cold Et2O (15 mL) and the combined solids were 
further purified via column chromatography (EtOAc: Petroleum 4:1) to afford the title 
compound as a pale white solid (72 mg, 0.29 mmol, 85%). 
Method C:  Methyl ester (277) (100 mg, 0.34 mmol, 1.00 equiv.) and PTSA 
monohydrate (66 mg, 0.35 mmol, 1.02 equiv.) were added PhMe (2 ml) under stirring in a 
microwave vial, the reaction vessel was then sealed and heated to 135 οC (external) for 21 
h.  The reaction mixture was then slowly cooled to −25 οC and the resultant creamy 
precipitate was filtered and washed with cold Et2O (15 mL).  The resultant white solid 
was further purified via column chromatography (EtOAc: Petroleum 4:1) to afford the 
title compound as a pale white solid (80 mg, 0.32 mmol, 94%). 
mp = 136-138 οC; Rf = 0.21 (EtOAc:Petroleum 4:1);  νmax (film)/cm-1 3241br (-OH), 
3083w (CH), 2944w (OCH), 1695 (C=O ester), 1592m, 15992m, 1509m, 1494m (C=C), 
1306s (-O-H) 1237s and 1071s (C-O-CH3); 1H NMR (400 MHz, d6-DMSO) δ 10.36 (brs, 
1H, COH), 7.58 (s, 1H, CH=Cquat.), 7.51 (d, 1H, J = 8.49, ArCH), 7.42 (d, 1H, J = 8.49, 
ArCH), 3.85 (s, 3H, OMe), 3.80 (s, 3H, CO2Me); 13C NMR (100.0 MHz, d6-DMSO) δ = 
160.3 (CO2Me), 156.8 (ArCCO2), 153.2 (COH), 148.3 (COMe), 139.7 (CH=Cquat.), 127.7 
(ArCquat.), 124.9 (ArCH), 124.4 (ArCH), 116.3 (ArCquat.), 112.9 (CH=Cquat.), 60.9 (OMe), 
52.50 (CO2Me); HRMS (EI) calcd for [C12H11O6]+251.0550; found [M+H]+ 251.0552. 
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Methyl 6-(2,3-dimethoxy-3-oxoprop-1-en-1-yl)-3-hydroxy-4-
iodo-2-methoxybenzoate (270).103  To a solution of phenol (277) 
(1.69 g, 5.7 mmol, 1.0 equiv.) in CH2Cl2 (25 mL) was added 
tetramethylammonium dichloroiodate122 (1.86 g, 6.9 mmol, 1.2 equiv.) and NaHCO3 (1.1 
g, 12.6 mmol, 2.2 equiv.) at 0 οC and the reaction was allowed to stir at r.t. for 8 h.  The 
reaction mixture was then re-cooled to 0 οC before addition of a solution of aq. HCl (1M, 
20 mL) and CH2Cl2 (25 mL) and the organics were then washed with Na2S2O3 (30 mL).  
The organics were dried over MgSO4 and concentrated under reduced pressure before 
silica gel chromatography (EtOAc:Petroleum; 3:1) afforded the title compound (E:Z; 1:5) 
as a yellow oil, which solidified to give a faintly yellow solid (2.01 g, 86%) upon storage 
at 3 οC for 60 min. 
 
mp = 103-105 οC [lit. 109 οC (7:13)]; Rf = 0.23 (EtOAc:Petroleum 3:1); νmax (film)/cm-1 
3380br (OH), 2950w (CH), 2849w (OCH3), 1717s (C=O, ester), 1633m (C=C, conj.), 
1561m (C=C), 1434m (C-H), 1407m (C-H), 1235s, 1199s, 1133s, 1106s (C-O-CH3); 
GCMS (CI) calc for [C14H16IO7]+ 423; found 423 [M+H]+; (Z)-isomer: 1H NMR 
(400 MHz, CDCl3) δ = 1H NMR (400 MHz, CDCl3) δ = 8.24 (s, 1H, ArCH), 6.76 (s, 1H, 
CH=Cquat.), 3.94 (s, 3H, OMe), 3.85 (s, 3H, OMe), 3.81 (s, 3H, CO2Me), 3.72 
(s, 3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) δ =166.6 (CO2Me), 164.3 (CO2Me), 
149.2 (COH), 146.2 (COMe), 143.5 (CH=Cquat.), 135.6 (ArCH) 128.6 (ArCquat.), 125.2 
(ArCquat.), 117.8 (CH=Cquat.) 85.5 (CI), 62.2 (OMe), 59.4 (OMe), 52.6 (CO2Me), 52.2 
(CO2Me); (E)-isomer: 1H NMR (400 MHz, CDCl3) δ = 1H NMR (400 MHz, CDCl3) δ = 
7.33 (s, 1H, ArCH), 6.06 (s, 1H, CH=Cquat.), 3.88 (s, 6H, 2 × OMe), 3.71 (s, 3H, CO2Me), 
3.66 (s, 3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) δ =166.7 (CO2Me), 163.4 (CO2Me), 
148.2 (COH), 148.1 (COMe), 143.3 (CH=Cquat.), 134.6 (ArCH) 127.4 (ArCquat), 126.9 
(ArCquat.), 105.8 (CH=Cquat.) 84.6 (CI), 62.2 (OMe), 56.0 (OMe), 52.4 (CO2Me), 52.3 
(CO2Me); spectroscopic data is in agreement with that previously reported.103 
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Methyl 7-hydroxy-8-methoxy-1-oxo-1H-isochromene-3-
carboxylate (271).103  Method A: A solution of (270) (128 mg, 
0.34 mmol) dissolved in a 1:1 mixture of MeOH:HBr(aq.) (37%) 
was heated to 95 oC in a sealed microwave vial for 12 h before 
slowly cooling to −25 οC.  The resultant creamy precipitate was filtered and washed with 
cold Et2O (15 mL).  The mother liquors were then diluted with H2O (10 mL) before 
further extraction with EtOAc (3 × 15 mL), the organics were then concentrated under 
reduced pressure to give a mixture of white solid in a pale yellow oil.  The subsequent 
oil/solid mixture was washed with cold Et2O (15 mL) and the combined solids were 
further purified via column chromatography (EtOAc: Petroleum 4:1) to afford the title 
compound as a pale pink solid (87 mg, 0.23 mmol, 68%). 
Method B: A solution of (270) (128 mg, 0.34 mmol) dissolved in a 2:1 mixture of 
MeOH:3N H2SO4 (2 mL) was heated to 95 oC in a sealed microwave vial for 4 h before 
slowly cooling to −25 οC.  The resultant creamy precipitate was filtered and washed with 
cold Et2O (15 mL).  The mother liquors were then diluted with H2O (10 mL) before 
further extraction with EtOAc (3 × 15 mL), the organic layers were then concentrated 
under reduced pressure to give a mixture of white solid in a pale yellow oil.  The 
subsequent oil/solid mixture was washed with cold Et2O (15 mL) and the combined solids 
were further purified via column chromatography (EtOAc: Petroleum 4:1) to afford the 
title compound as a pale pink solid (107 mg, 0.28 mmol, 83%). 
Method C: Methyl ester (270) (128 mg, 0.34 mmol, 1.00 equiv.) and PTSA monohydrate 
(66 mg, 0.35 mmol, 1.02 equiv.) were added to PhMe (2 ml) under stirring in a 
microwave vial, the reaction vessel was then sealed and heated to 135 οC (external) for 21 
h.  The reaction mixture was then slowly cooled to −25 οC and the resultant creamy 
precipitate was filtered and washed with cold Et2O (15 mL).  The resultant white solid 
was further purified via column chromatography (EtOAc: Petroleum 4:1) to afford the 
title compound as a pale pink solid (71 mg, 0.26 mmol, 75%) 
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mp = >200 οC; [lit. 249 oC, dec.]; Rf = 0.12 (EtOAc:Petroleum 3:1); νmax (film)/cm-1 
3450br (OH), 3091w and 2984w (CH), 2940 (OCH3), 1741s and 1715m (C=O, ester), 
1572m, 1553m and 1497m (C=C); 1H NMR (400 MHz, d6-DMSO) δ = 10.80 (brs, 1H, 
OH), 8.14 (s, 1H, ArCH), 7.57 (s, 1H, ArCH=CR2), 3.84 (s, 3H, OMe), 3.79 (s, 3H, 
CO2Me); 13C NMR (100.0 MHz, d6-DMSO) δ = 160.3 (CO2Me), 156.9 (CO2R), 153.0 
(ArOH); 147.0 (ArOMe); 140.6 (ArCH=CHR), 134.0 (ACrH), 129.0 (ArCH=CHR), 
116.0 (ArCO2Me), 111.9 (ArCH=CHR), 96.6 (ArI); 62.1 (OMe), 52.8 (CO2Me); GCMS 
(CI) calcd [C12H10IO6]+ 377; found 377 [M+H]+; spectroscopic data is in agreement with 
that previously reported.103 
Methyl 7-(allyloxy)-8-methoxy-1-oxo-1H-isochromene-
3-carboxylate (278a).98  To a solution of (278) (250 mg, 
1.0 mmol 1.0 equiv) in DMF (8 mL) in a microwave 
microwave vial fitted with a rubber septum was added 
Hünig’s base (0.35 mL, 2.0 mmol, 2.0 equiv.) and ally bromide (175 μL, 2.0 mmol, 2.0 
equiv.).  The reaction vessel was then fitted with a “crimp cap” and heated at 80 οC for 
24 h.  After cooling the reaction mixture to r.t. the reaction mixture was filtered though a 
short plug of silica (1 cm w × 1 cm h), washing through with EtOAc (50 mL) and MeCN 
(20 mL).  The combined organics were then washed with sat. aq. NaCl solution (10 × 15 
mL), dried over MgSO4 and concentrated under reduced pressure before silica gel 
chromatography (EtOAc:Petroleum; 4:5) afforded the title compound as a pale 
yellow/green solid (272 mg, 0.94 mmol, 90%). 
mp = 120-121 οC [lit. 120-122 οC]; Rf = 0.14 (EtOAc:Petroleum 1:2); νmax (film)/cm-1 
3090w, 2999w, 2941w and 2845w (CH), 1723s (2 × C=O, ester), 1634m (CO-O), 1594m, 
1490m and 1478m (C=C); 1H NMR (400 MHz, CDCl3) δ = 6.85 (d, 1H, J = 8.3 Hz, 
ArCH), 6.83 (s, 1H, HC=Cquat.), 6.76 (d, 1H, J = 8.3 Hz, ArCH), 5.63-5.48 (m, 1H, 
OCH2CH=CH2), 4.93 (d, 1H, J = 17.4 Hz, OCH2CH=CHaHb), 4.81 (d, 1H, J = 10.0 Hz, 
OCH2CH=CHaHb), 4.17 (d, 2H, J = 4.4 Hz, OCH2CH=CH2) 3.46 (s, 3H, OMe), 3.40 (s, 
3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) δ = 161.0 (CO2Me), 157.6 (CCO2), 149.8 
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(COMe), 147.3 (COAllyl), 141.5 (CH=Cquat.), 136.2 (OCH2CH=CH2), 134.4 (ArCH), 
128.8 (ArCquat.), 124.7 (ArCH), 117.8 (OCH2CH=CH2), 113.9 (ArCquat.), 113.0 
(CH=Cquat.), 63.1 (OMe), 53.0 (CO2Me), 34.5 (OCH2); GCMS (CI) calcd for [C15H15O6]+ 
291; found 291 [M+H]+; spectroscopic data is in agreement with that previously 
reported.98 
Methyl 6-allyl-7-hydroxy-8-methoxy-1-oxo-1H-
isochromene-3-carboxylate (279).98 To a microwave 
microwave vial fitted with a septum was added isocoumarin 
(278a) (265 mg, 0.92 mmol, 1.0 equiv.) and chorobenzene (3 
mL).  The reaction vessel was fitted with a “crimp-cap” and heated in a microwave 
reactor at 150 οC (0-300 W, variable power) for 6 h.  After the reaction vessel was cooled 
to r.t., the reaction mixture was diluted with EtOAc (30 mL) and washed with sat. aq. 
NH4Cl solution (3 × 20 mL).  The organics were dried over MgSO4 and concentrated 
under reduced pressure before silica gel chromatography (EtOAc) afforded the title 
compound as an off-white solid. 
mp 188-189 oC [lit. 188-190.5 oC]; Rf = 0.65 (EtOAc); νmax (film)/cm-1 3400br (OH), 
3080w, 2999w and 2964w (CH), 2853w (OCH3), 1724s (C=O, ester), 1649m (C=O, 
ester), 1600m, 1490m and 1465 cm (C=C); 1H NMR (400 MHz, CDCl3) δ 7.37 (s, 1H, 
ArCH), 7.16 (s, 1H, CH=Cquat.), 6.59 (brs,1H, OH), 6.04-5.94 (m, 1H, CH2CH=CH2), 
5.19-5.12 (m, 2H, CH2CH=CH2), 4.02 (s, 3H, OMe), 3.93 (s, 3H, OMe), 3.52 (d, 2H, J = 
5.3 Hz, CH2CH=CH2); 13C NMR (100.0 MHz, CDCl3) δ = 160.9 (CO2Me), 157.4 
(CCO2), 149.7 (COH), 147.2 (COMe), 141.3 (CH=Cquat.), 136.1 (ArCquat), 134.3 (ArCH), 
128.6 (ArCquat.), 124.6 (ArCquat.), 117.6 (CH2CH=CH2), 113.8 (CH=Cquat), 112.9 
(CH2CH=CH2), 62.9 (OMe), 52.8 (CO2Me), 34.3 (CH2CH=CH2); GCMS (CI) calcd for 
[C15H15O6]+ 291; found 291 [M+H]+; spectroscopic data is in agreement with that 
previously reported.98 
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(Z)-Methyl 7-hydroxy-8-methoxy-1-oxo-6-(prop-1-en-1-yl)-1H-
isochromene-3-carboxylate (282). To a suspension of phenol 
(279) (30 mg, 0.10 mmol, 1.0 equiv.) in EtOH (2 mL) was added 
RhCl3.xH2O (38-40% Rh, 10 mg, ~0.03 mmol, 0.32 equiv.) and the 
reaction mixture was stirred at r.t. for 16 h.  The reaction mixture was then diluted with 
EtOAc (50 mL) and MeOH (5 mL) and the filtered through a silica plug (0.5 cm w × 0.3 
cm h) and the filtrate was concentrated under reduced pressure at r.t. to provide the title 
compound as light brown solid (28 mg, 0.09 mmol, 95%). 
mp = > 200οC; Rf = 0.42 (EtOAc); νmax (film)/cm-1 3430br (OH), 3075w, 2990w and 
2972w (CH), 2848w (OCH3), 1719s (C=O, ester), 1630m (C=O, ester), 1610m, 1490m 
and 1465 cm (C=C);  1H NMR (400 MHz, CDCl3) δ = 7.37 (d, J = 1.8 Hz, 1H, ArCH), 
7.34 (d, J = 1.8 Hz,  CH=Cquat.), 6.75-6.68 (m, 1H, CH=CHCH3), 6.65 (brs, 1H, OH), 
6.62-6.58 (dq, J = 6.5, 1.9 Hz, 1H, CH=CHCH3), 4.03 (s, 3H, OMe), 3.94 (s, 3H, 
CO2Me), 2.05-1.96 (m, 3H, ArCH=CHCH3); 13C NMR (100.0 MHz) δ = 160.7 (CO2Me), 
156.0 (CCO2), 148.4 (COH), 147.7 (COMe), 141.4 (CH=Cquat.), 132.9 (ArCquat.), 128.5 
(ArCquat.), 124.2 (ArCH=Cquat.), 121.0 (ArCH=CHCH3), 116.0 (ArCO2R), 112.9 (ArCH), 
111.9 (CH=Cquat.), 62.9 (OMe), 52.8 (CO2Me), 19.2 (CH3); GCMS (CI) calcd for 
[C15H15O6]+ 291; found 291 [M+H]+. 
3-(Ethoxymethyl)-4-hydroxy-5-methoxybenzaldehyde (285).  To 
a solution of morpholine (0.86 g, 9.9 mmol, 1.5 equiv.) in EtOH 
(3 mL) over 3Å molecular sieves was added paraformaldehyde 
(1.0 g, 9.9 mmol, 1.5 equiv.) at r.t. and the suspension was stirred for 
24 h before a solution of vanillin (1.0 g, 6.6 mmol, 1.0 equiv.) in EtOH (4 mL) was added 
via cannula and the reaction mixture was stirred at 120 οC for 48 h.  The reaction mixture 
was cooled to r.t. and the crude mixture was concentrated under reduced pressure to give 
a grey sticky residue, which was partly dissolved in EtOAc (100 mL) and then eluted 
through a short silica plug (1 cm × 1 cm).  The filtrate was dried over MgSO4 and 
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concentrated under reduced pressure and the resultant pale yellow oil was purified by 
silica gel chromatography (EtOAc) to give the title compound as an off-white solid 
(0.58 g, 2.8 mmol, 28%). 
mp = 64-66 οC; Rf = 0.87 (EtOAc); νmax (film)/cm-1 3163br (OH), 2971w and 2958w 
(CH), 2866w and 2852w (OCH3), 1666s (C=O, aldehyde), 1592m, 1465m and 1434m 
(C=C); 1H NMR (400 MHz, CDCl3) δ = 9.55 (s, 1H, CHO), 7.21 (dd, J = 1.7, 1.6 Hz, 1H, 
ArCH), 7.09 (d, 1H, J = 1.6 Hz, ArCH), 4.40 (s, 2H, CH2OEt), 3.65 (s, 3H, OMe), 3.37 
(dq, J = 6.9, 1.7 Hz, 2H, OCH2CH3), 1.02 (dt J = 6.9, 1.7, 3H, CH2CH3); 13C NMR (100.0 
MHz) δ = 191.3 (CHO), 150.2 (COH), 147.8 (COMe), 129.5 (ArCquat.), 126.7 (ArCH), 
124.3 (CCHO), 108.6 (ArCH), 68.3 (CH2OEt), 66.8 (OCH2CH3), 56.8(OMe), 15.5 
(OCH2CH3); GCMS (CI) calcd for [C11H15O4]+ 211; found 211 [M+H]+. 
5-Formyl-2-hydroxy-3-methoxybenzyl acetate (289). To a 
solution of morpholine (0.86 g, 9.9 mmol, 1.5 equiv.) in AcOH 
(3 mL) over 3Å molecular sieves was added paraformaldehyde 
(1.0 g, 9.9 mmol, 1.5 equiv.) at r.t. and the suspension was stirred for 
24 h before a solution of vanillin (1.0 g, 6.6 mmol, 1.0 equiv.) in AcOH (4 mL) was 
added via cannula and the reaction mixture was stirred at 120 οC for 48 h.  The reaction 
mixture was cooled to r.t. and the crude mixture was concentrated under reduced pressure 
to give a grey sticky residue, which was partly dissolved in EtOAc (100 mL) and then 
eluted through a short silica plug (1 cm × 1 cm).  The filtrate was dried over MgSO4 and 
concentrated under reduced pressure and the resultant pale yellow oil was purified by 
silica gel chromatography (EtOAc:Petroleum; 1:1) to give the title compound as an off-
white solid (0.77 g, 3.5 mmol, 35%). 
mp = 90-92 οC; Rf = 0.77 (EtOAc:Petroleum; 1:1); νmax (film)/cm-1 3133br (OH), 2974w 
(CH), 2855w (OCH3), 1729s (C=O, ester), 1664s (C=O, aldehyde), 1592m, 1501m 
and1470m (C=C); 1H NMR (400 MHz, CDCl3) δ = 9.84 (s, 1H, CHO), 7.49 (s, 1H, 
ArCH), 7.41 (s, 1H, ArCH), 6.62 (s, 1H, OH), 5.23 (s, 2H, CH2OAc), 3.98 (s,3H, OMe), 
2.14 (s, 3H, CH3CO); 13C NMR (100.0 MHz) δ = 190.9 (CHO), 171.3 (CH3CO), 150.0 
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(COH), 147.4 (COMe), 129.4 (ArCquat.), 127.9 (ArCH), 122.1 (CCHO), 108.8 (ArCH), 
60.9 (OMe), 56.5 (CH2OAc), 21.1 (MeCO); GCMS (CI) calcd for [C11H13O5]+ 225; found 
225 [M+H]+. 
Methyl 6-(2,3-dimethoxy-3-oxoprop-1-en-1-yl)-3-
hydroxy-2-methoxy-4-(morpholinomethyl)benzoate (290).  
Method A:  To a solution of phenol (277; E:Z; 1:5) (50 mg, 
0.17 mmol, 1.0 equiv.) in MeCN (1 mL) in a microwave vial 
fitted with a septa, was added 4-methylenemorpholin-4-ium chloride123 (46 mg, 
0.34 mmol, 2.0 equiv.), the vial was then sealed with a “crimp cap” and then headed at 
150 οC for 16 h.  The clear yellow solution was allowed to cool to r.t. and then diluted 
with EtOAc (10 mL) and filtered before concentration under reduced pressure afforded a 
pale yellow oil.  Purification via column chromatography (EtOAc: Petroleum 1:2) 
afforded a isomeric mixture (E:Z; 16:84) of the title compound (290) as a clear colourless 
oil which solidified upon storage at −5 οC (61 mg, 0.15 mmol, 91%).  Stereochemical 
assignments were made on the basis of NOESY experiments. 
Method B:  To a microwave vial fitted with a septa, was added paraformaldehyde (101 
mg, 3.9 mmol, 2.0 equiv.), acetic acid (6 mL) and then morpholine 
(0.3 mL, 3.9 mmol, 2.0 equiv.).  The resultant slurry was left to stir at r.t. for 24 h before 
addition of (277) (574 mg, 1.9 mmol, 1.0 equiv.).  The vial was then sealed and then 
headed at 130 οC for 16 h.  The clear yellow solution was allowed to cool to r.t. and then 
diluted with EtOAc (30 mL) and filtered before concentration under reduced pressure 
afforded a pale yellow oil.  Purification via column chromatography (EtOAc: Petroleum 
1:2) afforded a isoomeric mixture (E:Z; 13:87) of the title compound (290) as a clear 
colourless oil which solidified upon storage at −5 οC (76.5 mg, 1.94 mmol, quant.).  
Stereochemical assignments were made on the basis of NOESY experiments. 
mp = 22-23 οC; Rf = 0.23 (CH2Cl2;MeCN; 9:1); νmax (film)/cm-1 2948w (CH), 2841w 
(OCH3), 1726s (C=O, ester), 1636m (C=C, conj.), 1450m (C-H), 1274s and 1057s (C-O-
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CH3); HRMS (CI) calcd for [C19H26O8N1]+ 396.1653; found 396.1653 [M+H]+; 
(Z)-isomer: 1H NMR (400 MHz, CDCl3) δ = 9.77 (s, 1H, OH), 6.62 (s, 1H, ArCH), 6.09 
(s, 1H, HC=Cquant.), 3.92 (s, 3H, OMe), 3.86 (s, 3H, OMe), 3.78-3.75 (m, 4H, 2 × 
NCH2CH2O), 3.71-3.68 (brs, 5H, 1 × CO2Me and CCH2), 3.63 (s, 3H, CO2Me), 2.57 
(brs, 4H, 2 × OCH2CH2N); 13C NMR (100.0 MHz) δ = 167.8 (CO2Me), 163.9 (CO2Me), 
149.7 (ArOH), 147.8 (ArOMe), 144.9 (CH=Cquat.), 124.7 (ArCH), 124.5 (ArCquat.), 123.6 
(ArCquat.), 122.9 (ArCquat.), 107.1 (CH=Cquat.), 66.7 (2 × RNCH2CH2O), 61.60 (CH2N), 
61.20 (OMe), 55.98 (OMe), 52.86 (2 × OCH2CH2N), 52.11 (CO2Me), 51.96 (CO2Me); 
(E)-isomer: δ = 1H NMR (400 MHz, CDCl3) δ = 9.87 (s, 1H, OH), 7.62 (s, 1H, ArCH), 
6.81 (s, 1H, ArHC=CR2), 3.95 (s, 3H, OMe), 3.94 (s, 2H, ArCH2), 3.91 (s, 3H, OMe), 
3.81 (s, 3H, OMe), 3.76-3.73 (m, 4H, 2 × NCH2CH2O), 3.72 (s, 3H, OMe), 2.57 
(brs, 4H, 2 × OCH2CH2N); The 13C NMR spectrum could not be clearly distinguished 
from the major (Z)-isomer. 
 Methyl 3-acetoxy-4-(acetoxymethyl)-6-(2,3-dimethoxy-3-
oxoprop-1-en-1-yl)-2-methoxybenzoate (294). To a 
microwave vial fitted with a septa, was added a solution of 
(290) (100 mg, 0.25 mmol, 1.0 equiv.) in Ac2O (2 mL, 21.2 
mmol, 84.6 equiv), the vial was then sealed and then headed at 155 οC for 24 h.  Once 
cooled the solution was washed into a round-bottomed flask with MeOH (10 mL) and 
concentrated under reduced pressure to give a clear pale brown oil.  Purification via 
column chromatography (CH2Cl2;MeCN; 19:1) afforded a isomeric mixture (E:Z; 1:4) of 
the title compound as a clear, pale yellow oil (89 mg,  0.20 mmol, 84%).  Stereochemical 
assignments were made on the basis of NOESY experiments. 
Rf = 0.26 (CH2Cl2:MeCN; 19:1); νmax (film)/cm-1 2953w (CH), a 2851w (OCH3), 1770m 
(C=O, ester),  1727s (C=O, ester), 1635m (C=C, conj.), 1454m (C-H), 1221s, 1183s and 
1154s (C-O-CH3); HRMS (CI) calcd for [C19H26O10N1]+ 428.1551; found 428.1551 
[M+NH4]+; (Z)-isomer: 1H NMR (400 MHz, CDCl3) δ = 1H NMR (400 MHz, CDCl3) δ = 
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7.01 (s, 1H, ArCH), 6.13 (s, H, CH=Cquat.), 5.02 (s, 2H, CH2OAc), 3.85 (s, 3H, OMe), 
3.81 (s, 3H, OMe), 3.72  (s, 3H, CO2Me), 3.61 (s, 3H, CO2Me), 2.33 (s, 3H, OAc), 2.06 
(s, 3H, OAc); 13C NMR (100.0 MHz) δ = 171.1 (OCOMe), 168.8 (OCOMe), 167.3 
(CO2Me), 164.8 (CO2Me), 150.2 (COMe), 147.8 (CH=Cquat.), 142.9 (COAc), 132.3 
(ArCH), 131.9 (Arquat.), 130.4 (Arquat.), 127.1 (Arquat.), 118.8 (CH=Cquat.), 62.9 (OMe), 
61.6 (CH2OAc), 60.3 (OMe), 53.3 (CO2Me), 53.0 (CO2Me), 21.4 (OCOMe), 21.1 
(OCOMe); (E)-isomer: 1H NMR (400 MHz, CDCl3) δ = 1H NMR (400 MHz, CDCl3) δ = 
7.91 (s, 1H, ArCH), 6.86 (s, H, CH=Cquat.), 5.05 (s, 2H, CH2OAc), 3.93 (s, 3H, OMe), 
3.83 (s, 6H, 1 × OMe, 1 × CO2Me), 3.74  (s, 3H, CO2Me), 2.35 (s, 3H, OAc), 2.09 (s, 3H, 
OAc); 13C NMR (100.0 MHz) δ = 171.1 (OCOMe), 168.9 (OCOMe), 167.4 (CO2Me), 
164.1 (CO2Me), 150.3 (COMe), 149.2 (CH=Cquat.), 141.9 (COAc), 133.0 (ArCH), 130.2 
(CH2), 128.8 (ArCquat.), 127.1 (ArCquat.), 118.8 (CH=Cquat.), 62.8 (OMe), 61.4 (ArCH2), 
56.7 (OMe), 53.0 (CO2Me), 52.8 (CO2Me), 21.4 (COMe), 21.1 (COMe). 
(E)-Methyl 3-(4-hydroxy-3-iodo-5-methoxyphenyl)acrylate 
(302a).124  To a solution of iodovanillin (1.12 g, 4.0 mmol, 
1.0 equiv.) in THF (50 mL) was added methyl 
(triphenylphosphoranylidene)acetate (3.8 g, 11.3 mmol, 2.8 equiv.) and the resultant 
suspension was heated to reflux for 12 h.  The reaction mixture was then cooled to r.t. 
before the filtered reaction mixture was dried over MgSO4 and concentrated under 
reduced pressure to give a pale yellow solid, which was purified via silica gel 
chromatography (EtOAc:Petroleum; 1:4) to afford the title compound as an off-white 
solid (1.31 g, 3.9 mmol, 98%). 
mp 138-139 oC [lit. 140-143οC]; Rf = 0.25 (EtOAc:Petroleum; 1:4); νmax (film)/cm-1 
3232br (OH), 2971w and 2940w (CH), 2854w (OCH3), 1667s (C=O, ester), 1590s, 994m 
and 914m (RH=CH2); 1H NMR (400 MHz, CDCl3) δ = 7.51 (d, J = 16.3 Hz, 1H, 
CH=CHCO2Me), 7.49 (s, 1H, ArCH), 6.95 (s, 1H, ArCH), 6.51 (brs, 1H, COH), 6.27 (d, 
J = 16.3 Hz, 1H, CH=CHCO2Me), 3.90 (s, 3H, OMe), 3.78 (s, 3H, CO2Me); 13C NMR 
(100.0 MHz, CDCl3) δ = 167.4 (CO2Me), 147.8 (COH), 146.2 (COMe), 
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143.4 (CH=CHCO2Me), 132.1 (ArCquat.), 128.5 (ArCH), 116.4 (CH=CHCO2Me), 
109.4 (ArCH), 81.3 (CI), 56.0 (OMe), 51.7 (CO2Me); GCMS (CI) calc [C11H10IO4]+ 335;  
found 335 [M+H]+; spectroscopic data is in agreement with that previously reported.125 
(E)-Methyl 3-(4-((tert-butyldimethylsilyl)oxy)-3-iodo-5-
methoxyphenyl)acrylate (302).125  Et3N (0.8 mL, 5.8 mmol, 1.5 
equiv.) was added at r.t. to a mixture of phenol (302a) (1.3 g, 3.9 
mmol, 1.0 equiv.), TBSCl (650 mg, 4.3 mmol, 1.1 equiv.) and DMAP (24 mg, 0.2 mmol, 
5 mol %) in CH2Cl2 (1.0 mL).  After stirring at r.t. for 24 h, the organics were diluted 
with CH2Cl2 (10 mL) and washed with sat. aq. NH4Cl solution (2 × 10 mL).  The organic 
layer was then separated and dried over MgSO4, filtered and concentrated under reduced 
pressure to a pale yellow/brown oil.  Flash chromatography (EtOAc:Petroleum, 1:5) 
afforded the title compound as a pale yellow solid  (1.69 g , 3.8 mmol, 97%). 
mp = 105-107 οC; Rf = 0.23 (EtOAc:Petroleum; 1:6); νmax (film)/cm-1 2952w and 2928w 
(C-H), 2854w (OCH3), 1730m (C=O, ester), 1698s (C=O, aldehyde), 1550w, 1479m and 
1460m (C=C); 1H NMR (400 MHz, CDCl3) δ = 7.53 (d, J = 1.7 Hz, 1H, ArCH), 7.52 (dd, 
J = 16.4 Hz, 2.0 Hz, 1H, CH=CHCO2Me), 6.95 (d, J = 1.7 Hz, 1H, ArCH), 6.28 (dd, J = 
16.4 Hz, 2.0 Hz, 1H, CH=CHCO2Me), 3.81 (s, 3H, OMe), 3.79 (s, 3H, CO2Me), 1.04 (s, 
9H, SiMe2tBu), 0.25 (s, 6H, SiMe2tBu); 13C NMR (100.0 MHz, CDCl3) δ = 167.6 
(CO2Me), 149.6 (COMe), 147.7 (COTBS), 143.5 (CH=CHCO2Me), 131.9 (ArCquat.), 
129.2 (ArCH), 116.7 (CH=CHCO2Me), 110.5 (ArCH), 90.7 (CI), 55.1 (OMe), 55.9 
(CO2Me), 26.2 (SiC(CH3)3), 19.2(SiC(CH3)3), -3.2 (SiMe2); GCMS (CI) calc 
[C17H26IO4Si]+ 449;  found 449 [M+H]+; spectroscopic data is in agreement with that 
previously reported.125 
 (E)-methyl 3-(4-hydroxy-3-methoxy-5-vinylphenyl)acrylate 
(302).  To a microwave vial fitted with a septa, was added (301) 
(100 mg, 0.2 mmol, 1.0 equiv. ), Na2CO3 (140 mg, 1.3 mmol, 
6.0 equiv.), DMF (4 mL), H2O (0.4 mL) and vinylboronicacid pinacol ester (120 µl, 
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0.7 mmol, 3.5 equiv.) and the solution was thoroughly deoxygenated with argon before 
addition of Pd(PPh3)4 (25 mg, 0.02 mmol., 10 mol %).  The vial was then fitted with a 
‘crimp-cap’ and then heated to 80 oC for 5 h.  The reaction mixture was then diluted with 
Et2O (50 mL) and filtered through a small plug of silica under suction filtration to remove 
any inorganic impurities before concentration of the organics under reduced pressure.  
The crude residue was then dissolved in H2O (10 mL) and extracted with Et2O 
(2 × 15mL) before further washing of the organic layer with sat. aq. NaCl solution 
(5 × 10 mL) to remove any remaining DMF.  The organics were dried over MgSO4, 
filtered and concentrated under reduced pressure before purification by silica gel 
chromatography (Petroleum:Et2O; 1:1) furnished the title compound as a clear colourless 
oil (27 mg, 0.12 mmol 53%).  
mp 138-139 oC; Rf = 0.25 (EtOAc:Petroleum; 1:4); νmax (film)/cm-1 3232br (OH), 2971w 
and 2940w (CH), 2854w (OCH3), 1667s (C=O, ester), 1590s, 994m and 914m 
(RH=CH2); 1H NMR (400 MHz, CDCl3) δ = 7.64 (d, J = 16.2 Hz, 1H, CH=CHCO2Me), 
7.27-7.22 (m, 1H, ArH), 7.02-6.93 (m, 2H, 1 x ArH, 1 x CH=CH2), 6.31 (d, J = 16.2 Hz, 
1H, CH=CHCO2Me), 5.84 (d, J = 16.9 Hz, 1H, CH=CHaHb), 5.36 (d, J = 10.3 Hz, 1H, 
CH=CHaHb), 3.94 (s, 3H, OMe), 3.80 (s, 3H, CO2Me); 13C NMR (100.0 MHz, CDCl3) 
δ = 167.4 (CO2Me), 147.8 (COH), 146.2 (COMe), 143.4 (CH=CHCO2Me), 132.1 
(ArCquat.), 128.5 (ArCH), 116.4 (CH=CHCO2Me), 109.4 (ArCH), 81.3 (CI), 56.0 (OMe), 
51.7 (CO2Me); GCMS (CI) calc [C13H15O4]+ 335;  found 335 [M+H]+.  
 
Methyl 3-((tert-butyldimethylsilyl)oxy)-6-(2,3-dimethoxy-3-
oxoprop-1-en-1-yl)-4-iodo-2-methoxybenzoate (303).  To a 
solution of (270) (280 mg, 0.66 mmol, 1.0 equiv.) in CH2Cl2 
(7 mL) was added Et3N (0.13 mL, 0.90 mmol, 1.35 equiv.), 
4-(dimethylaminopyridine (12.5 mg, 0.10 mmol, 0.15 equiv.) and tert-butyldimethylsilyl 
chloride (125 mg, 0.83 mmol, 1.25 equiv.).  The solution was stirred at rt for 16 h before 
addition of sat. aq. Na2CO3 solution (15 mL), the layers were then separated and the 
aqueous layer was then extracted further with CH2Cl2 (3 × 30 mL). The combined 
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organics were dried over MgSO4 and concentrated under reduced pressure, before 
purification of the crude residue by silica gel chromatography (Et2O:Petroleum; 1:4) 
afforded (Z-303) as an off white solid (230 mg, 0.43 mmol, 65%) and (E-303) as a pale 
yellow oil (106 mg, 0.20 mmol, 30%).  Stereochemical assignments were made on the 
basis of NOESY experiments and correllation of chemical shifts of closely related 
literature compounds.103 
(Z)-isomer: mp = 38-39 οC, Rf = 0.23 (Et2O:Petroleum; 1:4); νmax (film)/cm-1 2943w, 
2926w and 2895w (CH), 2855 (O-C-H3), 1722s (2 × C=O, ester), 1633w (O-CO), 1570w, 
1536w and 1446m (C=C); 1H NMR (400 MHz, CDCl3) δ = 8.34 (s, 1H, ArCH), 6.72 (s, 
1H, CH=Cquat.), 3.94 (s, 3H, OMe), 3.83 (s, 3H, OMe), 3.76 (s, 3H, CO2Me), 3.73 (s, 3H, 
CO2Me), 1.07 (s, 9H, SiMe2tBu), 0.29 (s, 6H, SiMe2tBu); 13C NMR (100.0 MHz, CDCl3) 
δ = 167.0 (CO2Me), 164.1 (CO2Me), 149.1 (CH=Cquat.), 147.4 (COMe), 146.1 (COTBS), 
136.3 (ArCH), 130.3 (ArCquat.), 125.8 (ArCquat.), 117.4 (CH=Cquat.), 93.5 (CI), 61.5 
(OMe), 59.3 (OMe), 52.4 (CO2Me), 52.1 (CO2Me), 26.1 (SiC(CH3)3), 18.6 (SiC(CH3)3), 
−3.4 (SiMe2); HRMS (EI) calcd for [C20H30I1O7Si]+ 537.0800; found [M+H]+ 537.0794. 
 (E)-isomer: Rf = 0.25 (Et2O:Petroleum; 1:4); max (film)/cm-1 2933w and 2927w (CH), 
2850 (O-C-H3), 1734s (2 × C=O, ester), 1612w (O-CO), 1510m, and 1454m (C=C); 1H 
NMR (400 MHz, CDCl3) δ = 7.39 (s, 1H, ArCH), 6.02 (s, 1H, CH=Cquat.), 3.85 (s, 3H, 
OMe), 3.74 (s, 3H, OMe), 3.70 (s, 3H, CO2Me), 3.64 (s, 3H, CO2Me), 1.07 (s, 9H, 
SiMe2tBu), 0.28 (s, 6H, SiMe2tBu); 13C NMR (100.0 MHz, CDCl3) δ = 167.0 (CO2Me), 
164.1 (CO2Me), 149.1 (CH=Cquat.), 147.4 (COMe), 146.1 (COTBS), 136.8 (ArCH), 130.4 
(ArCquat.), 125.7 (ArCquat.), 107.8 (CH=Cquat.), 93.5 (CI), 61.4 (OMe), 59.3 (OMe), 52.4 
(CO2Me), 52.1 (CO2Me), 26.1 (SiC(CH3)3), 18.6 (SiC(CH3)3), −3.4 (SiMe2); HRMS (EI) 
calcd for [C20H30IO7Si]+ 537.0800; found 537.0795 [M+H]+. 
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(Z)-Methyl 6-(2,3-dimethoxy-3-oxoprop-1-en-1-yl)-3-hydroxy-
2-methoxy-4-vinylbenzoate (304).  To a microwave vial fitted 
with a septa, was added (303a) (144 mg, 0.27 mmol, 1.0 equiv.), 
Na2CO3 (170 mg, 1.6 mmol, 6.0 equiv.), DMF (5 mL), H2O 
(0.5 mL) and vinylboronic acid pinacol ester (158 µl, 0.94 mmol, 3.5 equiv.) and the 
solution was thoroughly deoxygenated with argon before addition of Pd(PPh3)4 
(31 mg, 10 mol %).  The vial was then fitted with a ‘crimp-cap’ and then heated to 80 oC 
for 5 h.  The reaction mixture was then diluted with Et2O (50 mL) and filtered through a 
small plug of silica under suction filtration to remove any inorganic impurities before 
concentration of the organics under reduced pressure.  The crude residue was then 
dissolved in H2O (75 mL) and extracted with Et2O (15 mL) before further washing of the 
organic layer (5 × 75 mL) to remove any remaining DMF.  The organic layers were dried 
over MgSO4, filtered and concentrated under reduced pressure before purification by 
silica gel chromatography (Petroleum:Et2O; 1:2) afforded the title compound as a pale 
orange oil (86 mg, 0.27 mmol, quant.). 
Rf = 0.36 (Petroleum:Et2O; 1:2); νmax (film)/cm-1 3406br (OH), 2952w (CH), 2582w 
(OCH3), 1720s (C=O, ester), 1634w (C=C, conj.), 1596w (C=C), 1454m and 1435m (C-
H), 1286s, 1242s, 1198m and 1168m C-O-CH3);1H NMR (400 MHz, CDCl3) δ = 7.97 (s, 
1H, ArCH), 6.91 – 6.99 (m, 1H, CH=CH2), 6.92 (s, 1H, CH=Cquat.), 6.08 (s, 1H, OH), 
5.89 (dd, 1H, J = 17.7 Hz, J = 1.3 Hz, CH=CHaHb) 5.41 (dd, 1H, J = 11.2 Hz, J = 1.3 Hz, 
CH=CHaHb), 3.96 (s, 3H, OMe), 3.87 (s, 3H, OMe), 3.84 (s, 3H, CO2Me), 3.72 
(s, 3H, CO2Me); 13C NMR (100.0 MHz) δ = 167.3 (CO2Me), 164.9 (CO2Me), 146.9 
(COH), 145.9 (COMe), 144.9 (CH=Cquat.), 130.7 (CH=CH2), 126.8 (ArCquat.), 126.4 
(ArCquat.), 124.7 (ArCH), 123.5 (ArCquat.), 120.1 (CH=CH2), 117.3 (CH=Cquat.), 62.8 
(OMe), 59.7 (OMe), 52.9 (CO2Me), 52.5 (CO2Me);  HRMS (CI) calcd for [C16H19O7]+ 
323.1131; found  323.1130 [M+H]+. 
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4-Bromo-2-methoxyphenol (306a).125  To a solution of guaiacol (306) 
(22.2 mL, 201 mmol, 1.0 equiv) in DMF (175 mL) at 0 οC was added a 
solution of N-bromosuccinamide  (35.6 g, 200 mmol, 1.0 equiv.) in DMF 
(175 mL) dropwise via a pressure equalised dropping funnel. After 
stirring at this temperature for 1 h, the reaction mixture was diluted with Et2O (300 mL), 
filtered and then washed thoroughly with sat. aq. Na2S2O3 solution (700 mL), sat. aq. 
NaCl solution (700 mL) and H2O (700 mL). The combined aqueous extracts were then 
extracted with Et2O (2 × 250 mL) and the combined organics were dried over MgSO4.  
After filtration and concentration under reduced pressure the crude residue was purified 
by short silica gel chromatography (dimensions; 10 cm d × 20 cm h; Petroleum:Et2O; 4:1) 
to afford the title compound (306a) as a pale yellow oil (39.8 g, 196 mmol, 97%).  
spectroscopic data is in agreement with that previously reported.126 
Rf = 0.21 (Petroleum:Et2O; 4:1); νmax (film)/cm-1 3511br (O-H), 3011w, 2969w, 2940w 
(CH), 2844w (OCH3), 1496s (C=C), 1443s (C=C)s, 1255s (O-H), 873s (C-Br).  1H NMR 
(400 MHz, CDCl3) δ = 6.99 (dd, J = 8.3, 2.3 Hz, 1H, ArCH), 6.97 (d, J = 2.3 Hz, 1H, 
ArCH), 6.80 (d, J = 8.3 Hz, 1H, ArCH), 5.53 (s, 1H, OH), 3.32 (s, 3H, OMe). 
13C NMR (100.0 MHz) δ = 147.3 (COH), 145.0 (COMe), 124.3 (ArCH), 115.9 (ArCH), 
114.3 (ArCH), 111.7 (CBr), 56.3 (OMe); HRMS (EI) calcd for [C7H8O279Br]+ 202.9702 
and [C7H8O281Br]+ 204.9682; found 202.9704 and 204.9681 [M+H]+. 
4-Bromo-1-(ethoxymethoxy)-2-methoxybenzene (307).86  
Method A: To a mixture of phenol (306a) (19.33 g, 95.2 mmol, 
1.0 equiv.) and K2CO3 (15.6 g, 112.9 mmol, 1.19 equiv.) in DMF 
(50 mL) was slowly added chloromethyl ethyl ether (10 mL, 107.8 mmol, 1.13 equiv.) at 
0 οC. After 10 minutes at that temperature the external cooling bath was removed and the 
reaction vessel was stirred at ambient temperature for 16 h.  The mixture was then diluted 
with Et2O (100 mL), filtered and then the filtrate solution was washed with water (300 
mL). The organic layer was separated, and the aqueous layer was extracted with Et2O (2 × 
100 mL). The combined organic layers were washed with brine (200 mL), and dried over 
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MgSO4. After filtration and concentration under reduced pressure, the crude residue was 
purified by silica gel column chromatography (Petroleum:CH2Cl2; 3:2) to the title 
compound (307) (20.2 g, 77.3 mmol, 81%) as a yellow oil. 
Method B: To a mixture of phenol (306a) (30.2 g, 148.8 mmol, 1.0 equiv.) and Hünig’s 
base (31.1 mL, 178.5 mmol, 1.20 equiv.) in DMF (200 mL) was slowly added 
chloromethyl ethyl ether (15.6 mL, 168.1mmol, 1.13 equiv.) at 0 οC. After 10 minutes at 
that temperature the external cooling bath was removed and the reaction vessel was 
stirred at ambient temperature for 16 h.  The mixture was then diluted with Et2O (400 
mL), filtered and then the filtrate solution was washed with water (600 mL). The organic 
layer was separated, and the aqueous layer was extracted with Et2O (2 × 400 mL). The 
combined organic layers were washed with brine (400 mL), and dried over MgSO4. After 
filtration and concentration under reduced pressure, the crude residue was purified by 
silica gel column chromatography (Petroleum:CH2Cl2; 3:2) to the title compound (307) 
(34.1 g, 130.5 mmol, 88%) as a yellow oil. 
Rf = 0.21 (Petroleum:CH2Cl2; 3:2); νmax (film)/cm-1 2974w and 2532w (CH), 2948w 
(OCH3), 1589m, 1496s, 1463m, 1444m (C=C), 898s (C-Br); 1H NMR (400 MHz, CDCl3) 
δ = 6.99-7.07 (m, 3H, 3 × ArCH), 5.24 (s, 2H, OCH2O), 3.86 (s, 3H, OMe), 3.76 (q, 2H, J 
= 7.0 Hz, OCH2CH3), 1.22 (t, 3H, J = 7.0 Hz, OCH2CH3); 13C NMR (100.0 MHz) δ = 
150.4 (COMe), 145.9 (COEOM), 123.5 (ArCH), 117.6 (ArCH), 114.3 (ArCH), 94.2 
(OCH2O), 64.4 (OCH2CH3), 56.0 (OMe), 15.0 (OCH2CH3); HRMS (EI) calcd for 
[C10H1479Br1O3]+ 261.0121 and [C10H1481Br1O3]+ 263.0100; found 261.0124 and 263.0103 
[M+H]+; spectroscopic data was not previously reported.86 
Methyl 3-(ethoxymethoxy)-2-methoxy-6-(2-methoxy-2-
oxoethyl)benzoate (308).86  To a solution of HNiPr2 
(11.2 mL, 80 mmol, 2.45 equiv.), in THF (300 mL) was 
added n-BuLi (2.5 M in hexanes, 31.2 mL, 78 mmol, 
2.4 equiv.) dropwise at −78 οC.  After the addition, the external cooling bath temperature 
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was increased to 0 oC and the solution was stirred at this temperature for 30 minutes. 
Freshly distilled diethyl malonate (4.5 mL. 39 mmol, 1.2 equiv.) was added dropwise and 
left to stir at that temperature for a further 30 min. This was followed by dropwise 
addition (over 10 minutes) of bromide (307) (8.50 g, 32.6 mmol, 1.0 equiv) in THF 
(30 mL) and the solution was left to stir at 0 οC for a further 30 min, at which point TLC 
analysis (3:1; Petroleum:Et2O) indicated complete consumption of the starting material.  
The reaction mixture was then quenched at 0 οC by addition of MeOH (50 mL) and the 
mixture was allowed to warm to r.t. before concentration under reduced pressure.  The 
crude residue was then dissolved in EtOAc (300 mL) and filtered through a short silica 
gel plug (10 cm w × 3 cm h) and the filtrate was dried over MgSO4, filtered and 
concentrated under reduced pressure before silica gel chromatography (1% THF in 
CH2Cl2) afforded the title compound as an pale yellow oil (8.55g, 27.4 mmol, 84%).   
Rf = 0.23 (3:1; Petroleum:Et2O); 1H NMR (400 MHz, CDCl3) δ = 7.19 (d, J = 8.6 Hz, 1H, 
ArCH), 9.69 (d, J = 8.6 Hz, 1H, ArCH), 5.26 (s, 2H, OCH2O), 3.90 (s, 3H, OMe), 3.89 (s, 
3H, CO2Me), 3.77-3.73 (m, 2H, CH2CH3), 3.68 (s, 3H, CO2Me), 3.67 (s, 2H, 
CH2CO2Me), 1.23 (t, 3H, J = 7.1 Hz, OCH2CH3); 13C NMR (100.0 MHz)  δ = 171. 7 
(CO2Me), 167.7 (CO2Me), 149.9 (COMe), 147.8 (COEOM), 129.2 (ArCquat.), 126.6 
(ArCH), 125.8 (ArCquat.), 118.2 (ArCH), 93.9 (OCH2O), 64.7 (OCH2CH3), 61.8 (OMe), 
56.0 (CO2Me), 52.2 (CO2Me), 38.5 (CH2CO2Me), 15.2 (OCH2CH3); GCMS (CI) calc 
[C15H21O7]+ 313; found 313 [M+H]+; spectroscopic data was not previously reported. 86 
 
Methyl 3-hydroxy-2-methoxy-6-(2-methoxy-2-
oxoethyl)benzoate (308a).86  To a solution of (308, 8.6g, 27.4 
mmol, 1.0 equiv.) in CH2Cl2 (200 mL) was added NaHSO4-SiO2gg 
                                                 
gg To a solution of 18.0 g (150.0 mmol) of NaHSO4 in 100 mL of H2O was added 50.0 
g of SiO2 and the mixture was stirred for 30 min at r.t.  The mixture was then 
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at rt and the resultant suspension was stirred for a further 16 h. The reaction mixture was 
then filtered through a short silica plug (w = 10 cm × h = 5 cm) under gravity, washing 
with EtOAc (300 mL) and the combined organic layers were concentrated under reduced 
pressure.  The resultant oil was then triturated with a mixture of 1% THF in cyclohexane 
(2 × 75 mL) and the the resultant clear colourless oil was dried under vacuum, before 
addition of a mixture of 5% CH2Cl2 in cyclohexane (150 mL).  The mixture was left in an 
ultrasonic bath for 60 minutes, heated to gentle boiling before allowing to cool gradually 
to r.t. before being cooled to 3 οC for 48 h, at which time, needle like crytals had formed.  
The needles were collected via filtration and dried in a vacuum desicator over silica gel to 
provide the title compound as colourless crystals (7.0 g, 27.4 mmol, quant.). 
mp = 52-53 οC; νmax/cm-1 3415br (O-H), 3001w (CH), 2957w and 2853w (OCH3), 1728s 
(C=O, ester), 1601w and 1586w (CO-O), 1501m and 1436m (C=C);  1H NMR (400 MHz, 
CDCl3) δ = 7.00 (d, 1H, J = 8.3 Hz, ArCH), 6.93 (1H, d, J = 8.3 Hz, ArCH), 4.75 (brs, 
1H, OH), 3.92 (s, 3H, CO2Me), 3.85 (s, 3H, OMe), 3.68 (s, 3H, CO2Me), 3.65 (s, 3H, 
OMe); 13C NMR (100.0 MHz) δ = 172.0 (CO2Me), 167.6 (CO2Me), 148.6 (ArOH), 145.6 
(ArOMe), 127.7 (ArCH), 127.1 (ArCH2), 125.2 (ArCO2Me), 117.8 (ArCH), 62.7 (OMe), 
52.7 (CO2Me), 52.4 (CO2Me), 39.0 (CH2); HRMS (CI) calcd for [C12H15O6]+ 255.0863; 
found 255.0865 [M+H]+; spectroscopic data was not previously reported.86 
 
Methyl 3-hydroxy-4-iodo-2-methoxy-6-(2-methoxy-2-
oxoethyl)benzoate (309).86  To a mixture of (308a) (840 mg, 3.3 
mmol, 1.01 equiv.) and K2CO3 (680 mg, 4.9 mmol, 1.50 equiv.) in 
CH2Cl2 (25 mL) was added Me4NICl2 (890 mg, 3.3 mmol, 1.00 
equiv.) in five approximately equal portions over 2 hours at 0 oC and 
the reaction mixture was allowed to warm to 5 οC over 6 h.  The reaction mixture was 
                                                                                                                                            
concentrated under reduced pressure to give a fine white powder, which was further 
dried at 120 °C under reduced pressure for 16 h prior to use.  
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then quenched with sat. aq. NH4Cl solution (40 mL), the aqueous layer was extracted with 
CH2Cl2 (2 × 20 mL) and the combined organics were combined, dried over MgSO4 and 
concentrated under reduced pressure.  The crude residue was then purified by silica gel 
chromatography (Petroleum:EtOAc; 2:1) to afford the title compound as a pale yellow oil 
(1.15 g, 3.04 mmol, 92%). 
Rf = 0.85 (Petroleum:EtOAc; 2:1); νmax (film)/cm-1 3399 br (OH), 2947w, (OCH3), 1727 
brs (2 × C=O, ester), 1563w (CO-O), 1452w, 1443m and 1408m (C=C); 1H NMR (400 
MHz, CDCl3) δ = 7.39 (s, 1H, ArCH), 6.01 (brs, OH), 3.91 (s, 3H, OMe), 3.88 (s, 3H, 
CO2Me), 3.68 (s, 3H, CO2Me), 3.62 (s, 2H, CH2CO2Me); 13C NMR (100 MHz, CDCl3) δ 
= 171.5 (CO2Me), 167.0 (CO2Me), 149.0 (COH), 144.8 (COMe), 136.3 (ArCH), 127.5 
(ArCquat.), 126.6 (ArCquat.), 85.7 (CI), 62.7 (OMe), 52.8 (CO2Me), 52.5 (CO2Me), 38.5 
(CH2CO2Me); HRMS (NSI) calcd for [C12H12I1O6]- 378.9684; found 378.9677 [M−H]−; 
spectroscopic data was not previously reported.86 
 
Methyl 3-((tert-butyldimethylsilyl)oxy)-4-iodo-2-methoxy-6-(2-
methoxy-2-oxoethyl)benzoate (311).  To a solution of (309) 
(400 mg, 1.05 mmol, 1.0 equiv.) in CH2Cl2 (4.0 mL) at 0 οC was 
added NEt3 (0.25 mL, 1.78 mmol, 1.7 equiv.), then TBSCl (240 mg, 
1.6 mmol, 1.5 equiv.) followed by DMAP (32 mg, 0.26 mmol, 0.25 equiv.). The external 
cooling bath was then removed and the reaction mixture was allowed to stir at r.t. for 16 
h.  The reaction mixture was then quenched with sat. aq. Na2CO3 solution (40 mL), the 
aqueous layer was extracted with CH2Cl2 (2 × 20 mL) and the combined organics were 
combined, dried over MgSO4 and concentrated under reduced pressure.  The crude 
residue was then purified by silica gel chromatography (Petroleum:EtOAc; 8:1) to afford 
the title compound as a pale yellow crystalline solid (489 mg, 0.99 mmol, 94%). 
Mp = 36 οC, Rf = 0.31(Petroleum:EtOAc; 8:1); νmax (film)/cm-1 3003w (CH), 2958w, 
2928w, 2852w (OCH3), 1734s, 1709s (C=O, ester), 1579w and 1548w (CO-O), 1463m, 
1443s and 1430m (C=C); 1H NMR (400 MHz, CDCl3) δ = 7.46 (s, 1H, ArCH), 3.88 (s, 
TBSO
O O
O
OO
I
(311)
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3H, CO2Me), 3.74 (s, 3H, OMe), 3.68 (s, 3H, CO2Me), 3.57 (s, 2H, CH2CO2Me), 1.06 (s, 
9H, SiMe2t-Bu), 0.26 (s, 6H, SiMe2t-BuSi); 13C NMR (100.0 MHz) δ = 171.2 (CO2Me), 
167.3 (CO2Me), 149.2 (COTBS), 149.2 (COMe), 136.8 (ArCH), 129.5 (ArCquat.), 127.1 
(ArCquat.), 93.9 (CI), 61.6 (OMe), 52.4 (CO2Me), 52.3 (CO2Me), 38.0 (CH2CO2Me), 26.4 
(SiC(CH3)3), 18.8 (SiC(CH3)3), 3.1 (SiMe2); HRMS (CI) calcd for [C18H28IO6Si1]+ 
495.0694; found 495.0690 [M+H]+. 
 
Empirical formula              C18 H27 O6 Si I 
Formula weight            494.39 
Temperature    100.(2) 
Wavelength    1.54178 Å 
Crystal system    Orthorhombic 
Space group    −P 2ac 2ab 
Unit cell dimensions   a = 7.5894(3) Å a = 90 
b = 22.4932(10) Å b = 90 
c = 25.2819(10) g = 90 
Volume                        4315.9(3) 
Z                8 
Density    1.522 Mg/m3 
Absorption coefficient   12.443 mm-1 
F(100)     2000 
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Crystal size    0.300 × 0.040 × 0.040 mm3 
Theta range for data collection 3.4964 to 64.9843ο 
Index ranges    −6<=h<=8, −26<=k<=26, −29<=l<=29 
Reflections collected   9980   
Independent reflections  3640 [R(int) = 0.0556] 
Completeness to theta = 25.00ο 98.9% 
Absorption correction   Multi-scan 
Refinement method   Full-matrix least-squares on F2 
Data/restraints/parameters  3640/0 /243 
Goodness-of-fit F2   1.233 
Final R indices [I.2sigma(I)]  R1 = 0.0540, wR2 = 0.1357 
R indices (all data)   R1 = 0.0556, wR2 = 0.1351 
Largest diff. peak and hole  1.035 and −1.870 eÅ-3 
 
Methyl 3-hydroxy-2-methoxy-6-(2-methoxy-2-oxoethyl)-4-
vinylbenzoate (312).  In a microwave vial fitted with a septa was 
added (311) (100 mg, 0.20 mmol, 1.0 equiv.), DMF (4 mL), H2O 
(0.4 mL), vinylboronic acid pinacol ester (120 µl 0.71 mmol, 
3.5 equiv.), Na2CO3 (130 mg, 1.2 mmol, 6.1 equiv.) and Pd(PPh3)4 
(23 mg, 0.02 mmol, 0.1 equiv.).  The solution was degassed with Ar for 30 minutes 
before the reaction vessel was sealed with a ‘crimp-cap’ before heating to 80 οC for 16 h.  
The reaction mixture was then cooled to rt, diluted with Et2O (10 mL) and washed with 
H2O (2 × 25 mL).  The combined aqueous layers were then further extracted with Et2O (2 
× 20 mL) and the combined organics were dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude extract was then purified by silica gel chromatography 
(4:1 to 0:1; Petroleum:EtOAc) to give the title compound as a pale brown oil (55 mg, 0.20 
mmol, 98%). 
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Rf = 0.20 (100% EtOAc); νmax (film)/cm-1 3342br (OH), 2958w and 2955w, (OCH3), 
1718brs, (2 × C=O, ester), 1630m (C=C, conj.), 1530w (CO-O), 1481m, 1454s and 
1423m (C=C); 1H NMR (400 MHz, CDCl3) δ = 7.08 (s, 1H, ArCH), 6.92 (dd, J = 17.6, 
11.5 Hz, 1H, CH=CH2), 6.02 (s, 1H, OH), 5.86 (d, J = 17.6 Hz, 1H, CH=CHaHb), 5.39 (d, 
J = 11.5 Hz, 1H, CH=CHaHb), 3.91 (s, 3H, OMe), 3.85 (s, 3H, CO2Me), 3.68 (s, 3H, 
CO2Me); 13C NMR (100.0 MHz) δ = 171.9 (CO2Me), 167.3 (CO2Me), 146.0 (COH), 
146.0 (COMe), 130.6, (CH=CH2), 127.0 (ArCquat.), 125.0 (ArCquat.), 124.9 (ArCH), 124.6 
(ArCquat.), 117.2 (CH=CH2), 62.65 (OMe), 52.55 (CO2Me), 52.25 (CO2Me), 39.21 
(CH2CO2Me); HRMS (CI) calcd for [C14H17O6]+ 281.1020; found 281.1022 [M+H]+. 
Methyl 3-acetoxy-2-methoxy-6-(2-methoxy-2-oxoethyl)-4-
vinylbenzoate (313).  To a solution of (312) (50 mg, 0.18 mmol, 
1.0 equiv.) in pyridine (1.0 mL) at 0 οC was slowly added Ac2O 
(0.15 mL, 1.0 mmol, 8.3 equiv.), dropwise.  The reaction mixture 
was allowed to warm to r.t. over 16 h, before being concentrated under reduced pressure 
in an ice bath.  The resultant oil was diluted with MeOH (10 mL), and concentrated under 
reduced pressure in an ice bath again, before purification of the resultant oil via silica gel 
chromatography (Petroleum:Et2O; 4:1) afforded the title compound as a pale orange oil 
(56.4 mg, 0.17 mmol, 98%) 
Rf = 0.24 (Petroleum:Et2O; 4:1); νmax (film)/cm-1 2952w and 2947w (OCH3), 1768m and 
1734s, (C=O, ester), 1606w (C=C, conj.), 1562w (CO-O), 1455m, 1434m and 1413m 
(C=C); 1H NMR (400 MHz, CDCl3) δ = 7.23 (s, 1H, ArCH), 6.67 (dd, J = 17.6, 11.1 Hz, 
1H, CH=CH2), 5.80 (dd, 17.6, 0.8 Hz, CH=CHaHb), 5.41 (d, J = 11.5 Hz, CH=CHaHb), 
3.89 (s, 3H, OMe), 3.81 (CO2Me), 3.73 (s, 2H, CH2CO2Me), 3.69 (s, 3H, OMe), 2.35 (s, 
3H, OAc); 13C NMR (100.0 MHz) δ = 171.2 (OCOMe), 168.4 (CO2Me), 167.0 (CO2Me), 
150.9 (COMe), 145.2 (COAc), 141.1 (CH=CH2), 133.8 (ArCquat.), 131.1 (ArCquat.), 129.6 
(ArCquat.), 127.7 (CH=CH2), 124.0 (ArCH), 118.7 (CH=CH2), 62.3 (OMe), 52.5 (CO2Me), 
52.3 (CO2Me), 39.2 (CH2CO2Me), 20.6 (OAc); HRMS (EI) calcd for [C16H19O7]+ 
323.1125; found 323.1122 [M+H]+. 
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(3a±,9a±)-methyl 6-((Z)-2,3-dimethoxy-3-oxoprop-1-en-1-yl)-
8-methoxy-3,3a,4,9a-tetrahydro-2H-furo[2,3-b]chromene-7-
carboxylate (316).  Method A: To a solution of phenol (290) 
(20 mg, 51 μmol, 1.0 equiv.) dissolved in PhMe (0.2 mL) was 
added a 0.1 M solution of MeI in PhMe (0.5 mL, 50 μmol, 0.99 equiv.) in a microwave 
tube at 0 oC.  The reaction was warmed to r.t. and stirred for a further 2 h, at which time 
TLC analysis indicated complete consumption of the starting material.  2,3-Dihydrofuran 
(0.38 µl, 500 μmol, 10.0 equiv.) was then added to the reaction mixture and the reaction 
vessel was then fitted with a “crimp-cap” and heated at 130 οC for 16 h.  The reaction 
mixture was cooled to r.t., diluted with EtOAc and filtered through a short pad of silica (w 
= 1 cm × h = 0.5 cm).  The fitrate was then concentrated under reduced pressure and 
purified via silica gel chromatography (Petroleum:EtOAc; 3:1) to give the title compound 
isolated as clear colourless oil (12.4 mg, 33 μmol, 65%).  Stereochemical assignments 
were made on the basis of NOESY experiments. 
Method B: Morpholine (290) (20 mg, 51 μmol, 1.0 equiv.) was dissolved in 
2,3-dihydrofuran (0.10 mL, 6.81 mmol) in  a microwave vial, fitted with a “crimp cap” 
and heated at 130 oC for 16 h in a microwave reactor.  The reaction mixture was then 
cooled to r.t., concentrated under reduced pressure and purified by silica gel 
chromatography (Petroleum:EtOAc; 1 to 10% Et2O) to furnish the title compound as a 
clear colourless oil (14.0 mg, 35 μmol, 70%). 
Rf = 0.19 (Petroleum:EtOAc; 3:1); νmax (film)/cm-1 2938w and 2924w (CH), 2854 (O-C-
H3), 1724s (2 × C=O, ester), 1645w (O-CO), 1452m, and 1438m (C=C); 1H NMR (400 
MHz, CDCl3) δ = 7.58 (s, 1H, ArCH), 6.78 (s, 1H, CH=Cquat.), 5.71 (d, J = 5.3 Hz, 1H, 
O2CH), 3.98-3.88 (m, 2H, OCH2),  3.87 (s, 3H, OMe), 3.84 (s, 3H, OMe), 3.75 (s, 3H, 
CO2Me), 3.66 (s, 3H, CO2Me), 3.01 (dd, J = 15.9, 5.3 Hz, 1H, O2CHCH), 2.78-2.72 (m, 
1H, ArHaHb), 2.68 (dd, J = 15.9, 2.6 Hz, 1H, ArHaHb), 2.03-1.96 (m, 1H, OCH2CHaHb), 
1.62-1.57 (m, 1H, OCH2CHaHb); 13C NMR (100.0 MHz) δ = 164.5 (CO2Me), 163.5 
(CO2Me), 153.1 (COMe.), 148.3 (CH=Cquat.), 142.0 (ArCquat.), 129.8 (ArCquat.), 127.2 
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(ArCquat.), 119.0 (ArCquat.), 103.6 (CH=Cquat.), 103.2 (O2CH), 74.5 (OCH2), 67.0 (OMe), 
66.1 (OMe), 61.9 (CO2Me), 59.6 (CO2Me), 52.8 (O2CHCH), 30.7 (OCH2CH2), 29.8 
(CH2); HRMS (EI) calcd for [C19H26O8N]+ 396.1653; found 396.1654 [M+NH4]+. 
4-Methoxy-2-(morpholinomethyl)phenol (320).  To a solution of 
morpholine (0.7 mL, 8.3 mmol, 0.9 equiv.) in acetonitrile (5 mL) in a 
microwave microwave vial fitted with a septum was added 
paraformaldehyde (0.25 g, 8.3 mmol, 0.9 equiv.) and the reaction mixture 
was stirred at r.t. for 4 h, at which time the reaction mixture had become a clear solution.  
Paramethoxyphenol (1.15 g, 9.3 mmol, 1.0 equiv.) was added and the reaction vessel was 
fitted with a “crimp cap” and the resultant solution was heated to 100 oC for 10 h.  The 
reaction mixture was then cooled to r.t., diluted with EtOAc (30 mL) and washed with sat. 
aq. NH4Cl solution (2 × 20 mL).  The organics were dried over MgSO4, concentrated 
under reduced pressure and purified by silica gel chromatography (Petroleum:Et2O; 3:1) 
afforded the title compound as an orange/brown oil (1.62 g, 7.24 mmol, 87%). 
νmax (film)/cm-1 3490br (OH), 2952w, 2900w (CH), 2872w (OCH3), 1497m and 1448w 
(C=C), 1208m (CN); 1H NMR (400 MHz, CDCl3) δ = 10.17 (br, 1H, OH), 6.78-6.72 (m, 
2H, ArCH), 6.57 (d, J = 2.2 Hz, ArCH), 3.74 (s, 7H, OMe, 2 × OCH2), 3.67 (s, 2H, 
ArCH2), 2.56 (br, 4H, 2 × NCH2); 13C NMR (100.0 MHz) δ = 152.4 (ArOH) 151.1 
(ArOMe), 121.2 (ArCH2), 116.3 (ArCH), 114.5 (ArCH), 113.6 (ArCH), 66.6 (2 × OCH2), 
63.8 (ArCH2), 55.6 (OMe), 52.8 (2 × NCH2); HRMS (EI) calcd for [C12H18N1O3]+ 
224.1281; found 224.1282 [M+H]+. 
2-((Dibenzylamino)methyl)-4-methoxyphenol (321).  To a 
solution of dibenzylamine (1.6 mL, 8.3 mmol, 0.9 equiv.) in 
acetonitrile (5 mL) in a microwave microwave vial fitted with a 
septum was added paraformaldehyde (0.25 g, 8.3 mmol, 0.9 equiv.) 
and the reaction mixture was stirred at r.t. for 16 h, at which time the 
reaction mixture had become a clear solution.  Paramethoxyphenol (1.15 g, 9.3 mmol, 1.0 
equiv.) was added and the reaction vessel was fitted with a “crimp cap” and the resultant 
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solution was heated to 100 oC for 5 h.  The reaction mixture was then cooled to r.t., 
diluted with EtOAc (30 mL) and washed with sat. aq. NH4Cl solution (2 × 20 mL).  The 
organics were dried over MgSO4, concentrated under reduced pressure and purified by 
silica gel chromatography (Petroleum:Et2O; 3:1) afforded the title compound as an pale 
orange solid (2.35 g, 7.0 mmol, 85%). 
 
νmax (film)/cm-1 3025w and 2921w (CH), 2836w (OCH3), 1598w, 1490s and 1469m 
(C=C), 1206m (CN); 1H NMR (400 MHz, CDCl3) δ = 10.25 (br, 1H, OH), 7.38-7.27 (m, 
10H, 10 × ArCH), 6.77 (d, J = 8.8, 1H, ArCH), 6.72 (dd, J = 8.8, 2.5 Hz, 1H, ArCH), 
6.59 (d, J = 2.5 Hz, 1H, ArCH), 3.74 (s, 3H, OMe), 3.69 (s, 2H, NCH2), 3.61 (s, 4H, 2 × 
PhCH2); 13C NMR (100.0 MHz) δ = 152.2 (COH), 150.8 (COMe), 136.4 (2 × PhCH2), 
129.1 (4 × PhH), 128.2 (4 × PhH), 127.2 (2 × PhH), 122.2 (ArCquat.), 116.0 (ArCH), 114.5 
(ArCH), 113.1 (ArCH), 57.4 (2 × PhCH2), 56.5 (ArCH2), 55.3 (OMe); HRMS (EI) calcd 
for [C22H24N1O2]+ 334.1802; found 334.1805 [M+H]+. 
(3a±,9a±)-6-Methoxy-3,3a,4,9a-tetrahydro-2H-furo[2,3-b]chromene.  
Morpholine (320) (50 mg, 0.22 mmol, 1.0 equiv.) was dissolved in 2,3-
dihydrofuran (0.16 mL, 2.20 mmol, 10. Equiv.) in  microwave tube, 
fitted with a “crimp cap” and heated at 130 oC for 16 h in a microwave reactor.  The 
reaction mixture was then cooled to r.t., concentrated under reduced pressure and purified 
by silica gel chromatography (Petroleum:Et2O; 1 to 10% Et2O) to furnish the title 
compound as a clear colourless oil (35.9 mg, 0.17 mmol, 79%). 
Rf = 0.18 (Petroleum:Et2O; 9:1); νmax (film)/cm-1 2932br (multiple CH), 1496s 1463w and 
1437w (C=C); 1H NMR (400 MHz, CDCl3) δ = 6.82 (d, J = 8.7 Hz, 1H, ArCH), 6.69 (dd, 
J = 8.7, 2.9 Hz, 1H, ArCH), 6.63 (d, J = 2.9 Hz, 1H, ArCH), 5.64 (d, J = 5.5 Hz, O2CH), 
3.97 (dt, J = 8.5, 4.5 Hz, 1H, OCHaHb), 3.88 (d, J = 7.9 Hz, 1H, OCHaHb), 3.03 (dd, J = 
15.4, 5.7 Hz, 1H, ArCHaHb), 2.78-2.70 (m, 1H, ArCH2CHR2), 2.66 (dd, J = 15.8, 2.6 Hz, 
1H, ArCHaHb), 2.08-1.99 (m, 1H, OCH2CHaHb), 1.69-1.63 (m, 1H, OCH2CHaHb); 
13C NMR (100.0 MHz) δ = 154.2 (COMe), 147.3 (ArCquat.), 123.4 (ArCquat.), 117.8 
(ArCH), 114.2 (ArCH), 112.99 (ArCH), 102.1 (O2CR), 68.1 (OCH2), 55.7 (OMe), 38.1 
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(O2CHCH), 28.73 (OCH2CH2), 27.08 (ArCH2); HRMS (EI) calcd for [C12H15O3]+ 
207.1016; found 207.1016 [M+H]+. 
Methyl 6-(2,3-dimethoxy-3-oxoprop-1-en-1-yl)-8-
methoxy-5'-oxo-4',5'-dihydro-3'H-spiro[chroman-2,2'-
furan]-7-carboxylate (317).  Morpholine (290) (20 mg, 
51 μmol, 1.0 equiv.) was dissolved in γ-methylene-γ-
butyrolactone (0.10 mL, 1.12 mmol) in  microwave tube, fitted with a “crimp cap” and 
heated at 130 oC for 16 h in a microwave reactor.  The reaction mixture was then cooled 
to r.t., concentrated under reduced pressure and purified by silica gel chromatography 
(Petroleum:EtOAc; 1 to 10% EtOAc) to furnish the title compound as a clear colourless 
oil (14.2 mg, 35 μmol, 64.1%) in 1:3 ratio of E:Z isomers.   
Rf = 0.15 (Petroleum:Et2O); νmax (film)/cm-1 2939w and 2930w (CH), 2854 (O-C-H3), 
1792s and 1725s (C=O, ester), 1645w (O-CO), 1567m, 1475m, 1440m, 1436m (C=C); 
HRMS (EI) calcd for [C20H23O9]+407.1337; found  407.1339 [M+H]+.  
(Z)-isomer; 1H NMR (400 MHz, CDCl3) δ = 7.67 (s, 1H, ArCH), 6.81 (s, 1H, CH=Cquat.), 
3.96 (s, 3H, OMe), 3.91 (s, 3H, OMe), 3.82 (s, 3H, CO2Me), 3.74 (s, 3H, CO2Me), 3.09-
2.94 (m, 2H, CH2), 2.72-2.52 (m, 2H, CH2), 2.41-2.23 (m, 2H, CH2), 2.19-2.08 (m, 1H, 
CHaHb), 2.04 (m, 1H, CHaHb); 13C NMR (100.0 MHz) δ = 173.5 (CO2), 167.2 (CO2Me), 
164.3 (CO2Me), 147.3 (RH=Cquat.), 146.2 (COMe), 142.2 (ArCquat.), 125.5 (ArCquat.), 
125.4 (ArCquat.), 124.9 (ArCH), 118.6 (CH=Cquat.), 109.0 (spiro-C), 61.9 (OMe), 59.4 
(OMe), 52.6 (CO2Me), 52.3 (CO2Me), 38.8 (CH2), 32.9 (CH2), 26.9 (CH2), 25.7 (CH2); 
(E)-isomer; 1H NMR (400 MHz, CDCl3) δ = 7.65 (s, 1H, ArCH), 6.84 (s, 1H, CH=Cquat.), 
3.93 (s, 3H, OMe), 3.82 (s, 3H, OMe), 3.81 (s, 3H, CO2Me), 3.72 (s, 3H, CO2Me), 3.09-
2.94 (m, 2H, CH2), 2.72-2.52 (m, 2H, CH2), 2.41-2.23 (m, 2H, CH2), 2.19-2.08 (m, 1H, 
CHaHb), 2.04 (m, 1H, CHaHb); The 13C NMR spectrum could not be clearly distinguished 
from the major (Z)-isomer. 
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1H NMR Spectrum (Compound 235) 
 
 
13C NMR Spectrum (Compound 235) 
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1H NMR Spectrum (Compound 265a)
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1H NMR Spectrum (Compound 267) 
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1H NMR Spectrum (Compound 269) 
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31P NMR Spectrum (Compound 269) 
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1H NMR Spectrum (Compound 276; Z-isomer highlighted) 
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1H NMR Spectrum (Compound 276; E-isomer highlighted)
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1H NMR Spectrum (Compound 290; Z-isomer highlighted) 
13H NMR Spectrum (Compound 290) 
 
  
202 
 
1H NMR Spectrum (Compound 290; E-isomer highlighted) 
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1H NMR Spectrum (Compound 294; Z-isomer highlighted) 
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1H NMR Spectrum (Compound 294; E-isomer highlighted) 
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1H NMR Spectrum (Compound 323)
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1H NMR Spectrum (Compound 316) 
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1H NMR Spectrum (Compound 317) 
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